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Chapter 1
Introduction
Nutrition and genes importantly contribute to the development of numerous diseases, includingdiabetes, dyslipidemia and coronary artery disease. Recently, a new field emerged aimed at
investigating the interaction between nutrition and genes: Nutrigenomics. Nutrigenomics research
studies the link between nutrition and health using genomics tools. Within our group we have em-
braced nutrigenomics as an important experimental approach to better understand the effects of
dietary fatty acids. Past and current research within the group has illustrated the vast effects of
dietary fatty acids on gene expression and has demonstrated a major role for the Peroxisome Pro-
liferator Activated Receptors (PPARs) in mediating the effects of fatty acids on gene expression.
One of the genes that emerged from these studies encodes the Angiopoietin like protein 4. We
hypothesize that induction of Angptl4 may account for some of the molecular effects of dietary
fatty acids.(Figure 1.1). PPARs are nuclear receptors that bind to DNA as a heterodimer with the
Figure 1.1: Activation of PPAR target genes. Fatty acids enter the cell and the nucleus to bind PPAR. 9 cis retinoic
acid binds RXR. The heterodimer binds to response elements (PPRE) in PPAR target genes. Induction of target gene
transcription is followed by enhanced protein synthesis. Adapted from Arner P. Diabetes Obes Metab 2001; 3 (Suppl
1):S11-S19.
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retinoid X receptor (RXR). They are able to respond to both synthetic and endogenous ligands,
including fatty acids and various fatty acid-derived compounds. Three different PPARs can be dis-
tinguished: PPARα, PPARβ/δ and PPARγ. In response to binding of ligand, PPARs activate the
transcription of numerous genes involved in various pathways of lipid metabolism. As indicated
above, one of the genes that is highly induced by fatty acids and by PPARs in a variety of tissues
encodes the secreted protein Angptl4. In this thesis we pursued a variety of approaches to better
characterize the biological role and regulation of Angptl4.
1.1 Angiopoietin like protein 4.
Angptl4 is a secreted protein of about 50 KDa, which belongs to the family of fibrinogen/angiopoie-
tin like protein. Angptl4 is closely related to Angptl3 (Figure 1.2).
Similar to other angiopoietins and Angiopoietin like proteins, Angptl4 can be divided into dis-
tinct regions including a N-terminal signal sequence, a unique sequence, a coiled-coil domain and
a large fibrinogen/angiopoietin-like domain. Angptl4 is cleaved, most likely via specific propro-
tein convertases, to release a N-terminal and C-terminal fragment. Full length Angptl4 can thus
be considered a prohormone that serves as precursor for two distinct biological molecules. Recent
studies suggest that the C-terminal Angptl4 fragment is important for governing angiogenic func-
tion (Yang et al. 2008). Indeed, other members of the angipoietin family such as Angiopoietin 1
and 2 have been described to have angiogenic properties mediated by binding to the Tie2 receptor.
However, Angptl4 does not bind to Tie1 or Tie2 receptors. In analogy with Angptl3, which bind
to αVβ3 integrin, Angptl4 may be hypothesized to bind certain integrins. However, this thesis is
focused on the lipid related function of Angptl4.
1.2 LPL and lipoproteins
Fatty acids can circulate in the bloodstream as free fatty acid bound to albumin or as triglycerides
packaged within lipoproteins. Lipoproteins are particles that contain both proteins and lipids and
display variable densities depending on their lipid composition. Lipoproteins are classified from
larger and less dense, to smaller and more dense lipoproteins: chylomicrons (CM), very-low den-
sity lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL),
and high density lipoprotein (HDL). The larger lipoproteins have higher TG content and a higher
ratio of TG/proteins compared to the smaller lipoproteins. CMs are synthesized in the small in-
testine and contain dietary triglycerides. They are secreted into intestinal lymph vessels which
eventually drain into the blood circulation. Once the CM enters into plasma, the triglycerides are
hydrolyzed to release fatty acids, which are taken up by adipose tissue, heart and skeletal muscle,
while the remnants of CM particles are taken up by the liver. In contrast to CM, VLDL particles
contain endogenous triglycerides and are synthesized in liver. Hydrolysis of its TG and phospho-
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Figure 1.2: Phylogenetic tree of angiopoietin and angiopoietin-like family of proteins. Adapted from Ge et al. JLR 46:
1484-1490, 2005.
lipids allow the successive formation of IDL, LDL and indirectly HDL (Figure 1.3). Lipoprotein
lipase (LPL) is a member of triglyceride lipase gene family, which also includes hepatic lipase
(HL), pancreatic lipase (PL) and the recently discovered endothelial lipase (EL). LPL is a key reg-
ulator enzyme in the clearance of the TG rich chylomicrons (CM) and very-low density lipoprotein
(VLDL). In Chapter 2 we review regulation of LPL activity by the recently discovered proteins
Angptl3, Angptl4 and GPIHBP1. Beside the LPL protein, several other proteins play an impor-
tant function in lipoprotein metabolism. Enterocytes in the small intestine synthesize apoB48,
which undergoes lipidation by the microsomal TG transfer protein (MTP) within the endoplasmic
reticulum. Via transport through the Golgi the small lipidated apoB48 particle undergoes further
modifications to become a prechylomicron and subsequently a chylomicon, followed by secretion
via exocytosis. In the lymph and bloodstream, CM contains apoB48, apoAI and apoAIV. Through
a series of apolipoprotein exchanges with HDL, chylomicrons acquire apoCI, apoCII, apoCIII and
apoE. Moreover, CM can exchange TG and cholesteryl ester (CE) via the cholesteryl ester transfer
protein (CETP), and phospholipids via the phospholipid transfer protein (PLTP). The liver is a key
organ in lipoprotein metabolism. ApoE recognition by LDL receptor (LDLr) and LDLr-related
protein (LRP) mediate uptake of chylomicron remnants. To allow lipid transport from liver to the
periphery, hepatocytes synthesize VLDL via a mechanism comparable to intestinal CM synthesis,
with apoB100 replacing apoB48. Once secreted into the blood circulation, VLDL is enriched with
apolipoprotein analogous to CM. Within the capillaries of skeletal muscle, heart and adipose tis-
sue, the TG-rich lipoproteins are hydrolyzed via the action of lipoprotein lipase, which is attached
to the vascular endothelium. LPL mediates peripheral tissues FA uptake and promotes VLDL
remnant formation, leading to formation of IDL and ultimately LDL. LDL is taken up by the liver
via the LDL receptor, which is subject to regulation via the SREBP pathways. High plasma LDL
4 1. Introduction
CE/TG
CE/TG
CE
Muscle
Adipose
tissue
FFA
VLDL
IDL
LDL
Extra hepatic
tissue
LDL-R
Liver
LPL
Gall
bladder
Figure 1.3: LPL role in lipoprotein clearance. Represents the clearance of TG-rich lipoprotein by LPL, leading to fatty
acid uptake and cholesterol elimination.
levels have been shown to promote coronary heart disease as LDL undergoes oxidative modifica-
tions that render it a better ligand for uptake into macrophages, which is mediated by scavenger
receptors. In contrast, high plasma HDL levels have been shown to be protective against coronary
heart disease. Synthesis of HDL occurs via the lipidation of the apolipoprotein apoAI by ATP
binding cassette transporter A1 (ABCA1). Esterification of incoming cholesterol is catalyzed by
lecithin cholesterol acyltransferase (LCAT) to yield a mature HDL particle. As indicated above,
numerous exhanges occur between HDL and other lipoproteins, which are partially mediated by
CETP. HDL-cholesterol finally ends up in the liver, partially via exchange with LDL and partially
via SR-B1. By returning cholesterol from macrophages and other peripheral cells to the liver,
HDL is believed to exert an anti-atherogenic effect.
1.3 Small intestine, key organ in fatty acid absorption
The first tissue to be exposed to dietary constituents is the small intestine. The gastrointestinal
track is the key organ in charge of proper nutrient digestion and fat absorption. Its central role
in food absorption and nutrient distribution requires an elaborate vascular network that includes
lymph and blood vessels. Within the small intestine another organ has been described to be crucial
for nutrient absorption, which is the gut microbiota. The gut microbiota is composed of trillions
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of bacteria that colonize the infant’s gut throughout birth. Without microbiota, the human body
would be unable to utilize the undigested carbohydrates. Recent research has implicated the gut
microbiota in body weight control and energy homeostasis (Ley et al. 2006, Turnbaugh et al. 2006,
Backhed, Manchester, Semenkovich and Gordon 2007, Backhed et al. 2004, Ba¨ckhed et al. 2005,
Ley et al. 2005). Germ-free mice, uncolonized by bacteria, fed a normal chow diet showed a 40%
decrease in weight-gain (Backhed et al. 2004), compared to germ-free mice colonized with gut
microbiota from conventional mice. Obesity has been described to be associated with a state of
chronic low grade inflammation which has been suggested to be related to macrophage infiltration
into adipose tissue (Weisberg et al. 2003). Especially increased visceral fat has been associated
with elevated circulating inflammatory cytokines, such as C reactive protein (CRP) and serum
amyloid A (SAA) (van Dielen et al. 2001). Alternatively, it has been suggested that low grade
inflammation associated with obesity may be related to changes in intestinal microbiota. Evidence
has been provided that gut permeability is increased in mice fed high fat diet (Cani et al. 2008),
leading to enhanced entry of LPS into the circulation. Angptl4 is expressed in both adipose tissue
and small intestine, and expression of small intestine in subject to regulation by the intestinal
microbiota. Accordingly, a modulating role for Angptl4 in obesity-induced chronic inflammation
could be hypothesized. The role of Angptl4 in high fat diet-induced inflammation is explored in
this thesis.
1.4 Outline of this thesis
This thesis aims to better characterize the role of Angptl4 in the regulation of lipid metabolism.
The data collected thus far in mice indicate that Angptl4 inhibits clearance of plasma triglycerides
and stimulates adipose tissue lipolysis. In chapter 2 we provide an overview of the current knowl-
edge on Angptl4 and the related proteins Angptl3 and GPIHBP-1. In chapter 3 we took advantage
of the sensitivity of Angptl4-transgenic mice to fasting to better characterize the metabolic func-
tion of Angptl4. The data underscore the important role of Angptl4 in governing lipid metabolism,
especially during fasting. Furthermore we report the development of an ELISA for quantitative
measurement of Angptl4 in human plasma (Chapter 4). We show that plasma Angptl4 levels are
increased by fasting, caloric restriction, and exercise, which is likely mediated by elevated plasma
FFAs. Chapter 5 is aimed at studying the functional involvement of Angptl4 in a feedback loop
that minimizes large deviations in cardiac fatty acid uptake and thereby protects against lipid over-
load. Finally, former studies in our lab have pointed towards a possible role of Angptl4 in the
small intestine during high fat feeding. Accordingly, we have studied the effect of high fat diet
in mice lacking Angptl4, revealing that Angptl4 protects against the pro-inflammatory effects of
high fat feeding (Chapter 6).
L. Lichtenstein and S. Kersten – “LiPoLysis revisited,” submitted
Chapter 2
LiPoLysis revisited
Changes in the plasma level of lipoproteins are known to impact atherosclerosis and associatedcoronary heart disease (CHD). While elevated plasma low-density lipoprotein (LDL) levels
increase the risk for CHD, high levels of high-density lipoprotein (HDL) levels are considered
to be protective. In addition to high LDL, high plasma triglycerides (TG) are recognized as an
important, independent risk factor for CHD. TG are present in blood plasma mainly in the form
of chylomicrons and very low density lipoproteins (VLDL). Levels of TG in the plasma are thus
determined by the balance between the rate of production of chylomicrons and VLDL in intes-
tine and liver, respectively, and their rate of clearance in skeletal muscle, heart and adipose tissue.
Clearance of TG-rich lipoproteins is mediated by the enzyme lipoprotein lipase (LPL), which is
tethered to the capillary endothelium via heparin sulphate proteoglycans. LPL is a triglyceride
lipase that belongs to the same lipase family as hepatic lipase (HL), pancreatic lipase (PL), and
endothelial lipase (EL). It contains a number of distinct domains important for its lipolytic func-
tion including a 27-amino-acid signal peptide, a catalytic center and a C-terminal heparin binding
domain (Merkel et al. 2002, Sendak and Bensadoun 1998). LPL is produced by a variety of
cell types including adipocytes, (cardio)myocytes and macrophages, and is secreted towards the
vascular endothelium. Maturation of nascent LPL occurs the endoplasmic reticulum and is de-
pendent of the lipase maturation factor 1 (Pterfy et al. 2007). The enzyme is catalytically active
as a dimer composed of two glycosylated 55 kDa subunits connected in a head-to-tail fashion by
noncovalent interactions (Zhang et al. 2005). Consistent with the fat storage function of adipose
tissue, expression of LPL in adipose tissue is highest after a meal, whereas skeletal muscle LPL
expression is increased by fasting and exercise training. Expression of LPL is under control of a
number of ligand-activated transcription factors. In adipose tissue and macrophages, LPL is up-
regulated by the peroxisome proliferators activated receptor (PPAR)γ (Schoonjans et al. 1996, Li
et al. 2002), whereas liver LPL is stimulated by Liver X receptor (LXR)α and PPARα (Zhang
et al. 2001, Schoonjans et al. 1996). Besides at the level of gene transcription, LPL is extensively
regulated at the level of enzyme activity (Merkel et al. 2002). Several modulators of LPL activity
are known, including apolipoproteins APOC3, APOC2, APOC1, and APOA5. APOC2 stimulates
LPL activity by serving as a cofactor via interaction with the N-terminal part of LPL. Similarly,
APOA5 stimulates LPL activity, whereas APOC3 inhibits LPL. In the past few years two proteins
belonging to the family of angiopoietin-like proteins (ANGPTLs), ANGPTL3 and ANGPTL4,
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have emerged as novel modulators of LPL activity. Combined with the discovery of GPIHBP1
as likely LPL anchor, these findings have led to a readjustment of the mechanism of LPL func-
tion. This review provides an overview of our current understanding of the role and regulation of
ANGPTL3, ANGPTL4 and GPIHBP1, and places the newly acquired knowledge in the context of
the established function and mechanism of LPL-mediated lipolysis.
2.1 Angiopoietin Like Protein 4
ANGPTL4 was independently identified as a new member of the angiopoietin family (HFARP:
hepatic fibrinogen/angiopoietin-related protein) (Kim et al. 2000), as a novel target of PPARγ in
adipose tissue (PGAR: PPARγ angiopoietin related) (Yoon et al. 2000), and as a novel PPARα
target in liver (FIAF: fasting induced adipose factor) (Kersten et al. 2000, Kim et al. 2000). Simi-
lar to other Angiopoietins and Angiopoietin-like proteins, ANGPTL4 can be divided into distinct
regions including a N-terminal signal sequence, a unique sequence, a coiled-coil domain and a
large fibrinogen/angiopoietin-like domain. Upon secretion from HEK293 cells, ANGPTL4 is pro-
teolytically cleaved into a N-terminal portion (nANGPTL4) and a C-terminal portion containing
the fibrinogen like domain (cANGPTL4) (Figure 2.1) (Ge, Yang, Huang, Motola, Pourbahrami
and Li 2004, Yang et al. 2008). Cleavage occurs in a serum-dependent manner and appears to be
mediated by proprotein convertases including PCSK3 via recognition of the amino acid sequence
161RRKR164 (Yang et al. 2008, Chomel et al. 2009). There is some uncertainty as to whether
the same cleavage site is used in vivo as the N and C-terminal ANGPTL4 fragments observed
in human plasma are consistent with cleavage further downstream (Mandard, Zandbergen, Tan,
Escher, Patsouris, Koenig, Kleemann, Bakker, Veenman, Wahli, Muller and Kersten 2004, Xu
et al. 2005). In addition to proteolytic cleavage, ANGPTL4 undergoes oligomerization partially
via intermolecular disulfide bonds mediated by cysteine residues Cys76 and Cys80 and partially via
hydrophobic residues (Figure 2.1) (Ge, Yang, Huang, Motola, Pourbahrami and Li 2004, Man-
dard, Zandbergen, Tan, Escher, Patsouris, Koenig, Kleemann, Bakker, Veenman, Wahli, Muller
and Kersten 2004, Yin et al. 2009, Shan et al. 2009). Oligomer formation occurs prior to se-
cretion, in contrast to cleavage. Once secreted, ANGPTL4 interacts with the extra-cellular ma-
trix through heparin sulphate proteoglycans (Cazes et al. 2006). Furthermore, ANGPTL4 may
physically associate with plasma lipoproteins (Mandard et al. 2006). In mouse, the highest
ANGPTL4 mRNA levels are found in white and brown adipose tissue followed by ovary, liver,
lung, heart and intestine (Kersten et al. 2000, Yoon et al. 2000, Zandbergen et al. 2006). In human,
ANGPTL4 expression is ubiquitous with high expression in liver, adipose tissue, small intes-
tine and heart (Zandbergen et al. 2006, Kersten et al. 2009). At the functional level, a wealth
of data acquired using a variety of animal models of ANGPTL4 overexpression or deletion now
support a stimulatory effect of ANGPTL4 on plasma TG levels, which is achieved by inhibiting
LPL-dependent clearance of TG-rich lipoproteins (Yu et al. 2005, Koster et al. 2005, Mandard
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Figure 2.1: Inhibition of LPL-mediated lipolysis by ANGPTL4. Hydrolysis of TG-rich lipoproteins generates fatty
acids, which are taken up in underlying tissues including adipose tissue, skeletal muscle and heart. Fatty acids induce
ANGPTL4 gene expression via PPARs. ANGPTL4 forms oligomers inside the cell, and is cleaved upon secretion into
nANGPTL4 and cANGPTL4 by proprotein convertases (PCSKs). ANGPTL4 inhibits LPL activity by promoting the
conversion of active LPL dimers into inactive LPL monomers.
et al. 2006, Lichtenstein et al. 2007, Desai et al. 2007). As a consequence, uptake of fatty acids
and cholesterol into tissues is decreased (Lichtenstein et al. 2007). Compelling evidence indicates
that ANGPTL4 inhibits LPL by promoting the conversion from active LPL dimers to inactive LPL
monomers (Figure 2.1) (Sukonina et al. 2006).
In vitro studies have suggested that ANGPTL4 enzymatically catalyzes the dimer to monomer
conversion (Sukonina et al. 2006, Yau et al. 2009), whereas in vivo studies suggest that ANGPTL4
disables LPL by binding LPL monomers, thereby driving the LPL dimer-monomer equilibrium to-
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ward inactive monomers (Lichtenstein et al. 2007). Inhibition of LPL activity and conversion to
monomers is mediated by a short stretch of amino acids close to its N-terminus. Remarkably, a
12 AA peptide containing these 3 amino acids is already able to inhibit LPL, although less ef-
ficiently compared to nANGPTL4 and flANGPTL4 (Yau et al. 2009). According to the current
view, oligomerization of nANGPTL4 and flANGPTL4 is mainly aimed at stabilizing the pro-
tein and does not influence the intrinsic ability of ANGPTL4 to inhibit LPL (Yin et al. 2009, Shan
et al. 2009). Consistent with this notion, LPL can interact with several oligomeric forms of nANG-
PTL4 (Yau et al. 2009). In addition to LPL, there is evidence that ANGPTL4 also inhibits hepatic
lipase and possibly endothelial lipase (Lichtenstein et al. 2007)(plus unpublished data). Sup-
porting the role of ANGPTL4 as LPL inhibitor in human, carriers of a rare E40K variant of the
ANGPTL4 gene exhibit elevated plasma HDL and decreased TG levels (Talmud et al. 2008, Fol-
som et al. 2008, Nettleton et al. 2008, Romeo et al. 2007). The E40K mutation leads to a near
complete loss of ability of ANGPTL4 to inhibit LPL, which may be partially caused by destabiliz-
ing the protein (Yin et al. 2009, Shan et al. 2009). Interestingly, a recent genome-wide association
study showed that a common sequence variant at a locus near the ANGPTL4 gene is associ-
ated with plasma HDL but not TG concentration (Kathiresan et al. 2009). Together, these data
suggest that genetic variation within the ANGPTL4 gene contributes to the variation in plasma
lipid levels within specific populations. As its alternative name fasting-induced adipose factor
implies, ANGPTL4 is upregulated by fasting in adipose tissue (Kersten et al. 2000). Increased
ANGPTL4 mRNA is associated with a decrease in adipose LPL activity and can be hypothesized
to disfavour fat storage during fasting (Sukonina et al. 2006). Induction of ANGPTL4 by fasting,
however, is not limited to adipose tissue and occurs in a variety of organs including heart and
skeletal muscle (Kersten et al. 2000, Wiesner et al. 2004, Yu et al. 2005, Ge et al. 2005, Wiesner
et al. 2006, Sukonina et al. 2006, Lichtenstein et al. 2007). In humans, plasma ANGPTL4 lev-
els are increased by fasting and chronic caloric restriction, which is mediated by increased free
fatty acid levels (Kersten et al. 2009). Indeed, plasma ANGPTL4 levels in humans are corre-
lated with fasting plasma free fatty acids (Staiger et al. 2009). Since ANGPTL4 is also known
to stimulate adipose tissue lipolysis (Mandard et al. 2006), induction of ANGPTL4 during fast-
ing may be aimed at shifting fuel use from lipoprotein-derived fatty acids towards circulating free
fatty acids, and thus promote use of stored fat. The fasting- and fatty acid-induced increase in
ANGPTL4 is mediated by PPARs, which transcriptionally activate ANGPTL4 expression via a
set of PPAR-response elements in intron 3 of the ANGPTL4 gene (Figure 2.1)(Mandard et al.
2004, Heinaniemi et al. 2007). Supporting regulation by PPARs, synthetic agonists for PPARα
and PPARγ raise plasma ANGPTL4 levels in human subjects (Xu et al. 2005, Kersten et al. 2009).
In mice, agonists for all three PPARs upregulate ANGPTL4 expression in liver, skeletal muscle,
heart, WAT and intestine (Kersten et al. 2000, Yoon et al. 2000, Mandard et al. 2004, Yoshida et al.
2004, Ge et al. 2005, Dutton et al. 2008, Rieck et al. 2008, Gealekman et al. 2008, He et al. 2008,
Bunger et al. 2007). In addition to fasting, in heart ANGPTL4 mRNA is also induced following
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an oral fat load, which is mediated by PPARβ/δ . Induction of cardiac ANGPTL4 by dietary fatty
acids is part of a feedback mechanism aimed at protecting the heart against lipid overload and
consequently lipotoxicity (Georgiadi et al. Submitted). The dramatic induction of ANGPTL4 by
PPARβ/δ agonist and by fatty acids have led to the use of ANGPTL4 as PPARβ/δ and fatty acid
marker gene (He et al. 2008, Schug et al. 2007, Staiger et al. 2008),(ANGPTL4/FIAF as marker
for PPARδ modulation, European Patent Application EP1586902). Finally, via inhibition of LPL
activity ANGPTL4 has been suggested to serve as critical mediator of the effect of the intesti-
nal microbiota on bodyweight (Backhed et al. 2004). Apart from its role in lipid metabolism,
several studies have linked ANGPTL4 to processes such as angiogenesis, cell migration, en-
dothelial cell function, vascular leakage and cell adhesion (Zhu et al. 2002, Ito et al. 2003, Ge
et al. 2005, Cazes et al. 2006, Murata et al. 2009, Yang et al. 2008, Gealekman et al. 2008, Galaup
et al. 2006, Hermann et al. 2005, Padua et al. 2008). Consistent with a role in angiogenesis,
expression of ANGPTL4 is highly induced by hypoxia in cardiomyocytes, brain, endothelial
cells, and adipocytes (Le Jan et al. 2003, Belanger et al. 2002, Wiesner et al. 2006, Gustavs-
son et al. 2007, Wang et al. 2007). These functions are likely conferred by cANGPTL4, which
functions independently of nANGPTL4. Thus, flANGPTL4 may be considered a prohormone
whose pleiotropic actions are mediated by nANGPTL4 and cANGPTL4. Finally, in relation to
atherosclerosis, ANGPTL4 deletion was shown to exert a protective influence in the APOE KO
model (Adachi et al. 2009). Whether this effect is mediated via changes in lipid metabolism, or
via other pleiotropic activities of ANGPTL4 remains to be determined.
2.2 Angiopoietin Like Protein 3
ANGPTL3 was discovered while searching EST databases for signal sequences and amphipathic
helices (Conklin et al. 1999). Structurally and functionally, ANGPTL3 is highly similar to ANGPT-
L4. ANGPTL3 shares the modular structure of ANGPTL4 consisting of a signal sequence, a small
unique region, a coiled-coil domain and a large fibrinogen/angiopoietin-like domain. Similar to
ANGPTL4, ANGPTL3 is proteolytically cleaved by proprotein convertases via recognition of
the amino acid sequence 221RAPR224 to yield a N-terminal and C-terminal ANGPTL3 fragment
(Figure 2.2) (Ono et al. 2003, Jin et al. 2007). However, in contrast to ANGPTL4, ANGPTL3
is expressed almost exclusively in the liver, with minor expression found in kidney (Zandbergen
et al. 2006).
The plasma lipid modulating properties of ANGPTL3 were discovered via positional cloning
using KK/San mice, which represent a mutant strain of KK obese mice with markedly lower
plasma free fatty acid and TG levels (Koishi et al. 2002). Induction of plasma TG by ANGPTL3
was corroborated using a variety of animal models of ANGPTL3 overexpression or deletion, and
is achieved by inhibiting clearance of TG-rich lipoproteins (Shimizugawa et al. 2002, Koster
et al. 2005, Fujimoto et al. 2006). Similar to ANGPTL4, ANGPTL3 inhibits LPL activity, al-
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Figure 2.2: Inhibition of LPL-mediated lipolysis by ANGPTL3. Oxysterols induce ANGPTL3 gene expression in liver
via LXRs. ANGPTL3 forms oligomers inside the cell, and is cleaved upon secretion into nANGPTL3 and cANGPTL3 by
proprotein convertases (PCSKs). ANGPTL3 inhibits LPL activity via a mechanism that likely differs from ANGPTL4.
ANGPTL3 also inhibits endothelial lipase (EL) and possibly hepatic lipase.
though presumably via different mechanisms. Whereas ANGPTL4 catalyzes LPL inactivation,
ANGPTL3 suppresses LPL catalytic activity in the presence of substrates (Figure 2.2) (Shan
et al. 2009), which might explain its 100-fold lower potency towards LPL (Sonnenburg et al. 2009).
Supporting different mechanisms of action, heparin can rescue LPL from inhibition by ANGPTL3
but not ANGPTL4. Analogous to ANGPTL4, cleavage of ANGPTL3 does not impact the intrinsic
ability of ANGPTL3 to inhibit LPL as nANGPTL3 and flANGPTL3 are equally effective towards
inhibiting LPL activity in vitro (Ono et al. 2003). However, cleavage appears to be important for
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Figure 2.3: GPIHBP1 represents a high affinity anchor system for LPL. GPIHBP1 is expressed in the same tissues
that express LPL and similar to LPL is under control of PPARγ. Processing of LPL in the endoplasmic reticulum
requires lipase maturation factor 1 (LMF1). GPIHBP1 is tethered into the capillary endothelium and is capable of
binding chylomicrons and LPL. GPIHBP1 may represent a system for high affinity and stable attachment of LPL to the
endothelium, as opposed to the lower affinity attachment of LPL via heparin sulphate proteoglycans (HSPG).
activating ANGPTL3 in vivo (Ono et al. 2003).
Besides LPL, ANGPTL3 also inhibits the activity of EL and HL (Figure 2.2) (Shimizugawa
et al. 2002, Fujimoto et al. 2006, Shimamura et al. 2007). Supposedly, nANGPTL3 is a more
effective EL inhibitor compared to flANGPTL3 (Jin et al. 2007). ANGPTL3 has been suggested to
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mediate the effect of proprotein convertases on EL activity and plasma HDL levels (Jin et al. 2007).
As nANGPTL3 also inhibits LPL, this mechanism should impact plasma TG as well, although
no data are available. Currently, the relative importance of the various lipases in explaining the
effect of ANGPTL3 on plasma lipoprotein levels remains unclear. In analogy with ANGPTL4,
ANGPTL3 stimulates adipose tissue lipolysis, thereby raising plasma free fatty acid and glycerol
levels (Koishi et al. 2002, Fujimoto et al. 2006, Shimamura et al. 2007).
At the present time, the mechanism behind this effect remains unclear but must be indepen-
dent of LPL inhibition. Expression of ANGPTL3 is influenced by numerous stimuli. Dramatic
induction of ANGPTL3 mRNA is achieved by activation of LXR, which binds to a LXR re-
sponse element in the ANGPTL3 promoter (Figure 2.2) (Kaplan et al. 2003). Accordingly, it
has been suggested that induction of ANGPTL3 accounts for the stimulatory effect of LXR ag-
onists on plasma TG levels (Inaba et al. 2003). Hepatic ANGPTL3 expression has also been
shown to be under hormonal control. Both leptin and insulin down regulate ANGPTL3 mRNA
expression (Shimamura et al. 2004, Inukai et al. 2004) and a similar effect is exerted by thyroid
hormone mediated by the thyroid hormone receptor beta (Fugier et al. 2006). While PPARβ/δ is
a potent inducer of ANGPTL4, PPARβ/δ suppresses ANGPTL3 expression, probably by compet-
ing with LXRα for RXRα (Matsusue et al. 2006). Recent genome-wide association studies have
shown that a common sequence variant at a locus near the ANGPTL3 gene is associated with
plasma concentration of TG, but not other lipoprotein parameters (Kathiresan et al. 2009, Willer
et al. 2008). Moreover, a ANGPTL3 sequence variant (M259T) that failed to inhibit LPL activity
in in vitro studies was associated with lower plasma levels of TG. This sequence variant is com-
mon among African Americans but rare among European Americans (Romeo et al. 2009). These
data suggest that genetic variation within the ANGPTL3 gene contributes to variation in plasma
TG levels and furthermore validate the importance of ANGPTL3 in the regulation of lipoprotein
metabolism in humans. A limited number of studies have measured ANGPTL3 levels in human
plasma. Plasma ANGPTL3 levels varied between 218 and 764 ng/mL (Hatsuda et al. 2007, Shoji
et al. 2009, Yilmaz et al. 2009, Moon et al. 2008, Stejskal et al. 2007), which is markedly higher
than values reported for plasma ANGPTL4. In one study, ANGPTL3 was inversely correlated
with VLDL- and IDL-cholesterol levels, and positively with HDL-cholesterol (Shoji et al. 2009).
Significant correlations have also been reported with systolic blood pressure, plasma LDL, and
plasma A-FABP (Stejskal et al. 2007). Furthermore, a positive correlation was found between
plasma ANGPTL3 and carotic artery intima-media thickness (Hatsuda et al. 2007). Finally, levels
of ANGPTL3 were elevated in patients with non-alcoholic steatohepatitis (Yilmaz et al. 2009).
In addition to its role in lipid metabolism, ANGPTL3 has been shown to stimulate endothelial
cell adhesion and migration by serving as a ligand for integrin αVβ3 (Camenisch et al. 2002).
Furthermore, ANGPTL3 has been shown to stimulate ex vivo expansion of hematopoietic stem
cells (Zhang et al. 2006). With respect to atherosclerosis, ANGPTL3 deletion reduced hyper-
triglyceridemia and atherosclerosis in the apoE KO model (Ando et al. 2003). In human subjects,
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plasma ANGPTL3 was positively correlated with femoral artery intima-media thickness (Hatsuda
et al. 2007).
2.3 Glycosylphosphatidylinositol-Anchored HDL-Binding Protein 1
GPIHBP1 was initially identified by expression cloning in Chinese hamster ovary (CHO) cells as
a GPI-anchored high-density lipoprotein (HDL)-binding protein 1 (Ioka et al. 2003). GPIHBP1
is a protein of 28 kDa that consists of a signal sequence, a highly negatively charged N-terminal
domain, a short linker domain, a Ly-6 domain containing 10 cysteine residues, and a hydrophobic
carboxyl-terminal region harboring the GPI-anchored motif. GPIHBP1 is secured in the plasma
membrane by the GPI anchor, which can be cleaved by phosphatidylinositol-specific phospholi-
pase C. Similar to LPL, GPIHBP1 is expressed in the heart, adipose tissue, and skeletal muscle,
and is secreted to the capillary lumen of those tissues (Figure 2.3) (Beigneux et al. 2007). The pro-
tein is glycosylated at Asn-76 within the Ly-6 domain, which is important for the proper traffick-
ing of GPIHBP1 to the cell surface (Beigneux et al. 2008). Recently, it was shown that GPIHBP1
modulates LPL-mediated clearance of TG-rich lipoproteins as revealed by the severe hypertriglyc-
eridemia in mice lacking GPIHBP1 (Beigneux et al. 2007). Intriguingly, GPIHBP1 deficient mice
exhibit milky plasma already on a low fat diet. In vitro, GPIHBP1 binds to both chylomicrons
and LPL with high affinity (Kd =3.6 * 10−8 M). Binding is mediated by the acidic amino terminal
domain within GPIHBP1 and the positively charged heparin binding domain with LPL. Recently,
evidence was provided that membrane-anchored GPIHBP1 also represents an important binding
site for LPL in vivo (Figure 2.3) (Weinstein et al. 2008). Binding of LPL to GPIHBP1 may ren-
der LPL more stable and diminish inhibition of LPL by ANGPTL3 and ANGPTL4 (Sonnenburg
et al. 2009). Limited information is currently available about regulation of GPIHBP1 expression.
Fasting was found to increase GPIHBP1 expression level in heart, BAT and WAT, while high
fat feeding upregulated GPIHBP1 mRNA expression in WAT, skeletal muscle and liver (Davies
et al. 2008). Surprisingly, PPARγ agonist but not PPARα or PPARβ/δ agonists increased GPI-
HBP1 mRNA in WAT, BAT, heart and skeletal muscle (Figure 2.3).
We observed that a single oral fat load increased GPIHBP1 expression in heart, which was
independent of either PPARα or PPARβ/δ (unpublished data). Supporting the importance of
GPIHBP1 in plasma triglyceride clearance in humans, two rare mutations within the GPIHBP1
gene were recently found to be associated with severe hypertriglyceridemia and chylomicrone-
mia (Wang and Hegele 2007). The Q115P mutation gives rise to a protein that, despite being
present at the cell surface, binds poorly to LPL and chylomicrons (Beigneux et al. 2009). The
effect of the G56R mutation on GPIHBP1 function is not clear. Indeed, the ability of GPIHBP1
to reach the cell surface and to bind LPL, chylomicrons, or APOA5 are not affected by the muta-
tion (Gin et al. 2007). Overall, the data suggest that GPIHBP1 serves as a high affinity anchor for
LPL which may function additively to the lower affinity attachment of LPL to heparin sulphate
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proteoglycans. Currently, the functional and structural distinction between these two systems re-
quires further elaboration.
2.4 Conclusion
The recent elucidation of ANGPTL3, ANGPTL4 and GPIHBP1 as major modulators of LPL
function has highlighted the complexity of the process of plasma triglyceride clearance. While
ANGPTL3 and ANGPTL4 inhibit LPL, either reversibly or irreversibly, GPIHBP1 appears to
function as stabilizer or even anchor of LPL, which may counteract ANGPTL3 and ANGPTL4-
mediated LPL inhibition. Additional research is necessary to better define the intricacies of the
interaction between LPL, ANGPTLs, and GPIHBP1. Furthermore, more work is required to bet-
ter establish the overall role of ANGPTLs and GPIHBP1 in the physiological regulation of fuel
selection as well as its impact on cellular metabolism. Overall, the discovery and functional char-
acterization of ANGPTL3, ANGPTL4 and GPIHBP1 has greatly improved our understanding of
the regulation of LPL function.
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Chapter 3
Angptl4
up-regulates cholesterol synthesis in liver via inhibition of
LPL- and HL-dependent hepatic cholesterol uptake
Abstract
Dysregulation of plasma lipoprotein levels may increase the risk for atherosclerosis. Recently, Angiopoietin-
like proteins 3 and 4 were uncovered as novel modulators of plasma lipoprotein metabolism. Here we take
advantage of the fasting-dependent phenotype of Angptl4-transgenic (Angptl4-Tg) mice to better charac-
terize the metabolic function of Angptl4. In 24h fasted mice, Angptl4 over-expression caused a 24-fold
increase in plasma triglycerides (TG), which was attributable to elevated VLDL-, IDL/LDL- and HDL-
TG content. Angptl4 over-expression decreased post-heparin LPL activity by stimulating conversion of
endothelial-bound LPL dimers to circulating LPL monomers. In fasted but not fed state, Angptl4 over-
expression severely impaired LPL-dependent plasma TG and cholesteryl ester clearance and subsequent
uptake of fatty acids and cholesterol into tissues. Consequently, hepatic cholesterol content was signifi-
cantly decreased, leading to universal up-regulation of cholesterol and fatty acid synthesis pathways. The
hypertriglyceridemic effect of Angptl4 is attributable to inhibition of LPL-dependent VLDL lipolysis by
converting LPL dimers to monomers, and Angptl4 up-regulates cholesterol synthesis in liver secondary to
inhibition of LPL- and HL-dependent hepatic cholesterol uptake.
3.1 Introduction
The enzyme lipoprotein lipase (LPL) plays a pivotal role in the regulation of plasma TG levels.
By catalyzing the irreversible hydrolysis of plasma TG, LPL promotes the clearance of TG-rich
lipoproteins from plasma. Synthesized mainly by adipocytes and (cardio)myocytes, LPL pro-
tein is translocated to luminal endothelial cell surfaces where it is attached via heparan sulphate
proteoglycans (HSPG) (Merkel et al. 2002). Since LPL is rate-limiting for the clearance of TG-
rich lipoproteins, the activity of LPL is carefully regulated via numerous mechanisms. At the
level of gene transcription, LPL is upregulated by the transcription factors peroxisome prolifer-
ators activated receptor (PPAR)γ in adipose tissue and by liver X receptor (LXR)α and PPARα
in liver (Schoonjans et al. 1996). In accordance with the fat storage function of adipose tissue as
the major fat storage organ, expression of LPL in adipose tissue peaks in the postprandial state,
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whereas in skeletal muscle expression of LPL is highest in the post-absorptive state (Olivecrona
et al. 1995). LPL is also extensively regulated at the level of enzyme activity. Indeed, several mod-
ulators of LPL activity are known, including Apoc3, Apoc2, Apoc1, and Apoa5, all of which are
apolipoproteins associated with specific lipoproteins (Berbe´e et al. 2005, van Dijk et al. 2004, Jong
et al. 1999). In addition to apolipoproteins, recently it became evident that two proteins belonging
to the family of angiopoietin-like proteins (Angptls), Angptl3 and Angptl4, can modulate LPL
activity (Kersten 2005). In contrast to Angptl4, Angptl3 is produced exclusively in liver and is
a target of LXR. It was shown that a mutation in the gene for Angptl3 is responsible for the low
plasma TG of KK/Snk mice, a mutant strain of KK obese mice (Koishi et al. 2002). The stimula-
tory effect of Angptl3 on fasting plasma TG can be attributed to suppression of VLDL clearance
via LPL inhibition (Shimizugawa et al. 2002). Angptl4, also known as fasting-induced adipose
factor Fiaf, was discovered by screening for genes responsive to the PPARα and γ, which serve
as the molecular targets for the hypolipidemic fibrate and the insulin sensitizing thiazolidinedione
drugs, respectively (Kersten et al. 2000, Yoon et al. 2000). Angptl4 has a molecular mass of about
50 kDa, is secreted into the blood, and may act in a paracrine and endocrine fashion. In humans,
Angptl4 mRNA expression is highest in liver, followed by adipose tissue, whereas in mice the or-
der is reversed (Zandbergen et al. 2006). The abundance of Angptl4 in blood plasma is increased
by fasting and decreased by high fat diet, suggesting a potential role in lipid metabolism (Kersten
et al. 2000). Evidence linking Angptl4 to regulation of plasma lipoproteins was provided by
the demonstration that injecting mice with recombinant Angptl4 protein significantly increased
plasma TG concentrations, possibly by inhibiting LPL activity (Yoshida et al. 2002). Subsequent
studies using various models of in vivo Angptl4 overexpression or inactivation have confirmed
the stimulatory effect of Angptl4 on plasma TG levels via a mechanism independent of VLDL-
TG secretion (Ge, Yang, Yu, Pourbahrami and Li 2004, Yu et al. 2005, Xu et al. 2005, Koster
et al. 2005, Mandard et al. 2006). The hypertriglyceridemic effect of Angptl4 may be modu-
lated by formation of higher order oligomers as well as by proteolytic processing (Ge, Yang, Yu,
Pourbahrami and Li 2004). Recent in vitro studies suggest that Angptl4 inhibits LPL by promot-
ing the conversion of catalytically active LPL dimers into catalytically inactive LPL monomers,
thereby permanently inactivating LPL (Sukonina et al. 2006). Currently, it is unclear whether
this mechanism of LPL inhibition also occurs in vivo. It has been suggested that in addition to
lipid metabolism, Angptl4 also governs glucose homeostasis. Adenoviral-mediated Angptl4 over-
expression markedly reduced plasma glucose and improved glucose tolerance (Xu et al. 2005).
However, studies with Angptl4 knock-out mice failed to reveal an effect of Angptl4 on glucose
homeostasis (Koster et al. 2005). Thus, the effects of Angptl4 on glucose homeostasis remain am-
biguous. A partial analysis of the phenotype of our Angptl4 transgenic mouse model has been pre-
viously published (Mandard et al. 2006). The transgenic mice were generated using the full-length
mouse genomic Angptl4 sequence which contains the regulatory regions mediating responsiveness
to PPARs. As a result, Angptl4 over-expression is amplified by fasting. Here we take advantage
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of the sensitivity of Angptl4-Tg mice to fasting to better characterize the metabolic function of
Angptl4 and address: (1) the in vivo molecular mechanisms underlying its hypertriglyceridemic
effect, (2) the consequence of LPL-inhibition for hepatic cholesterol metabolism and cholesterol-
dependent hepatic gene regulation, and (3) the effect of Angptl4 on glucose homeostasis.
3.2 Materials and Methods
Animal experiments. The Angptl4-transgenic mice on FVB background have been previously
described (Mandard et al. 2006). Only male mice were used. Animals were kept in standard cages
with food and water ad libitum. Animal were fed normal laboratory chow (RMH-B 2181, Arie
Blok animal feed, Woerden, the Netherlands), containing 23.5% protein, 5% fat, 38.3% starch,
and 4% sugar. Mice in fed state were sacrificed at the beginning of the light cycle. Mice in
fasted state were deprived of food for 24 hours starting at the beginning of the light cycle. At the
time of sacrifice animals were between 2 and 4 months of age. Blood was collected via orbital
puncture into EDTA tubes. After sacrificing the mice by cervical dislocation, tissues were excised
and immediately frozen in liquid nitrogen. All animal experiments were approved by the animal
experimentation committee of Wageningen University.
Plasma metabolites. Blood was collected into paraoxon-coated capillaries to prevent ongoing
in vitro lipolysis. Blood samples were placed on ice and centrifuged at 4◦C for 10 minutes at
10,000 g. The plasma glucose concentration was determined using a kit from Elitech (Sopachem,
Wageningen, Netherlands). Plasma and tissue TG and plasma glycerol concentrations were de-
termined using kits from Instruchemie (Delfzijl, Netherlands). Plasma free fatty acids were de-
termined using a kit from WAKO Chemicals (Sopachem, Wageningen, Netherlands). Plasma
ketones (β-hydroxybutyrate) were determined using Precision Xtra (Abbott laboratories, Bedford,
MA, USA). Plasma lathosterol was determined by capillary gas chromatography. Plasma insulin
was determined using a kit from Linco (St. Charles, MO, USA).
Liver cholesterol. Liver cholesterol content was determined as previously described (Thompson
and Merola 1993). Briefly, a ∼100 mg liver samples was saponified by heating in ethanol-KOH,
and cholesterol was extracted from the saponified solution with hexane. After evaporation of hex-
ane, cholesterol was derivatized to trimethylesters using bis-silyl-tri-fluor-acetamide. Cholesterol
was subsequently quantified by gas chromatography.
Lipoprotein profiling. Plasma lipoproteins of wild-type and Angptl4-Tg mice were separated
using fast protein liquid chromatography (FPLC). 0.2 mL of pooled plasma was injected into a Su-
perose 6B 10/300 column (GE Healthcare Bio-Sciences AB, Roosendaal, Netherlands) and eluted
at a constant flow of 0.5 mL/minute with phosphate buffered saline (pH 7.4). The eﬄuent was
collected in 0.5 mL fractions and TG and cholesterol levels were determined (Instruchemie). Sep-
aration of lipoproteins by gel permeation HPLC was performed as a lipoprotein analysis service
by LipoSEARCH (Tokyo, Japan) using 10µL of pooled plasma.
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Modulated plasma LPL and HL activity assay. 24 hour fasted mice were injected via the tail
vein with heparin (0.1U/g; Leo Pharmaceutical Products B.V., Weesp, Netherlands) and blood was
collected after 10 min. The plasma was snap-frozen and stored at -80◦C until analysis of LPL and
HL activity as previously described (Duivenvoorden et al. 2005).
In vitro LPL activity assay. The effect of recombinant hAngptl4 (residues 26-229, hAngptl4
S2) (Biovendor Laboratory Medicine, Modrice, Czech Republic) on LPL-dependent TG Hydrol-
ysis of [3H]TO-VLDL-like emulsion particles was determined as described (solubilised LPL as-
say)(Berbe´e et al. 2005). A HSPG-bound LPL assay was performed by first coating plates with
HSPG (250ng/well), followed by coating with LPL (0.2U/well). HSPG-bound LPL was subse-
quently pre-incubated with recombinant hAngptl4 for 30 min at 37◦C, washed three times with
100 mM Tris-HCl pH 8.5, followed by addition of [3H]TO-VLDL-like emulsion particles. After
15 minutes incubation, the reaction was terminated and lipids extracted as described (Herrmann et
al. 1995). The amount of [3H]FFA released was measured by scintillation counting and expressed
as a percentage of [3H]FFA released in the absence of Angptl4.
Heparin-Sepharose Chromatography. Heparin-sepharose chromatography was carried out on
a Pharmacia FPLC system. A HiTrap Heparin HP 1 mL column (GE Healthcare Bio-Sciences
AB, Roosendaal, Netherlands) was equilibrated with 0.25M NaCl/20% glycerol/1% BSA/10mM
sodium pH 6.5. Pre- and post-heparin plasma was adjusted to the concentration of the equilibration
buffer before loading. After loading the equivalent of 0.2 ml mouse blood plasma, the column
was washed (10ml), followed by elution with a linear gradient of NaCl (from 0.25 to 1.5 M)
in equilibration buffer at a flow rate of 0.5 ml/minute. BSA was omitted when fractions were
intended for analysis by western blot. Murine LPL in fractions was measured by enzyme-linked
immunosorbent assay (van Vlijmen et al. 1999).
Isolation of total RNA and Q-PCR. Extraction of RNA, cDNA synthesis and quantitative PCR
were carried out as previously described (Mandard et al. 2006).
Western blot. Fractions collected of the HiTrap HP-column or Superose 6B column were
separated by SDS-PAGE and transferred to Immobilon-P membrane (Millipore, Bedford, MA,
USA). Western blotting was carried out as described previously (Kersten et al. 2000, Mandard et
al. 2004). The primary antibody (anti-mouse LPL CA1787, Cell Applications Inc., San Diego,
CA, USA) was used at a dilution of 1:500, and the secondary antibody (HRP-labelled anti-rabbit
IgG, Sigma) was used at a dilution of 1:4000. All incubations were performed in Tris-buffered
saline, pH 7.5, with 0.1% Tween-20 and 5% dry milk, except for the final washing when dry milk
was omitted.
Preparation of VLDL-like Emulsion Particles. TG-rich VLDL-like emulsion particles (80 nm)
were prepared as described (Rensen et al. 1997). Radiolabeled emulsions were obtained by adding
200 µCi of glycerol tri[3H]oleate (triolein, TO) and 20 µCi of [14C]cholesteryl oleate (CO) to 100
mg of emulsion lipids before sonication.
In Vivo Clearance of VLDL-Like Emulsion Particles. Mice were anesthetized with hypnorm
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(fentanyl)/midazolam and injected with the radiolabeled emulsion particles (1.0 mg TG in 200 µl
PBS) at 8:00 a.m. into the tail vein. At indicated time points after injection, blood was taken
from the tail vein, to determine the serum decay of [3H]TO and [14C]CO by scintillation counting
(Packard Instruments, Dowers Grove, IL, USA). At 30 min after injection, mice were sacrified
by cervical dislocation and tissues were collected. Tissues were weighed and dissolved overnight
in Solvable (Packard Bioscience, Meriden, CT, USA), followed by measurement of 3H- and 14C-
activities in Ultima Gold (Packard Bioscience). The total plasma volumes of the mice were cal-
culated from the equation V (ml) = 0.04706 x body weight (g), as determined from 125I-BSA
clearance studies as previously described (Jong et al. 1999).
Microarray. RNA was prepared from livers of 24h fasted wild-type and Angptl4-Tg mice
using Trizol and subsequently pooled per group (n=7). Pooled RNA was further purified using
Qiagen RNeasy columns and the quality verified by lab on a chip analysis (Bioanalyzer 2100,
Agilent, Amsterdam, Netherlands). 10 µg of RNA was used for one cycle of cRNA synthesis
(Affymetrix, Santa Clara, USA). Hybridization, washing and scanning of Affymetrix Genechip
mouse genome 430 2.0 arrays was according to standard Affymetrix protocols. Fluorimetric data
were processed by Affymetrix GeneChip Operating software and the gene chips were globally
scaled to all the probe sets with an identical target intensity value usingMAS5.0 algorithm. Further
analysis was performed by Data Mining Tool (Affymetrix). Only probe sets labeled present in both
wild-type and Angptl4-Tg mice were considered.
Hyperinsulinemic euglycemic clamp analysis. Wild-type and Angptl4-Tg mice were fasted for
24 hours prior to the clamp studies. The hyperinsulinemic euglycemic clamp and assays for blood
glucose and plasma insulin were carried out as previously described (Voshol et al. 2003).
3.3 Results
The Angptl4 transgenic (Angptl4-Tg) mice used in this manuscript have been previously de-
scribed (Mandard et al. 2006). While in the fed state Angptl4-Tg mice show only mildly increased
Angptl4 expression in skeletal muscle, heart, white adipose tissue (WAT) and brown adipose tis-
sue (BAT), in the 24h fasted state dramatic Angptl4 over-expression is observed in all tissues
examined, including liver (Figure 3.1).
To examine the effect of Angptl4 over-expression on lipid metabolism, several plasma param-
eters were determined. While Angptl4 over-expression increased plasma levels of FFA, glycerol,
and TG already in the fed state, the increase was much more pronounced in the 24h fasted state
(Figure 3.2). During the course of fasting plasma TG levels gradually decreased in WT mice,
whereas plasma TG showed a marked increase in the Angptl4-Tg mice, leading to an almost
24-fold difference after 24h of fasting (Figure 3.3a). The severe hypertriglyceridemia in fasted
Angptl4-Tg was mainly because of dramatically elevated plasma VLDL levels, as determined by
FPLC, although IDL/LDL levels were also increased to some extent (Figure 3.3b).
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Figure 3.1: Marked over-expression of Angptl4 mRNA in 24h fasted Angptl4- Tg mice. Angptl4 mRNA expression in
liver, heart, white adipose tissue (WAT), skeletal muscle, and brown adipose tissue (BAT) of fed and 24h fasted WT
(grey bars) and Angptl4- Tg (black bars) mice. Errors bars represent SEM. n=5-10 mice/group. Statistical significance
according to Students t test. ∗∗, p<0.01; ∗ ∗ ∗, p<0.001.
FFA Glycerol Ketones TG
(mM) (mM) (mM) (mM)
Fed
Wild-type 0.40±0.02 0.24±0.01 n.d. 1.79±0.15
Angptl4-Tg 0.57±0.05** 0.33±0.04* n.d. 3.36±0.64**
Fast 24h
Wild-type 0.58±0.04 0.31±0.02 1.20±0.07 0.74±0.07
Angptl4-Tg 1.32±0.09** 0.99±0.09** 1.38±0.06* 17.58±2.22**
Figure 3.2: Plasma parameters. FFA, glycerol, ketones bodies and TG concentrations were determined in EDTA
plasma of fed and 24h fasted WT and Angptl4-Tg mice. Values are mean±SEM. n=7-10 mice/group. Statistical signifi-
cance according to Students t test. *, p<0.05; **, p<0.01.
No difference in HDL-cholesterol levels was observed (Figure 3.3b). Detailed lipoprotein
profiling was performed by gel permeation HPLC, which allows for better separation between
the lipoprotein classes (Figure 3.4). In addition to VLDL, other lipoprotein fractions were also
markedly enriched in TG. Amazingly, chylomicrons were still detected in plasma of 24h fasted
Angptl4-Tg mice (Figure 3.4), which was visualized as a distinct peak in front of the VLDL
peak (data not shown). Previously, it was shown that Angptl4 inhibits the activity of LPL in
vitro (Yoshida et al. 2002). Using an endogenous LPL activity assay, a dramatic 90% reduc-
tion in post-heparin plasma LPL activity was observed in 24h fasted Angptl4-Tg compared with
WT mice. Similarly, activity of hepatic lipase (HL) was about 50% reduced (Figure 3.5a). In
contrast, mRNA levels of LPL in adipose tissue and of HL in liver were significantly increased
in Angplt4-Tg mice, likely reflecting a mechanism that attempts to compensate for the decrease
in enzyme activity (Figure 3.5b). Recent in vitro data suggest that Angptl4 inactivates LPL by
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Figure 3.3: Severe hypertriglyceridemia in Angptl4-Tg mice. (A), Time course of plasma TG during 24-hour fasting in
WT mice(gray squares, n=7) and Angptl4-Tg mice (black squares, n=10). Error bars reflect SEM. (B), Pooled plasma of
24-hour fasted WT mice (gray squares, n=7) and Angptl4-Tg mice (black squares, n=10) was analyzed for lipoprotein
profiles by FPLC. Elution of molecular weight markers is indicated.
Total
Cholesterol
CM
Cholesterol
VLDL
Cholesterol
IDL/LDL
Cholesterol
HDL
Cholesterol
Total
Triglyceride
CM
Triglyceride
VLDL
Triglyceride
IDL/LDL
Triglyceride
HDL
Triglyceride
Free
Glycerol
Wild-type 3.91 0.00 0.15 0.42 3.33 0.61 0.00 0.36 0.22 0.04 0.28
Angptl4-Tg 5.91 0.23 1.69 0.81 3.19 12.57 1.61 9.09 1.40 0.46 0.82
Figure 3.4: Lipoprotein cholesterol and TG content. Pooled plasma of 24h fasted wild-type and Angptl4-Tg mice was
separated by gel permeation HPLC using lipoprotein analysis service by LipoSEARCH. CM, chylomicron. Concentra-
tions are expressed in mM. n=7-10 mice/group.
promoting the conversion of catalytically active LPL dimers into inactive monomers (Sukonina
et al. 2006). This type of mechanism is expected to cause permanent inactivation of LPL. To ver-
ify whether this is the case, recombinant hAngptl4 was either pre-incubated with [3H]TO-labeled
VLDL-like emulsion particles, followed by mixing with LPL and measurement of LPL activity,
or alternatively pre-incubated with HSPG-bound LPL and removed by washing before addition
of the VLDL-like particles and measurement of LPL activity. Whereas the first assay revealed
an expected potent inhibition of LPL activity by Angptl4 (Figure 3.5c) (left panel), a similar ef-
fect was observed in the second assay (right panel), suggesting that Angptl4 may permanently
disable LPL. Because LPL monomers have much lower affinity for HSPG than LPL dimers, an
Angptl4-mediated LPL dimer to monomer conversion would be expected to translate into a de-
crease in LPL dimers in Angptl4-Tg mice in post-heparin plasma, and possibly an increase in LPL
monomers in pre-heparin plasma. To visualize LPL monomers and dimers, pre- and post-heparin
plasma from 24h fasted WT and Angptl4-Tg mice was separated by heparin-sepharose affinity
chromatography and fractions assayed for LPL content (Sukonina et al. 2006). Importantly a
marked decrease in LPL dimer content was observed in post-heparin plasma of Angptl4-Tg mice
(Figure 3.5d). No LPL was detected in fractions from pre-heparin plasma by ELISA (detection
limit 0.2 ng/150 µl). However, using a more sensitive Western blot assay LPL protein was detected
in fractions corresponding to LPL monomer in Angptl4-Tg but not WT mice (Figure 3.5e). These
data indicate that Angptl4 over-expression promotes the conversion of HSPG-bound LPL dimers
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into circulating LPL monomers. To investigate whether Angptl4 might physically associate with
circulating LPL monomers, we studied the co-elution of Angptl4 and LPL in pre-heparin plasma
fractions from the heparin-sepharose column and gel filtration FPLC column. It was observed
that Angptl4, present in the truncated form, was present in exactly the same heparin-sepharose
fractions as monomeric LPL (Figure 3.5e). The same observation was made in the FPLC frac-
tions: Angptl4 was present in the fractions corresponding to (large) LDL (Figure 3.5f), which
also harbors monomeric LPL, as previously published (Vilella et al. 1993). These data suggest
that in blood plasma Angptl4 is physically associated with LDL-bound LPL monomers. To exam-
ine whether inhibition of LPL by Angptl4 overexpression resulted in a decrease in LPL-dependent
VLDL-TG lipolysis, the decay of protein-free VLDL-like emulsion particles labeled with glycerol
tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) was monitored in fed and 24-hour
fasted WT and Angptl4-Tg mice. In the fed state, no difference in the clearance of [3H]TO was
observed between the two genotypes (Figure 3.6a)(serum half life 27±4.5 min vs. 32.2±5.2 min,
respectively). In contrast, in the 24-hour fasted state, clearance of [3H]TO was much lower in
Angptl4-Tg mice, as evidenced by an almost 8-fold increase in serum half-life (102±9.3 min vs.
13.8±2.6 min, respectively; p< 0.01). In fact, whereas in WT mice fasting accelerated [3H]TO
clearance, the opposite was true in Angptl4-Tg mice. This was supported by measurement of
tissue uptake of [3H]TO-derived [3H]oleate, which was markedly reduced in heart, liver, skeletal
muscle and adipose tissues of 24h fasted Angptl4-Tg mice in comparison with WT mice (Figure
3.6c). These data indicate that Angptl4 overexpression strongly inhibited LPL-dependent VLDL-
TG lipolysis. As the VLDL-like emulsion particles also contained [14C]CO, it was possible to
monitor clearance of VLDL-cholesteryl esters. Similar to the situation for [3H]TO, in WT mice
fasting accelerated [14C]CO clearance, whereas clearance was decelerated in Angptl4-Tg mice
(Figure 3.6b)(serum half life 29.5±10.4 min vs. 262±24.5 min, respectively; p<0.01). Tissue
uptake of [14C]CO, which occurs mainly in liver and is secondary to LPL-and HL-mediated con-
version of VLDL to LDL via IDL, was also strongly reduced in Angptl4-Tg mice (Figure 3.6d). To
find out if the decreased hepatic uptake of VLDL [3H]TO and [14C]CO in Angptl4-Tg mice was
paralleled by changes in liver lipids, we measured hepatic cholesterol and TG content. Whereas
in fed state no difference in liver cholesterol was observed between WT and Angptl4-Tg mice,
in the fasted state liver cholesterol was modestly but significantly decreased in Angptl4-Tg mice
(Figure 3.7a). In contrast, hepatic TG content was not changed significantly in Angptl4-Tg (Figure
3.8). In response to the decrease in hepatic cholesterol uptake and content in the fasted Angptl4-
Tg mice, one would expect marked changes in the expression of genes dependent on cholesterol.
To investigate the effect of Angptl4 over-expression on hepatic gene expression, we performed
micro-array analysis. RNA from liver of several animals was pooled and hybridized to Affymetrix
mouse genome 430 2.0 GeneChip arrays. Using a cut-off of 1.4-fold, expression of a total of 103
probe sets was increased in Angptl4-Tg mice compared with WT mice. Of the 103 probe sets, 40
probe sets represented genes directly involved in cholesterol and fatty acid biosynthesis, including
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Figure 3.5: Angptl4 inhibits lipoprotein lipase activity by promoting formation of LPL monomers. (A), Endogenous
post-heparin plasma HL and LPL activity in 24-hour fasted mice (n=8 per group). (B), mRNA expression of HL and
LPL in liver and WAT, respectively. Errors bars represent SEM. n=7 to 10 mice per group. Statistical significance
according to Student t test. *P<0.05; **P<0.01; ***P<0.001. (C), Left panel: Effect of Angptl4 on LPL activity
in solubilized LPL assay. Amount of [3H]FFA released at increasing concentrations of hAngptl4 is expressed as a
percentage of control treatment. Right panel: Effect of Angptl4 on LPL activity in HSPG-bound LPL assay. (D), Post-
heparin plasma from 24-hour fasted WT and Angptl4-Tg mice was applied to a heparin sepharose column and eluted
with a NaCl gradient in the presence of BSA. Fractions were analyzed for LPL by ELISA. (E), Pre-heparin plasma from
24-hour fasted WT and Angptl4-Tg mice was applied to a heparin sepharose column and eluted with a NaCl gradient in
the absence of BSA. Fractions were analyzed for LPL and Angptl4 by Western blot. Upper panel: NaCl concentration
in fractions. (F), Pooled plasma of 24-hour fasted WT mice was fractionated by FPLC. Fractions corresponding to
VLDL, LDL, and HDL were analyzed for LPL or Angplt4 protein by Western blot. Molecular weight markers (in kDa)
are shown.
3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) synthase 1, HMG-CoA reductase, and
Isopentenyl diphosphate isomerase (Figure 3.9). Up-regulation of these genes in Angptl4-Tg mice
was verified by qPCR (Figure 3.7b) and (Figure 3.10). The increased expression of cholesterol
biosynthetic enzymes at the mRNA level was supported by an increase in plasma lathosterol to
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Figure 3.6: Serum decay and tissue uptake of radiolabeled VLDL-like emulsion particles. VLDL-like particles labeled
with glycerol tri[3H]oleate and [14C]cholesteryl oleate were injected into anesthetized mice. Serum samples were col-
lected at indicated times and measured for 3H-activity (A) and 14C-activity (B). After 30 minutes, mice were euthanized
and tissues collected for measurement of 3H-activity (C) and for 14C-activity (D) (bottom). Errors bars represent SEM.
n=4 to 6 mice per group. Differences between WT and Angptl4-Tg mice were evaluated by MannWhitney test. *P<0.05;
**P<0.01.
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Figure 3.7: Upregulation of hepatic cholesterol synthesis in Angptl4-Tg mice. (A), Hepatic cholesterol concentration.
(B), mRNA expression of 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1. (C), Plasma lathosterol to cholesterol
ratio. Errors bars represent SEM. n=7 to 16 mice per group. Statistical significance according to Student t test.
*P<0.05; **P<0.01; ***P<0.001.
cholesterol ratio, which serves as a marker for cholesterol biosynthesis rate (Figure 3.7c). To-
gether, these data indicate that in the 24-hour fasted state Angptl4 overexpression causes a marked
reduction in hepatic cholesterol uptake, leading to a decrease in hepatic cholesterol content and
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Figure 3.8: No significant change in hepatic triglycerides in Angptl4-Tg mice. Hepatic triglyceride concentration in
fed and 24h fasted WT and Angptl4-Tg mice. Similar results were obtained by Oil red O staining of liver sections.
subsequent upregulation of cholesterol biosynthesis. Besides major changes in lipid metabolism,
Angptl4 over-expression also caused alterations at the level of glucose metabolism. While in the
fed state no difference in plasma glucose was observed between WT and Angptl4-Tg mice, in
the 24-hour fasted state Angptl4-Tg mice exhibited a modest yet significant increase in plasma
glucose (Figure 3.11a). In contrast, no difference in plasma insulin was observed between the
two sets of mice in either fed or fasted state (Figure 3.11b). These data suggest that Angptl4-
Tg mice may be mildly insulin resistant. To investigate whether this is the case, we performed
a hyperinsulinemic-euglycemic clamp in 24-hour fasted mice. Under basal conditions, glucose
metabolism was not different between the two sets of mice. However, under hyperinsulinemic con-
ditions glucose utilization was significantly decreased in Angptl4-Tg mice compared to WT mice
(Figure 3.11c). Indeed, whereas in WT mice glucose utilization increased by 125% after insulin
infusion, in Angptl4-Tg mice glucose utilization only went up 59% (Figure 3.11d). Interestingly,
endogenous glucose production was not affected by insulin infusion in WT mice, characteristics
of the highly insulin-resistant FVB strain, yet was clearly inhibited by insulin in Angptl4-Tg mice
(Figure 3.11e&f). These data suggest that Angptl4-Tg mice are insulin-resistant in the periphery,
but more insulin-sensitive at the hepatic level.
3.4 Discussion
In the present paper we took advantage of the sensitivity of our Angptl4 overexpression model to
fasting in order to better characterize the metabolic role of Angptl4. The most dramatic metabolic
abnormality in Angptl4-Tg mice is the fasting-dependent elevation of plasma TG levels. The
severe hypertriglyceridemia, with plasma TG levels reaching 20 mmol/L after 24 hours of fast-
ing, can be attributed to marked inhibition of LPL-dependent VLDL and chylomicron lipolysis.
Accordingly, we provide the definitive in vivo evidence that the hypertriglyceridemic effect of
Angptl4 observed in several studies is due to impaired clearance of plasma TG via inhibition of
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Angptl4
fold- gene gene
Affy ID change name title
1433446_at 2.41 Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
1422973_a_at 2.33 Thrsp thyroid hormone responsive SPOT14 homolog (Rattus)
1424737_at 2.30 Thrsp thyroid hormone responsive SPOT14 homolog (Rattus)
1423804_a_at 2.25 Idi1 isopentenyl-diphosphate delta isomerase
1423418_at 2.20 Fdps farnesyl diphosphate synthetase
1433445_x_at 2.14 Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
1451122_at 2.13 Idi1 isopentenyl-diphosphate delta isomerase
1416222_at 2.13 Nsdhl NAD(P) dependent steroid dehydrogenase-like
1433444_at 2.04 Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
1415993_at 2.04 Sqle squalene epoxidase
1433443_a_at 2.00 Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
1421262_at 1.95 Lipg lipase, endothelial
1423078_a_at 1.89 Sc4mol sterol-C4-methyl oxidase-like
1437453_s_at 1.85 Pcsk9 proprotein convertase subtilisin/kexin type 9
1459497_at 1.80 Fdft1 Farnesyl diphosphate farnesyl transferase 1
1426913_at 1.77 Lss lanosterol synthase
1450883_a_at 1.75 Cd36 CD36 antigen
1427229_at 1.69 Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
1448130_at 1.69 Fdft1 farnesyl diphosphate farnesyl transferase 1
1416022_at 1.68 Fabp5 fatty acid binding protein 5, epidermal
1448663_s_at 1.65 Mvd mevalonate (diphospho) decarboxylase
1438322_x_at 1.56 Fdft1 farnesyl diphosphate farnesyl transferase 1
1418052_at 1.56 Mvk mevalonate kinase
1434520_at 1.55 Sc5d sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog
1454671_at 1.53 Insig1 insulin induced gene 1
1439459_x_at 1.52 Acly ATP citrate lyase
1416021_a_at 1.49 Fabp5 fatty acid binding protein 5, epidermal
1451457_at 1.49 Sc5d sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog
1435630_s_at 1.48 Acat2 acetyl-Coenzyme A acetyltransferase 2
1449854_at 1.47 Nr0b2 nuclear receptor subfamily 0, group B, member 2 (SHP)
1455011_at 1.45 Stard4 StAR-related lipid transfer (START) domain containing 4
1427893_a_at 1.45 Pmvk phosphomevalonate kinase
1450188_s_at 1.45 Lipg lipase, endothelial
1448619_at 1.43 Dhcr7 7-dehydrocholesterol reductase
1423166_at 1.42 Cd36 CD36 antigen
1451263_a_at 1.41 Fabp4 fatty acid binding protein 4, adipocyte
1421821_at 1.40 Ldlr Low density lipoprotein receptor
1417303_at 1.40 Mvd mevalonate (diphospho) decarboxylase
1426690_a_at 1.40 Srebf1 sterol regulatory element binding factor 1
1429239_a_at 1.40 Stard4 StAR-related lipid transfer (START) domain containing 4
Figure 3.9: Upregulation of genes involved in hepatic cholesterol synthesis in Angptl4-Tg mice. Microarray analysis
was performed on pooled livers (n=7) of 24h fasted WT and Angptl4-Tg mice. The threshold for fold-induction was set
at 1.4. Approximately 40% of the probe sets upregulated in Angptl4-Tg mice represented genes involved in cholesterol
synthesis or lipogenesis.
LPL-dependent lipolysis of TG-rich lipoproteins. The inhibition of LPL activity by Angptl4 was
linked to conversion of endothelial-bound catalytically active LPL dimers into circulating catalyt-
ically inactive LPL monomers, as previously demonstrated in vitro (Sukonina et al. 2006). One
major consequence of inhibition of LPL- and HL-dependent VLDL lipolysis in Angptl4-Tg mice
is a reduced formation of LDL, leading to a marked decreased in cholesterol uptake in liver and
subsequent decrease in hepatic cholesterol content. The decrease in hepatic cholesterol led to up-
regulation of almost every single gene that is part of the cholesterol synthesis pathway. In fact,
close to 40% of the genes identified by micro-array as being upregulated in livers of Angptl4-Tg
mice were involved in either fatty acid or cholesterol synthesis. Thus, by inhibiting LPL and HL,
Angptl4 has a major impact on cellular cholesterol-uptake and consequently cholesterol-dependent
gene regulation. The changes in gene expression are translated into a functional change in the rate
of cholesterol synthesis, as shown by elevated plasma lathosterol to cholesterol ratio. We sus-
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Figure 3.10: Upregulation of genes involved in hepatic cholesterol synthesis in Angptl4-Tg mice. mRNA expression of
two genes involved in cholesterol synthesis was measured by real-time quantitative PCR. Errors bars represent SEM.
n=7-10 mice/group. Statistical significance according to Students t test. ***, p<0.001.
pect that Angptl4 over-expression may similarly suppress fatty acid-dependent gene regulation,
especially in tissues that rely heavily on LPL for fatty acid uptake. Fatty acid-dependent gene
regulation is mainly mediated by PPARs. Previous studies have indicated that LPL can act on
circulating lipoproteins to generate endogenous PPARα ligands, thus providing a potentially im-
portant link between lipoprotein metabolism and transcriptional effects of PPARα (Ziouzenkova
et al. 2003). Indeed, it was shown that cardiac-specific knock-out of lipoprotein lipase resulted
in decreased expression of several PPARα target genes (Augustus et al. 2004). Future studies
will have to clarify whether Angptl4 over-expression has any influence on fatty acid and PPARα-
dependent gene regulation in tissues that express LPL. Recently, it was shown that the N-terminal
domain of Angptl4 (residues 1 to 187) is able to dissociate catalytically active LPL dimers into
catalytically inactive LPL monomers in vitro, suggesting a novel mechanism for regulating LPL
activity (Sukonina et al. 2006). Our data indicate that overexpression of Angptl4 in mice leads
to conversion of endothelial-bound LPL dimers into circulating LPL monomers. Consequently,
in Angptl4-Tg mice less LPL dimers are released into the circulation upon heparin injection, pro-
viding an explanation for the marked decrease in post-heparin LPL activity. Interestingly, the
relative decrease in post-heparin LPL activity exceeded the relative decrease in heparin-releasable
LPL dimers, suggesting that Angptl4 may inhibit LPL activity via an additional mechanism. An
Angptl4-mediated LPL dimer to monomer conversion was supported by the presence of LPL
monomers in pre-heparin plasma of Angptl4-Tg mice but not WT mice. However, the low con-
centration of LPL monomers suggests that they are rapidly cleared from the circulation. Our data
also suggest that in blood plasma Angptl4 is physically associated with LPL monomers, which
in turn are bound to LDL. It can be hypothesized that by binding LPL monomers, Angptl4 pulls
the equilibrium between LPL dimers and monomers towards monomers, which effectively results
in an inhibition of LPL activity. This model conflicts with the mechanism proposed by Sukonina
et al. based on experiments carried out in vitro (Sukonina et al. 2006). More research is neces-
sary to elucidate the precise mechanism by which Angptl4 promotes conversion of LPL dimers
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Figure 3.11: Peripheral insulin resistance in fasted Angptl4-Tg mice. Plasma glucose (A) and insulin (B) levels in fed
and 24-hour fasted WT and Angptl4-Tg mice. n=7 to 10 mice per group. A hyperinsulinemic euglycemic clamp was
carried out in 24-hour fasted WT and Angptl4-Tg mice. (C), Whole body glucose use under basal and hyperinsulinemic
conditions. (D), Percentage induction of glucose use by insulin. (E), Endogenous glucose production (EGP) under
basal and hyperinsulinemic conditions. (F), Percentage inhibition of EGP by insulin. Errors bars represent SEM. n=3
to 6 mice per group. Statistical significance according to Student t test. *P<0.05; **P<0.01.
to monomers in vivo. In addition to inhibition of LPL activity, we also observed that Angptl4
overexpression resulted in a significant decrease in post-heparin plasma HL activity, although the
effect was less pronounced compared to LPL. Inhibition of HL may contribute to the elevated
levels of IDL/LDL, especially the increase in IDL/LDL-TG content, and likely contributes to the
observed decrease in hepatic cholesterol uptake. The latter result could also be linked to increased
IDL/LDL-particle size, which has been shown to lead to reduced hepatic uptake via a mechanism
independent of the LDL receptor (Rensen et al. 1997). In line with the role of HL in converting
HDL2 to HDL3, inhibition of HL may contribute to the elevated HDL-TG content in Angptl4-Tg
mice. Similar to LPL, HL is functionally active as a dimer (Hill et al. 1996, Berryman et al. 1998).
Accordingly, it is possible that inhibition of HL activity by Angplt4 is accounted for by conver-
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sion of HL dimers to monomers. In contrast to our observations, Koster et al did not observe any
change in post-heparin plasma HL activity in mice with liver-specific Angptl4 overexpression or
in Angptl4 KO mice (Koster et al. 2005). The reason for this discrepancy is not clear but may be
related to differences in the sensitivity of the HL activity assay employed or to differences in the
magnitude of Angptl4 overexpression. In contrast to HDL-TG, HDL-Chol levels were identical
between the two sets of mice. Although LPL activity and HDL-Chol levels are positively corre-
lated in humans, no link between LPL activity and HDL-Chol levels has been observed in mice
overexpressing LPL or in LPL null mice, which is probably explained by the absence of CETP
activity in mice (Clee et al. 1997). Recently, it was reported that Angptl3, which is structurally and
functionally highly related to Angptl4, inhibits activity of endothelial lipase, an important deter-
minant of HDL-Chol levels (Shimamura et al. 2007). Mice lacking Angptl3 showed a decrease in
plasma HDL-Chol and HDL phospholipid, coupled with increased phospholipase activity in post-
heparin plasma. Furthermore, Angptl3 inhibited the phospholipase activity of endothelial lipase in
vitro. Whether Angptl4 may inhibit EL as well remains to be investigated. Whereas the impact of
Angptl4 on plasma lipoprotein metabolism is well established, much less is known about the role
of Angptl4 in glucose homeostasis. Recently it was reported that adenoviral-mediated overexpres-
sion of Angptl4 causes an abrupt and dramatic decrease in plasma glucose coupled to a marked
improvement in glucose tolerance (Xu et al. 2005). In contrast to the hypertriglyceridemia elicited
by Angptl4 overexpression, which was transient, the hypoglycemia was persistent up to two weeks
after virus injection, when plasma levels of Angptl4 had almost returned to normal. Infection of
primary hepatocytes with Angptl4 adenovirus significantly decreased secretion of glucose into the
medium, suggesting that Angptl4 may lower plasma glucose by decreasing hepatic glucose output.
In partial support of this notion, we find decreased endogenous glucose production in Angptl4-Tg
mice under hyperinsulinemic conditions, whereas no change was found under basal conditions.
At the same time, Angptl4 overexpression was associated with a decrease in insulin-mediated glu-
cose disposal, suggesting peripheral insulin resistance. Under conditions of prolonged fasting,
the effect of Angptl4 on insulin resistance seems to dominate as plasma glucose was modestly
increased in Angptl4-Tg mice compared to wild-type mice, while plasma insulin levels remained
unaltered. The decreased peripheral insulin sensitivity in Angptl4-Tg mice may be related to el-
evated plasma FFAs, which are known to induce insulin resistance (Kahn et al. 2006), although
a direct effect of Angptl4 protein on insulin signaling cannot be excluded. In mice, the over-
all impact of Angptl4 on plasma glucose levels appears to be limited, and may only be evident
at higher plasma Angptl4 concentrations since inactivation of the Angptl4 did not result in any
change in plasma glucose (Koster et al. 2005). However, this observation does not exclude an
effect of Angptl4 inactivation on glucose fluxes. It was reported that in humans, levels of Angptl4
in blood plasma of obese diabetics appear to be significantly decreased in comparison with obese
non-diabetics (Xu et al. 2005). Although these data still have to be verified, they suggest that in
humans Angptl4 might serve as a marker for insulin sensitivity. Whereas the effects of Angptl4
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on lipoprotein metabolism in mice are supported by numerous studies, much less is known about
the role of Angptl4 in humans. Recently, it was shown that a variant of the human Angptl4 gene
(E40K), which is present in approximately 3% of European Americans, was associated with sig-
nificantly lower plasma TG levels and higher HDL chol levels (Romeo et al. 2007). These data
suggest that, at least with respect to plasma TG, the effect of Angptl4 is similar between mice and
humans. The picture is a little bit more complicated for HDL chol. Previously, we found a positive
correlation between plasma Angptl4 concentration, assessed semi-quantitatively by immunoblot,
and HDL chol levels (Mandard et al. 2004). In the present study, no change in plasma HDL-Chol
level was observed in Angptl4-Tg mice, despite a >20-fold increase in plasma TG. Thus, the link
between Angptl4 and HDL, and the impact of Angptl4 on effectors of plasma HDL levels, de-
serve further study. In conclusion, we show that (1) the hypertriglyceridemic effect of Angptl4
is attributable to inhibition of LPL-dependent VLDL lipolysis by converting endothelial-bound
LPL dimers to circulating LPL monomers, (2) Angptl4 up-regulates cholesterol synthesis in liver
via inhibition of LPL- and HL-dependent hepatic cholesterol uptake, (3) Angptl4 overexpression
increases insulin sensitivity in liver but decreases insulin sensitivity in the periphery.
Adapted from: S. Kersten, L. Lichtenstein, E. Steenbergen, K. Mudde, H.F.J. Hendricks, M.K. Hesselink, P.
Schrauwen and M. Mu¨ller – “Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via
elevated free fatty acids,” ATVB 2009 Jun;29(6): 969-74
Chapter 4
Caloric restriction and exercise increase plasma
ANGPTL4 levels in humans via elevated free fatty acids
Abstract
Plasma lipoprotein levels are determined by the balance between lipoprotein production and clearance.
Recently, Angiopoietin-like protein 4 was uncovered as a novel endocrine factor that potently raises plasma
triglyceride levels by inhibiting triglyceride clearance. However, very little is known about ANGPTL4
in human.Here we set out to identify physiological determinants of plasma ANGPTL4 levels in humans,
focusing on the effect of energy restriction and plasma FFAs. We developed an ELISA for quantitative
measurement of ANGPTL4 in human plasma. Using this assay we found major variations in baseline
plasma ANGPTL4 levels between individuals. Within an individual, plasma ANGPTL4 levels remain stable
throughout the day but increase significantly in response to long term fasting, chronic caloric restriction,
and endurance exercise. Intralipid injection as well as treatment with a β-adrenergic agonist, both of which
lead to elevated plasma FFA levels, increased plasma ANGPTL4 levels compared to control treatment. Fatty
acids markedly induced ANGPTL4 gene expression in rat hepatoma FAO cells, human primary myocytes,
and mouse intestinal MSIE cells. In conclusion, our results show that plasma ANGPTL4 levels are increased
by fasting, caloric restriction, and exercise, which is likely mediated by elevated plasma FFAs.
4.1 Introduction
Changes in plasma lipoproteins are known to affect atherosclerosis and associated coronary heart
disease (CHD). Indeed, it is well established that elevated plasma low-density lipoprotein (LDL)
concentrations increase the risk for CHD, whereas elevated high-density lipoprotein (HDL) con-
centrations are considered atheroprotective. Plasma lipoprotein levels are determined by the bal-
ance between lipoprotein production and clearance. Recently, Angiopoietin-like protein 4 was
uncovered as a novel endocrine factor that impact plasma lipoprotein levels. ANGPTL4, which is
also referred to as fasting induced adipose factor Fiaf, is a secreted protein of about 50 kDa that
belongs to the family of Angiopoietin-like proteins (Kim et al. 2000). ANGPTL4 was discovered
by screening for target genes of the peroxisome proliferators activated receptors alpha and gamma,
which serve as the molecular targets of the hypolipidemic fibrate and the insulin sensitizing thi-
azolidinedione drugs, respectively (Kersten et al. 2000, Yoon et al. 2000). In mice, ANGPTL4
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is produced by a number of tissues including adipose tissue, liver, skeletal muscle, heart, skin
and intestine. Evidence abounds that ANGPTL4 plays a major role in the regulation of lipid
metabolism (Kersten 2005). ANGPTL4 inhibits the enzyme lipoprotein lipase, thereby suppress-
ing clearance of TG-rich lipoproteins and thus raising plasma TG levels (Yoshida et al. 2002). Inhi-
bition of LPL occurs by inducing dissociation of catalytically active LPL dimers into inactive LPL
monomers (Sukonina et al. 2006). Experiments with transgenic mice over-expressing ANGPTL4
suggest that ANGPTL4 inhibits LPL via paracrine and endocrine signaling (Xu et al. 2005, Yu
et al. 2005, Koster et al. 2005, Mandard et al. 2006). Furthermore, ANGPTL4 stimulates adipose
tissue lipolysis, leading to elevation of plasma free fatty acid levels (Yoshida et al. 2002, Mandard
et al. 2006, Lichtenstein et al. 2007). Analogous to numerous other protein hormones, ANGPTL4
is proteolytically processed to produce N-terminal and C-terminal fragments that can be detected
in human serum (Mandard et al. 2004, Ge et al. 2004a). Processing seems to occur in a tissue-
specific manner. Indeed, the liver actively cleaves ANGPTL4, whereas human adipose tissue
shows no proteolytic activity (Mandard et al. 2004). In addition to governing clearance of plasma
lipoproteins, ANGPTL4 has been suggested to play a role in angiogenesis. It has been shown that
ANGPTL4 is a structural and likely regulatory component of the extra-cellular matrix that affects
numerous aspects of endothelial function including angiogenesis, endothelial cell migration, vas-
cular leakage, and cell adhesion (Le Jan et al. 2003, Ito et al. 2003, Cazes et al. 2006, Galaup
et al. 2006, Hermann et al. 2005, Padua et al. 2008). Presently, very limited information is avail-
able about ANGPTL4 in human. It has been shown that carriers of a rare sequence variant of
the ANGPTL4 gene have elevated plasma HDL and decreased TG levels (Romeo et al. 2007).
However, due to the absence of a commercial assay to quantitatively assess ANGPTL4, very little
is known about plasma ANGPTL4 levels in human. Here, we describe the development, vali-
dation and application of a novel ELISA for quantitative determination of ANGPTL4 in human
plasma. We used this newly developed ELISA to identify physiological determinants of plasma
ANGPTL4, focusing on the role of fasting and plasma FFAs
4.2 Materials and Methods
Human interventions Study 1: Blood was taken after an overnight fast from 25 male mildly hy-
perlipidemic subjects before and after a 4-week treatment with 250 mg of micronized fenofibrate
daily. All subjects had significant coronary artery disease as documented by angiography(Patsouris
et al. 2004). Study 2: A fasting blood sample was taken in 36 apparently healthy post-menopausal
women varying in body mass index from 20.7 to 35 kg/m2. (age: 56.5±4.2 years, BMI: 25.4±3.3
kg/m2, fasting glucose: 5.5±0.4 mM). The women participated in a randomised, open label,
placebo-controlled trial that investigated the effects of daily wine or grape juice consumption on
markers of insulin sensitivity. Blood samples were obtained from the antecubital vein of the fore-
arm and collected in EDTA-coated tubes (Joosten et al. 2008). Study 3: Two male and seven fe-
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male subjects between the age of 24-32 yr came to the laboratory in fasted state (BMI: 19.1±26.6,
mean 22.4 kg/m2; fasting glucose: 4.8±0.6 mM). Blood samples were taken via finger prick at
selected time before, after and in between meals. Subjects maintained their normal pattern of ac-
tivities including meal choice. Study 4: Four healthy male volunteers, between 19 and 22 years of
age, were recruited from the Wageningen student population(age:19-22, mean 20.6; BMI: 20.4-
22.6, mean 21.3 kg/m2; fasting glucose: 4.9-5.7, mean 5.2 mM). Volunteers received an identical
meal at 1700, before the start of a 48-h fasting period. At baseline and after 24h and 48 h of fast-
ing, blood was drawn from the antecubital vein of the forearm into EDTA-coated tubes (Bouwens
et al. 2007). Study 5: Participants were overweight men with a mean (± SEM) age of 34.8±1.3 y
and body mass index (in kg/m2) of 28.8±0.5. All 22 subjects reduced their energy intake to 2.1
MJ/d by means of a very-low-energy diet for the duration of 25 days. Fasting blood samples were
obtained from the antecubital vein of the forearm and collected in EDTA-coated tubes (Hukshorn
et al. 2003). Study 6: Seven healthy, untrained male volunteers participated in the study (age:
22.7±0.6 years, BMI: 23.8±1.0 kg/m2, height: 1.79±0.03 m, VO2max: 50.5±2.4 mL/min/kg). Af-
ter an overnight fast, subjects came to the laboratory at 8:00 a.m.. After local anesthesia, a Teflon
cannula was inserted in an antecubital vein for sampling of blood. Subjects rested on a bed, and a
baseline blood sample was taken. Immediately thereafter, subjects ingested 1.4 g/kg bodyweight
glucose or water. Subject exercised at 50% VO2 max for 2 h and then rested for 4 h. Blood was
samples at regular intervals throughout the study. Also, at regular intervals subjects ingested 0.35
g/kg bodyweight glucose or water. All subjects underwent the experimental protocol two times,
once with glucose ingestion and once while fasting (Schrauwen et al. 2002). Study 7: Nine healthy
lean male volunteers participated in the present study (age: 20.1±0.5 years, BMI: 21.7±0.6 kg/m2,
bodyfat: 16.0±1.3%). All subjects underwent two euglycaemic-hyperinsulinaemic clamps with 40
mU/m2/min insulin and variable co-infusion of a 20% glucose solution to reach a blood glucose
level of ∼5 mmol/L with simultaneous infusion of glycerol (73 mL/h) or intralipid (81 mL/h) in
randomised order. Test days were separated by at least 1 week. On both experimental days, sub-
jects arrived at the laboratory at 8.00 h after an overnight fast. Blood was sampled at regular time
points throughout the clamp (Hoeks et al. 2003). Study 8: Nine healthy lean male volunteers par-
ticipated in this study (age: 24.4±1.3 years, BMI: 22.2±0.8 kg/m2, height: 1.79±0.03 m). Upon
arrival at the laboratory after an overnight fast, two Teflon cannulas were inserted into an antecu-
bital vein of each arm. One cannula was used for the infusion of β2-adrenergic agonist and one
cannula for sampling of blood. A first blood sample was taken, followed by a continuous infusion
of 77 ng/min/kg FFM salbutamol maintained for 3 h. In addition, two doses of 250 mg acipimox
or placebo were given orally at -120 min and time 0. Blood samples were taken at regular intervals
throughout the study (Aas et al. 2006). All human interventions were approved by the Medical
Ethics Committee of the institute involved as outlined in the original research publications.
Elisa: 96-well microtiter plates were coated with the anti-hANGPTL4 polyclonal goat IgG
antibody (AF3485, R&D Systems) at 0.16µg/well and incubated overnight at 4◦C. This antibody
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was obtained by immunization of goats with NS0-derived recombinant human Angiopoietin-like
4 (aa 26 - 406). After four washes with 300µL PBS-Tween 0.1%, 300 µL of blocking solution
(PBS containing 1% BSA) was added per well and left for 1 hour at room temperature under
gentle agitation. 100 µL of 20-fold diluted human plasma was applied to each well, followed
by 2 hour incubation at room temperature under gentle agitation. A standard curve of increasing
amounts of recombinant human ANGPTL4 (3485-AN, R&D Systems) was prepared (0.03-0.21
ng/well) and incubated under similar conditions. After four washes, 100 µL of diluted biotinylated
anti-hANGPTL4 polyclonal goat IgG antibody (BAF3485, R&D Systems) was added at 0.02µg
per well, followed by another 2 hour incubation. After four washes, streptavidine-conjugated
horseradish peroxidase was added for 1 h. Subsequent reaction with tetramethyla-benzidine sub-
strate reagent was allowed to proceed for 6 min. The reaction was stopped by addition of 50 µl
of 10% H2SO4 and the absorbance was measured at 450 nm on a MultiSkan Ascent spectropho-
tometer (Thermo Scientific, Breda, the Netherlands). The ELISA assay used is virtually identical
to the DuoSet Elisa hANGPTL4 offered commercially by R&D systems with several minor mod-
ifications. Importantly, absorbance values remain within the linear range of the standard curve,
which does not exceed 2.1 ng/mL.
Cell culture: Partially confluent HepG2 cells were transfected with a GFP control vector
(pEGFP-N2) or the expression vector pcDNA3.1/V5-HisA encoding mAngptl4 or hANGPTL4.
After transfection, cells were incubated in serum-free DMEM. 24 hours posttransfection, medium
and cell lysates were collected and used for ANGPTL4 Elisa assay. Human primary myocytes
were prepared from 3 individuals as previously described (Aas et al. 2006). Rat hepatoma FAO
cells, human primary myocytes, and mouse intestinal MSIE cells were grown in DMEM contain-
ing 10% (vol/vol) fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin. Cells
were incubated with albumin only (control), albumin-bound oleic or linoleic acid (100 µmol/L),
or synthetic PPAR agonists for 24 hours, followed by RNA isolation and qRT-PCR. Wy14643 was
used at a concentration of 5 µmol/L (FAO, MSIE). GW501516 was used at 1 µmol/L (FAO, MSIE)
or 10 µmol/L (primary myocytes), and TTA (Tetradecylthioacetic Acid) was used at 100 µmol/L.
Electrophoresis and Western Blot: 0.25 µL of human plasma was separated by SDS-PAGE and
transferred to immobilon-P membrane. Western blotting was carried out using an ECL system (GE
Healthcare, Diegem, Belgium) according to the manufacturer’s instructions. The primary antibody
was used at a dilution of 1:2500, and the secondary antibody (anti-rabbit IgG, Sigma) was used
at a dilution of 1:8000. All incubations were performed in 1x Tris-buffered saline, pH 7.5, with
0.1% Tween 20 and 5% dry milk, except for the final washings, when milk was omitted. Primary
antibody was the same as used for Elisa or was a human polyclonal antibody directed against the
epitope CQGTEGSTDLPLAPE (Mandard et al. 2004).
Quantitative PCR: cDNA was prepared from FirstChoice Human Total RNA Survey Panel
(Ambion) using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories BV, Veenendaal, The
Netherlands). Real-Time PCR was carried out using platinum Taq polymerase (Invitrogen, Breda,
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Figure 4.1: Expression profile of ANGPTL4 mRNA in human tissues. The FirstChoice Human Total RNA Survey Panel
(Ambion) was reverse transcribed and used for qPCR using primers specific for human ANGPTL4. Expression levels
are expressed relative to liver, which showed the highest expression level (100%).
the Netherlands) and SYBR green using an iCycler PCR machine (Bio-Rad Laboratories BV).
Melt curve analysis was performed to assure a single PCR product was formed. hANGPTL4
cDNAwas amplified using primers: 5’-CACAGCCTGCAGACACAACTC-3’ and 5’-GGAGGCC
AAACTGGCTTTGC-3’; m/rAngptl4 cDNA was amplified using primers: 5’-GTTTGCAGACTC
AGCTCAAGG-3’ and 5’-CCAAGAGGTCTATCTGGCTCTG-3’. ANGPTL4 expression data
were normalized against the housekeeping genes 36B4 (FAO, MSIE) or actin (primary myocytes).
Primer sequences are available upon request.
4.3 Results
To better characterize ANGPTL4 in human, we first determined ANGPTL4 gene expression levels
in a large number of human tissues. In general, ANGPTL4 expression was relatively ubiquitous.
Highest expression levels were found in liver, followed by adipose tissue, thyroid, brain and small
intestine (Figure 4.1).
To better understand the role of ANGPTL4 in human, we developed an ELISA assay to quanti-
tatively assess serum or plasma ANGPTL4 levels in human subjects. A standard curve was gener-
ated using recombinant human ANGPTL4, showing a clear linear relationship between ANGPTL4
concentration and absorbance at 450 nm (Figure 4.2a). As shown by Western blot, the antibody
used in the ELISA detected a single band at 50 kD, corresponding to the molecular weight of
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Figure 4.2: Characteristics of the ANGPTL4 Elisa assay. (A), standard curve showing linear relationship between
concentration of ANGPTL4 protein and absorbance. Plasma samples were diluted 20-50 fold to fall within the linear
range. (B), western blot of human blood plasma using the same antibody as used in the Elisa assay. (C), western blot
of human blood plasma using an antibody directed against a N-terminal epitope of ANGPTL4. Same individuals are
shown as in panel B. (D), concentration of ANGPTL4 in medium and cell lysate of HepG2 cells 24h after transfection
with GFP control vector or expression vector encoding ANGPTL4. (E), plasma ANGPTL4 levels in 25 individuals
before and after 4 weeks of fenofibrate treatment (study1).
full length ANGPTL4 (Figure 4.2b). The same band and an additional band corresponding to
the N-terminal truncated portion of ANGPTL4 were detected using an antibody directed against
a N-terminal peptide-epitope (Figure 4.2c). To test the specificity of the assay, HepG2 cells were
transiently transfected with expression vectors encoding mouse Angptl4, human ANGPTL4 or
EFGP, and cells and medium were harvested 24 hours thereafter. ANGPTL4 was specifically
detected in medium and cell lysate of HepG2 cells transfected with hANGPTL4, indicating the
absence of any cross-reactivity with mAngptl4 (Figure 4.2d). As a final verification, we confirmed
the increase in plasma ANGPTL4 levels in patients after treatment with the PPAR agonist fenofi-
brate (Figure 4.2e), as previously demonstrated by semi-quantitative Western blot (Mandard et al.
2004). We first determined a number of basic characteristics of the hANGPTL4 ELISA assay.
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The intra-assay coefficient of variation (CV) for the assay was determined at 6.8%. The within-
subject intra-day CV, which was determined by measuring plasma ANGPTL4 levels at numerous
time points throughout the day, was slightly higher at 10%, while the within-subject inter-day CV
was similarly low at 14%. In contrast to the low variability within subjects, we found a large
inter-individual variation in plasma ANGPTL4 levels, as shown by a between-subject CV of 78%.
These data indicate that plasma ANGPTL4 levels are relatively constant within an individual, yet
differ markedly between subjects. As plasma ANGPTL4 levels were highly variable between
individuals, we were interested to study the potential relationship with plasma TG, which have
been shown to be impacted by ANGPTL4 overexpression or deletion in mice. Interestingly, in
a samples of 36 middle-aged women (study 2), we did not find any association between plasma
ANGPTL4 and plasma TG levels (data not shown). Similarly, no association was found with BMI
or other plasma metabolic parameters such as insulin, glucose, and adiponectin. In an effort to
ascertain the physiological determinants of plasma ANGPTL4 levels, we first determined the cir-
cadian rhythm of plasma ANGPTL4 in nine subjects that took their meals at specific times. While
normal post-prandial responses in plasma free fatty acids and glucose were observed (Figure 4.3
a&b), plasma ANGPTL4 levels remained remarkably stable (Figure 4.3c). As mentioned above,
however, major variation in plasma ANGPTL4 levels was observed between subjects. To metabol-
ically challenge subjects, 4 young males were fasted for 48 hours (Bouwens et al. 2007). Plasma
ANGPTL4 levels went up in all individuals (Figure 4.4a, mean relative increase: 80%, p<0.01).
Plasma ANGPTL4 also significantly increased in obese patients subjected to 25 days of severe
food deprivation (Figure 4.4b), mean relative increase: 79%, p<0.001) (Hukshorn et al. 2003)
These data indicate that plasma ANGPTL4 levels increase in response to both short term and
long term energy restriction, which are associated with elevated plasma FFA levels (Figure 4.5).
Expression of ANGPTL4 in numerous tissues was highly sensitive to free fatty acids, as shown by
dramatic induction of ANGPTL4 mRNA by the fatty acids oleic acid and linoleic acid in rat FAO
hepatoma cells, primary human myocytes, and mouse intestinal MSIE cells (Figure 4.6). Angptl4
induction was mimicked by synthetic agonists of PPARs, which serve as receptors for fatty acids,
indicating a role for PPARs. These data suggest that the effect of severe energy restriction on
plasma ANGPTL4 may be mediated by elevated plasma FFAs. Another physiological stressor
that increases plasma FFA is endurance exercise. Remarkably, we found that fasting plasma
ANGPTL4 levels further increased during endurance exercise and especially during subsequent
recovery, concurrent with an increase in plasma FFAs (Figure 4.7a) and (Figure 4.8) (Schrauwen
et al. 2002). Importantly, the increase in plasma ANGPTL4 was entirely abolished when subjects
were given oral glucose, which elicits insulin release and thereby suppresses plasma FFA levels.
To further explore the impact of plasma FFA, plasma ANGPTL4 levels were measured in subjects
that underwent a hyperinsulinemic clamp while receiving an infusion of either glycerol (control) or
lipids together with heparin, which causes a massive increase in plasma FFAs (Figure 4.8) (Hoeks
et al. 2006). Whereas plasma ANGPTL4 declined significantly on control treatment, which may
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Figure 4.3: Plasma ANGPTL4 shows little diurnal variation. Blood plasma was sampled from nine subjects before,
after and in-between meals for measurement of FFA (A), glucose (B), and ANGPTL4 (C) (study 3). Dotted lines
represent plasma ANGPTL4 levels of individual subjects. Straight lines represent means of nine subjects. Error bars
represent SD.
reflect a direct effect of insulin or may be due to an insulin-induced suppression of plasma FFAs,
the decrease in plasma ANGPTL4 was significantly diminished after lipid infusion (Figure 4.7b).
Similarly, treatment with the -adrenergic agonist salbutamol, which causes a marked increase in
plasma FFA (Figure 4.8) (Hoeks et al. 2003), significantly raised plasma ANGPTL4 levels. This
response was entirely blunted when subjects were simultaneously given acipimox, a lipolysis in-
hibitor that reduces plasma free fatty acids (Figure 4.7c). These data suggest that plasma FFAs
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Figure 4.4: Plasma ANGPTL4 levels are increased by fasting and caloric restriction. (A) Plasma ANGPTL4 was
measured in four subjects after a meal, and after 24h or 48h of fasting (study 4). (B) ANGPTL4 levels were measured
in overnight fasting plasma from 22 overweight males before and after 25 days of caloric restriction (study 5).
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Figure 4.5: Plasma FFA levels are increased by fasting and caloric restriction. (A) FFA levels were measured in plasma
sampled from four young healthy males right after a meal, and after 24h or 48h of fasting (study 4). (B) FFA levels
were measured in overnight fasting plasma sampled from 22 healthy overweight males (BMI 25-32) before and after
25 days of subsisting on a proteinenriched formula diet that provided 2.1 MJ/d (study 5). Error bars represent SEM. ∗
= significantly different according to Student’s T-test p < 0.05.
increase plasma ANGPTL4 levels.
4.4 Discussion
Very little is known about determinants of plasma ANGPTL4 levels in humans. Our data point
to a large inter-individual variation in plasma ANGPTL4 levels. In contrast, plasma ANGPTL4
levels are very constant within an individual, which is true during normal circadian rhythm as well
as between days. From our data it is evident that major physiological stressors such as fasting
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Figure 4.6: Fatty acids markedly induce ANGPTL4 mRNA. Cultured cells were incubated with oleic or linoleic acid,
Wy14643, GW501516 or tetradecylthioacetic acid (TTA) for 24 hours, followed by RNA isolation and qRT-PCR.
CYP4A14 or ADFP served as positive PPAR control genes. Error bars represent SEM. ∗ = significantly different
according to Student’s T-test (p<0.05).
and exercise are required to elicit significant changes in plasma ANGPTL4. Specifically, we ob-
served that 48h of fasting and 25 days of severe caloric restriction both raised plasma ANGPTL4
by an average of 80%. Fasting plasma ANGPTL4 levels were further stimulated by endurance
exercise and post-exercise recovery. Additional experiments indicated that the increase in plasma
ANGPTL4 levels is likely mediated by elevated FFAs via activation of ANGPTL4 gene transcrip-
tion via PPARs. Alternatively, it may be argued that instead of or in addition to FFAs raising
plasma ANGPTL4, ANGPTL4 may raise plasma FFAs via stimulation of adipose tissue lipol-
ysis. Studies using Angptl4 knock-out or transgenic mice (Mandard et al. 2006), as well as iv
injection of recombinant Angptl4 (Yoshida et al. 2002) support a potent pro-lipolytic activity of
ANGPTL4 in adipose tissue. It is possible that both mechanisms operate in concert as part of a
positive feedback loop. The increase in plasma ANGPTL4 levels during fasting is in line with a
wealth of mouse data showing induction of Angptl4 gene expression by fasting in numerous tis-
sues (Kersten et al. 2000, Mandard et al. 2006, Lichtenstein et al. 2007, Ge et al. 2005, Dutton and
Trayhurn 2008). By inhibiting lipolysis of TG-rich lipoproteins, which results in decreased tissue
uptake of plasma TG-derived fatty acids, while at the same time increasing plasma FFAs by stim-
ulating adipose tissue lipolysis, we hypothesize that ANGPTL4 may cause a shift in overall fuel
utilization from plasma TG towards TG stored in the adipose tissue. Depending on whether the
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Figure 4.7: Plasma ANGPTL4 levels increase during exercise in fasted but not fed state. (A) After overnight fasting,
seven subjects performed 2 hours of endurance exercise followed by 4 hours of post-exercise recovery while fasted
(grey bar) or with glucose ingestion (white bar) (study 6).To normalize for large differences in baseline ANGPTL4
values, levels are shown as % change over baseline (= fasted state, pre-exercise). (B) Plasma ANGPTL4 levels were
determined in nine subjects before (baseline) and after a 6h hyperinsulinaemic-euglycaemic clamp with simultaneous
infusion of either glycerol or lipid emulsion study 7). The percentage change in plasma ANGPTL4 from 0 to 6 hours is
shown. (C) Plasma ANGPTL4 levels in nine males before (baseline) and after receiving a 3-h infusion of salbutamol
with or without simultaneous administration of acipimox (study 8). The percentage change in plasma ANGPTL4 from
0 to 3 hours is shown. Error bars represent SEM. ∗ = significantly different according to Student’s T-test (p<0.05).
tissue primarily uses plasma TG-derived fatty acids or FFA (Teusink et al. 2003), ANGPTL4 up-
regulation is expected to either cause a decrease or increase in net fatty acid uptake. Upregulation
of ANGPTL4 by fasting may thus be aimed at promoting use of fat in favor of fat storage. This
mechanism may be supported by the above mentioned positive feedback loop in which ANGPTL4
stimulates release of FFAs, which in turn stimulates ANGPTL4 production. Depending on the
type of tissue involved, the effect of fatty acids on ANGPTL4 mRNA can be mediated by differ-
ent PPAR isotypes. Our results suggest that fatty acids induce ANGPTL4 mRNA via PPARα in
rat hepatoma cells and via PPARβ/δ in mouse intestinal cells MSIE cells. In human myocytes,
both PPARα and PPARβ/δ likely play a role in ANGPTL4 gene induction by fatty acids. Using
semi-quantitative Western Blot, we previously showed that 4 weeks of treatment with the PPARα
agonist fenofibrate significantly raised plasma levels of the N-terminal ANGPTL4 fragment (Man-
dard et al. 2004). Our present ELISA data similarly reveal a marked increase in plasma levels of
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Figure 4.8: Plasma FFA levels increase during exercise in fasted but not fed state. (A) After an overnight fast, seven
subjects underwent a protocol of 2 hours of endurance exercise followed by 4 hours of post-exercise recovery either in
the fasted state (grey bar) or with glucose ingestion (white bar) (study 6). Blood was samples at various time points for
assessment of plasma FFA. (B) Plasma FFA levels were determined in nine healthy lean male subjects after undergoing
a 6-h hyperinsulinaemiceuglycaemic clamp with simultaneous infusion of either glycerol or a lipid emulsion (study 7).
(C) Plasma FFA levels were determined in nine lean males after receiving a 3-h infusion of salbutamol with or without
simultaneous administration of acipimox (study 8). Error bars represent SEM. ∗ = significantly different according to
Students T-test (p<0.05).
full length ANGPTL4 upon fenofibrate treatment. As fibrates primarily target liver, these data
suggest that liver is the most important source of plasma ANGPTL4, which is supported by the
dominant expression of ANGPTL4 in human liver. Previously, Xu and colleagues found that
plasma ANGPTL4 levels were decreased in obese diabetics compared to obese non-diabetics or
normal weight individuals (Xu et al. 2005). It should be emphasized that, in contrast to the an-
tibody used by Xu and colleagues, the antibody used in our ELISA specifically detects the full
length ANGPTL4 protein and does not recognize any of the truncated variants of ANGPTL4. It is
known that ANGPTL4 is cleaved into N- and C-terminal fragments of about equal size, which
may each carry an entirely different function (Mandard et al. 2004). N-terminal ANGPTL4
has been shown to potently inhibit lipoprotein lipase, while C-terminal ANGPTL4 influences
endothelial cell migration and function, possibly via suppressing the Raf/MEK/ERK signaling
cascade (Yang et al. 2008). Future research will have to better address possible changes in full
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length ANGPTL4 in diabetic patients. Since Angptl4 over-expression markedly elevates plasma
TG levels in mice (Xu et al. 2005, Yu et al. 2005, Koster et al. 2005, Mandard et al. 2006), it is of
interest to study whether in humans a positive correlation may exist between plasma ANGPTL4
and plasma TG levels. In a limited sample of 36 women, we could not find such a correlation,
nor between plasma ANGPTL4 and other metabolic parameters. Although these data might ar-
gue against a major impact of ANGPTL4 on plasma TG levels in humans, recent studies indicate
that a rare sequence variant of ANGPTL4 that gives rise to a dysfunctional protein is associated
with decreased plasma TG levels (Romeo et al. 2007, Folsom et al. 2008, Shan et al. 2009, Tal-
mud et al. 2008). More extensive investigations using large cohorts will need to be carried out
to further explore the relation between plasma ANGPTL4 and various plasma lipid parameters.
In conclusion, our data show major variation in plasma ANGPTL4 levels between individuals.
Within an individual, plasma ANGPTL4 levels remain stable throughout the day but increase in
response to fasting, chronic caloric restriction, and endurance exercise. Long term changes in
plasma ANGPTL4 levels are likely mediated by changes in plasma FFA, which potently raise
ANGPTL4 gene expression.
In revision: A. Georgiadi, L. Lichtenstein, T. Degenhardt, M. Boekschoten, M. van Bilsen, B. Desvergne, M. Mu¨ller
and S. Kersten – “Induction of cardiac Angptl4 by dietary fatty acids is mediated by PPARβ/δ and protects against
oxidative stress,” 2009
Chapter 5
Induction of cardiac Angptl4 by dietary fatty acids is
mediated by PPARβ/δ and protects against oxidative stress
Abstract
Little is known about the direct effects of dietary fatty acids on gene expression in the intact heart. In the
present paper we show that oral administration of synthetic triglycerides composed of one single fatty acid
alters cardiac expression of numerous genes, many of which are involved in the oxidative stress response.
The gene most significantly and consistently upregulated by dietary fatty acids encoded angiopoietin-like 4
(Angptl4), a circulating inhibitor of lipoprotein lipase expressed by cardiomyocytes. Induction of Angptl4
was specifically abolished in peroxisome proliferator activated receptor beta/delta (PPARβ/δ) -/- and not
peroxisome proliferator activated receptor alpha (PPARα) -/- mice. Consistent with these data, fatty acids
stimulated binding of PPARβ/δ but not PPARα to the Angptl4 gene. Upregulation of Angptl4 resulted in
decreased cardiac uptake of plasma triglyceride (TG)-derived fatty acids and decreased fatty acid-induced
oxidative stress and lipid peroxidation. In contrast, Angptl4 deletion led to enhanced oxidative stress in the
heart, both after a acute oral fat load and after prolonged high fat feeding. We conclude that stimulation
of cardiac Angptl4 gene expression by dietary fatty acids and via PPARβ/δ is part of a feedback mechanism
aimed at protecting the heart against lipid overload and consequently fatty-acid induced oxidative stress.
5.1 Introduction
Cardiac contractility is dependent on the adequate delivery of oxygen and energy substrates to
the heart followed by their efficient metabolic degradation to yield adenosine triphosphate (ATP).
The energy requirements of the contracting heart are primarily met by fatty acid oxidation, with
the remainder of the energy coming from glucose and lactate (Abozguia et al. 2006, Stanley
et al. 2005). While fatty acids are thus of major importance to the heart, excessive uptake of
fatty acids causes lipid overload or lipotoxicity and may compromise cardiac function, possibly
leading to cardiomyopathy (Park et al. 2007). Consequently, cardiac uptake of fatty acids needs
to be well adjusted to fatty acid utilization. Since most of the fatty acids taken up by the heart
are derived from lipoprotein lipase (LPL)-dependent hydrolysis of circulating triglyceride-rich
lipoproteins (Teusink et al. 2003), the activity of LPL needs to be carefully regulated via specific
activators and inhibitors, especially after a fatty meal. Besides serving as a major fuel for the heart
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and a potential lipotoxic substrate, fatty acids are able to regulate gene expression (Clarke 2004).
In vitro experiments in rat cardiomyocytes have shown that fatty acids increase expression of
uncoupling protein 2 (Ucp2), carnitine palmitoyltransferase 1 (Cpt1), Cd36 molecule (Cd36),
fatty acid binding protein 3 (Fabp3), acyl-CoA synthetase long-chain family member 1 (Acsl1),
acyl-coA thioesterase (Acot1), and acyl-Coenzyme A dehydrogenase, long chain (Acadl) (Brandt
et al. 1998, Durgan et al. 2006, van der Lee et al. 2000, Lee et al. 2000). As these genes all repre-
sent target genes of peroxisome proliferator activated receptor alpha (PPARα) (Mandard, Muller
and Kersten 2004, Rakhshandehroo et al. 2007), they suggest an important role of PPARα in fatty
acid-dependent gene regulation in the heart (Finck et al. 2002). However, little is known about the
direct effects of dietary fatty acids on gene expression in the intact heart. In addition, it is unclear
what pathways are activated by fatty acids besides their own catabolism. Here we studied the com-
prehensive effects of dietary fatty acids on cardiac gene expression in vivo by giving mice a single
oral bolus of synthetic triglyceride composed entirely of one single fatty acid, which were either
linolenic acid (C18:3), linoleic (C18:2) acid or oleic acid (C18:1). Subsequent microarrays analy-
sis yielded Angptl4 as the gene most highly induced in the heart after oral fat administration. The
collective data suggest that induction of Angptl4 by dietary fatty acids is mediated by peroxisome
proliferator activated receptor beta/delta (PPARβ/δ) and is part of a feedback mechanism aimed
at protecting cardiomyocytes against lipid overload and consequently fatty-acid induced oxidative
stress, e.g. lipotoxicity.
5.2 Materials and Methods
Materials: GW501516 was purchased from Alexis (Axxora, Raamsdonkveer, The Netherlands).
Wy14643 was obtained from Eagle Picher Technologies laboratories (Lenexa, KS, USA). Trili-
nolein (9c,12c) and trilinolenin (9c,12c,15c) were from Larodan free chemicals (Malmo, Sweden).
SYBR green was from Eurogentec (Seraing, Belgium) and all other chemicals were from Sigma
(Zwijndrecht, The Netherlands).
Animals: Pure-bred Sv129 PPARα-/- mice (129S4/SvJae) and corresponding wildtype mice
(129S1/SvImJ) were purchased from Jackson Laboratory (Bar Harbor, Maine, USA). The Angptl4-
/- and transgenic mice were on C57Bl/6 background and have been previously described (Koster
et al. 2005, Mandard et al. 2006). The PPARβ/δ-/- mice were on a mixed background (Sv129/C57Bl
/6) and have been previously described (Nadra et al. 2006). Males mice were used at 2.5 to
4 months of age. Mice were anaesthetized with a mixture of isofluorane (1,5%), nitrous oxide
(70%), and oxygen (30%). Blood was collected via orbital puncture into EDTA tubes. After sac-
rifice, the hearts were excised and stored in -80 ◦C until further analysis. The animal studies were
approved by the Local Committee for Care and Use of the Laboratory Animals at Wageningen
University and the University of Lausanne, Switzerland.
Oral lipid load: Starting at 5 a.m. the animals were fasted for 4 hours followed by an intra-
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gastric gavage of 400µL synthetic triglyceride (triolein, trilinolein, and trilinolenin). The control
group received only carboxymethylcellulose (CMC). The mice were killed 6 hours thereafter. Four
to five mice per group were used.
High fat diet: Angptl4 -/-, +/+ and transgenic mice on C57Bl/6 background received a low
fat diet (LFD) or high fat diet (HFD) for 8 weeks, providing 10 or 45 energy percent in the form
of triglycerides, respectively (D12450B or D12451, Research Diets, New Brunswick, USA). The
major source of fat in the diet was palm oil, with 5 energy percent provided as soybean oil.
RNA isolation and qRT-PCR: Total RNAwas isolated with TRIzol Reagent (Invitrogen, Breda,
the Netherlands). 1µg of total RNA for the in vivo studies and 350ng of total RNA for the in vitro
experiment was reverse transcribed using iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA
was amplified on BioRad MyIQ or iCycler machine using Platinum Taq polymerase (Invitrogen,
Breda, the Netherlands). PCR primer sequences were taken from the PrimerBank and ordered
from Eurogentec (Seraing, Belgium). Sequences of the primers used are available upon request.
Cell culture: Neonatal cardiomyocytes were isolated and cultured as described using differ-
ential plating to separate myocytes from non-myocytes (de Vries et al. 1997). The experiments
were approved by the Institutional Animal Care and User Committee of Maastricht University.
Neonatal cardiomyocytes were incubated with 1µM of GW501516 or 62.5µM, 125µM or 250µM
of linolenic for 6h as previously described (de Vogel-van den Bosch et al. 2008). In a second
experiment, cardiomyocytes were incubated with 1µM GW501516, 10µM Wy14643, or 250µM
linolenic acid for 24h.
Plasma lipid parameters: Plasma was obtained from blood by centrifugation for 10 min at
10,000g. The plasma free fatty acids and TG concentration were determined using kits from
Instruchemie (Delfzijl, The Netherlands).
Chromatin immunoprecipitation assay (ChIP): Wildtype C57Bl/6 mice were fasted for 4 hours
followed by an oral gavage of Trilinolenin (n=3). Six hours thereafter the mice were killed by
cervical dislocation and the hearts excised. The fresh hearts were cut into half and placed into
PBS containing 1% formaldehyde. Cross-linking was stopped after 15 min by adding glycine to
a final concentration of 0.125M for 5 min at room temperature. The samples were centrifuged
for 5 min at 700 g at 4◦C to collect the heart pieces, the supernatant was removed and washed
once again with ice-cold PBS. Fresh PBS containing protease inhibitors (Roche, Almere, Nether-
lands) was added and the tissue was disaggregated with a homogenizer Ultra Turrax T25 basic
(Ika Werke, Staufen, Germany). The tissue was distributed into 3 tubes (2 mL each), centrifuged
for 5 min at 700 g at 4◦C. After the supernatant was removed, heart homogenate was resus-
pended in lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl pH 8.1, protease inhibitors)
and the lysates were sonicated with a Bioruptor TM (Diagenode, Lige, Belgium) to achieve a
DNA length of 300-800 bp. After removal of cellular debris by centrifugation, supernatants
were diluted 1:10 in ChIP dilution buffer (150mM NaCl, 1% Triton X-100, 2mM EDTA, 20 mM
Tris-HCl pH 7.5, protease inhibitors). Chromatin was incubated overnight at 4◦C with 2µg an-
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tibody, 25µl BSA (100 mg/ml) and 2.4µl sonicated salmon sperm (10 mg/ml). The following
antibodies were used: anti-PPARα (sc-9000), and anti-PPARβ/δ (sc-7197). All were obtained
by Santa Cruz Biotechnologies (Heidelberg, Germany). Immunocomplexes were collected with
25µl MagaCell c©Protein A Magnetic beads (Isogen Life Science) for 1hour at room tempera-
ture, and subsequently washed with 700µL of the following buffers: ChIP was buffer 1 (150 mM
NaCl, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, protease inhibitors) two times,
ChIP wash buffer 2 (500mM NaCl, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, pro-
tease inhibitors), ChIP wash buffer 3 (250 mM LiCi, 1% NP40, 1% Deoxycholate, 1mM EDTA,
10 mM Tris-HCl pH 8), two times TE buffer (1 mM EDTA, 10 mM Tris-HCl pH 8). Elution
of immucomplexes were carried out in 250µL elution buffer (10 mM EDTA, 0.5% SDS, 25mM
Tris-HCl pH 7.5) at 64◦C for 30 min. After collection of supernatant, elution was repeated with
250µl elution buffer at room temperature for 2 min. After combining the supernatants, cross-
linking was reversed at 64◦C overnight with 2.5µl Proteinase K (20 mg/ml) for digestion of any
remaining proteins. Genomic DNA fragments were recovered by phenol-chloroform extraction
with phase lock gel (Eppendorf, Wesseling-Berzdorf, Germany), followed by salt-ethanol precip-
itation. Samples were diluted in sterile H2O, and analyzed with qPCR. The ChIP data are nor-
malized against IgG to account for non-specific immunoprecipitation. A fold-enrichment value
of 1 represents baseline thus no enrichment and no specific precipitation. Primers were chosen
to study binding of PPARs to the transcriptional start site of the Angptl4 and Ucp3 genes, and to
the previously identified PPRE within intron 3 of the Angptl4 gene. The ribosomal phosphopro-
tein P0 (Rplp0) was used as negative control for PPAR binding. The sequences of primers used
in ChIP were as follows: Ucp3-TSS: (For:5’-GAGCCCCAGGTCACGGAAG-3’, Rev:5’- CT-
GTGCGTCTAGCCA AGGTTG-3’), Angptl4-TSS: (For:5’-CCAGCAAGTTCATCTCGTCC-3’,
Rev:5’-TCCCTCCCACTCCCACACC-3’), Angptl4-PPRE: (For:5’-TCTGGGTCTGCCCCCAC
TCCTGG-3’, Rev:5’-GTGTGTGTGTGGGATACGGCTAT-3’), Rplp0 (For:5’-CGAGGACCGCC
TGGTTCTC-3’, Rev:5’-GTCACTGGGGAGAGAGAGG-3’).
In Vivo Clearance of very low density lipoprotein (VLDL)-Like Emulsion Particles: Tissue
uptake of [3H]-labeled TG packaged into VLDL-like emulsion particles was measured as previ-
ously described (Lichtenstein et al. 2007). The data shown represent the percentage of injected
radioactivity taken up by the heart after 30 min.
Immunohistochemistry: Deep frozen tissues (-80◦C ). were cryosectioned (5µm) with a cryo-
stat (Leica, CM1900 UV). Immunostaining of protein adducts of the lipid peroxidation byproduct
4-hydroxy-2-nonenal (4-HNE) was performed on freshly cut frozen sections using a rabbit poly-
clonal antibody (Calbiochem, San Diego, CA, USA). All steps were carried out at room temper-
ature. The tissue was fixed in 70% ethanol for 3 min and then rinsed in PBS 1X for 3 min. To
block endogenous peroxidase activity, slides were incubated with 3% H2O2 for 10 min. Incu-
bation with the primary antibody (rabbit anti 4-HNE protein-adducts, 1:50 dilution in PBS 1X)
was performed for 1h. After rinsing with PBS 1X, tissue was incubated for 45 min with the
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Figure 5.1: Induction of oxidative stress response 6 hours after the oral ingestion of fatty acids. Bars show the
percentage of upregulated genes (red) and downregulated genes (green) out of the total number of eligible genes for
each pathway, based on the Ingenuity knowledge database. The white part represents the percentage of genes that
do not overlap with the experimental dataset. The pathways are displayed from the direction of the most significantly
regulated to least significantly regulated based on Fisher’s Exact Test p-value (cut off p<0.05). The -log(p-value) is
displayed on the top of each pathway (yellow square).
secondary antibody (Dako EnVision+ System Labelled Polymer-HRP AntiRabbit). Visualization
of the complex was carried out using AEC substrate chromogen (Dako Cytomation) for 15 min-
utes. Sections were mounted with Kaiser’s glycerol gelatin mounting medium (Merck KGaA,
Darmstadt, Germany). Normal rabbit serum was used as a negative control (Vector Laboratories).
Immunostaining of Angptl4 in human heart was performed using an antibody directed against
the C-terminus of Angptl4. Five-micrometer sections of paraffin-embedded human heart were
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mounted on Superfrost microscope slides. These sections were dewaxed in xylene and rehydrated
in a series of graded alcohols. To block endogenous peroxidase activity, slides were incubated with
3% H2O2 for 20 min. Antigen retrieval was performed by placing the slides in citrate buffer (pH
6.0) and heat them in a microwave oven 5 min 700 W (without lid) and 4 times 5 min 500 W (with
lid). After cooling down to room temperature, the sections were briefly washed with PBS. Prior to
staining, a 20 min preincubation was performed using 20% normal goat serum (Vector Laborato-
ries, Burlingame, CA, USA). Incubation with the primary antibody (1:50) was performed for 1h.
After rinsing with PBS 1X, tissue was incubated for 45 min with the secondary antibody (Dako
EnVision+ System Labelled Polymer-HRP AntiRabbit). Visualization of the complex was carried
out using AEC substrate chromogen (Dako Cytomation) for 15 minutes. After counterstaining
with Meyer’s hematoxylin, sections were mounted with DePex mounting medium (Gurr, BDH,
Poole, Dorset, UK). Negative control staining was performed using only the secondary antibody.
Tissue homigenization and quantification of oxidative stress: The extent of lipid peroxidation
in heart homogenates was determined by measuring the levels of hydroxynonenal-histidine (HNE-
His) protein adducts and malondialdehyde (MDA) adducts. 25mg of heart tissue were homoge-
nized in 250µL of tissue homogenation buffer (1mM EDTA, PBS 1X pH 7.4 containing protease
inhibitors). Heart tissue was homogenized over ice by needle sonication for 15sec at 40V. Heart
homogenates were centrifuged at 1600xg for 10min at 4◦C. Protein content was determined in
tissue supernatants by BCA Protein assay reagent. Starting from a protein concentration of 10
µg/mL 4-HNE-His protein adducts and MDA adducts content were quantified using the Oxiselect
HNE-His Adduct ELISA kit (Cell Biolabs Inc., San Diego, USA) and MDA Adduct ELISA kit
(Cell Biolabs Inc.), respectively. The quantity of HNE-His protein adducts was determined by us-
ing a standard curve containing known amounts of HNE-BSA (0-10µg/ml). For the quantification
of MDA adducts a standard curve of known amounts of MDA-BSA (0-120pmol/mg) was used.
Tissue triglyceride content: Triglycerides content was measured in tissue homogenates with
Triglyceride LiquiColor Test (Mono) HUMAN GmbH, kit (Instruchemie, Delfzijl, The Nether-
lands). 5% tissue homogenates were prepared by needle sonication over ice in tissue homogeniza-
tion buffer consisting of 10mM Tris, 2mM EDTA, 0.25M sucrose pH 7.5.
Affymetrix microarray and pathway analysis: Expression profiling was carried out on indi-
vidual mouse hearts. Total RNA (5 µg) was labeled using the Affymetrix One-cycle Target La-
beling Assay kit (Affymetrix, Santa Clara, CA). The correspondingly labeled RNA samples were
hybridized on Affymetrix Mouse Genome 430 2.0 Arrays, washed, stained and scanned on an
Affymetrix GeneChip 3000 7G scanner. Packages from the Bioconductor project, integrated in an
in-house developed on-line management and analysis database for multiplatform microarray ex-
periments, were used for analyzing the scanned arrays (Sanderson et al. 2008). Probesets were re-
defined according to Dai et al. as the genome information utilized by Affymetrix at the time of de-
signing the arrays is not current anymore, resulting in unreliable reconstruction of expression lev-
els (Yoshida et al. 2002). In this study probes were reorganized based on the Entrez Gene database,
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build 36, version 2 (remapped CDF v10). Expression estimates were obtained by GC-robust multi-
array (GCRMA) analysis, employing the empirical Bayes approach for background adjustment,
followed by quantile normalization and summarization. Differentially expressed probesets were
identified using linear models, applying moderated t-statistics that implement empirical Bayes
regularisation of standard errors (Sukonina et al. 2006). A probeset was found to be significantly
changed after treatment if p<0.05. For the pathway analysis ingenuity software version 6.5 was
used.
5.3 Results
In order to study the acute effects of dietary fatty acids on cardiac gene expression in vivo, SV129
mice were given a single oral gavage of synthetic TGs composed entirely of either C18:1, C18:2, or
C18:3 (Sanderson et al. 2008), thus mimicking a post-prandial lipid challenge. Animals receiving
carboxymethylcellulose were used as control in order to study the absolute effect of dietary fatty
acids. Expression profiling was carried out on individual mouse hearts collected 6 hours after
the gavage using Affymetrix Mouse Genome 430 2.0 Arrays. Pathway analysis using Ingenuity
revealed that the dominant pathway affected by the oral fat load was nuclear factor-like 2 (Nrf2)-
related oxidative stress, indicating that the fatty acids induced oxidative stress (Figure 5.1). This
was supported by examination of the top 20 of upregulated genes, most of which were involved in
the oxidative stress response, including uncoupling protein 3 (Ucp3), heme oxygenase 1 (Hmox1),
FK506 binding protein 5 (Fkbp5), lipocalin 2 (Lcn2), glutathione S-tranferase A3 (Gsta3),and
metallothionein 2 (Mt2) (Figure 5.2).
A large correspondence in gene regulation between the fatty acids was observed, especially be-
tween C18:2 and C18:3. Indeed, scatter plot analysis indicated that the effects of C18:2 and C18:3
on cardiac gene expression were remarkably similar, whereas effects of C18:1 were somewhat
different (Figure 5.3). Therefore the remainder of the paper will focus on effects of C18:3. Apart
from genes involved in the oxidative stress response, various genes involved in lipid metabolism
were also induced by the fatty acids. Interestingly, the gene most significantly and consistently
upregulated by each of the dietary fatty acids was Angptl4 (Figure 5.2), which encodes a secreted
protein involved in the regulation of plasma TG levels. Previous studies have shown that Angptl4
potently inhibits LPL and accordingly plasma TG clearance by converting active LPL-dimers into
inactive LPL-monomers (Lichtenstein et al. 2007, Yoshida et al. 2002, Sukonina et al. 2006). Al-
though Angptl4 is known to be expressed in heart (Yu et al. 2005, Zandbergen et al. 2006) the
specific cardiac cell types that produce Angptl4 remain unclear. Accordingly, we performed im-
munohistological staining of Angptl4 in human heart samples. The results reveal the presence
of Angptl4 protein in cardiomyocytes and vascular smooth muscle cells but not endothelial cells
and fibroblasts (Figure 5.4). Significant production of Angptl4 by cardiomyocytes was confirmed
by the relatively low Ct values for amplification of Angptl4 cDNA from rat cardiomyocytes (Ct
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gene name Description Function
Hmox1 Heme oxyganase 1 Oxidative stress response
Lcn2 Lipocalin 2 Oxidative stress response
Angptl4 Angiopoietin like 4 Lipidmetabolism
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Lipidmetabolism
Fkbp5 FK506 binding protein 5 Oxidative stress response
A930018M24Rik RIKEN cDNA A930018M24 gene Unknown
Setdb2 SET domain, bifurcated 2 Oxidative stress response
Mt2 Metallothionein 2 Oxidative stress response
Zbtb16 Zinc finger and BTB domain containing 16 Oxidative stress response
BC031353 cDNA sequence BC031353 Unknown
Ucp3 Uncouplingprotein 3 Lipidmetabolism and oxidative stress response
Pnpla7 Patatin-like phospholipase domain containing 7 Lipidmetabolism
Ddit4 DNA-damage-inducible transcript 4 Oxidative stress response
Chac1 ChaC, cation transport regulator-like 1 Regulator of cation tansport
LOC667597 Similar to immunity-related GTPase family, cinema 1 Unknown
Ccrl2 Chemokine (C-C motif) receptor-like 2 Oxidative stress response
Slc46a3 Solute carrier family 46, member 3 Unknown
Gsta3 Glutathione S-transferase, alpha 3 Antioxidant response
Rasd1 RAS, dexamethasone-induced Oxidative stress response
Cyp2e1 Cytochrome P450, family 2, subfamily e, polypeptide 1 Oxidative stress response
Control C18:3
gene name Description Function
Angptl4 Angiopoietin like 4 Lipidmetabolism
Hmox1 Heme oxyganase 1 Oxidative stress response
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Lipidmetabolism
A930018M24Rik RIKEN cDNA A930018M24 gene Unkown
LOC667597 Similar to immunity-related GTPase family, cinema 1 Unkown
Fkbp5 FK506 binding protein 5 Oxidative stress response
Ucp3 Uncouplingprotein 3 Oxidative stress response
Lcn2 Lipocalin 2 Oxidative stress response
Zbtb16 Zinc finger and BTB domain containing 16 Oxidative stress response
Mt2 Metallothionein 2 Oxidative stress response
Cldn5 Claudin 5 Extracellular matrix remodelling
Isyna1 Myo-inositol 1-phosphate synthase A1 Phosholipids synthesis; cell membrane remodelling
BC031353 cDNA sequence BC031353 Unknown
Ccrl2 Chemokine (C-C motif) receptor-like 2 Oxidative stress response
Iigp1 Interferon inducible GTPase 1 Antinflammatory signalling
4833442J19Rik RIKEN cDNA 4833442J19 gene Unkown
Acot1 Acyl-CoA thioesterase 1 Lipidmetabolism
Trmt5 TRM5 tRNAmethyltransferase 5 homolog Methyltranferase activity
Abhd1 Abhydrolase containing domain 1 Oxidative stress response
1200006F02Rik Solute carrier family 46, member 3 Unknown
Control C18:2
gene name Description Function
Angptl4 Angiopoietin like 4 Lipidmetabolism
Mybphl Myosin binding protein H-like Unknown
Sln Sarcolipin Unkown
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Lipidmetabolism
Myl7 Myosin, light polypeptide 7, regulatory Cell remodelling
Ucp3 Uncouplingprotein 3 Oxidative stress response
Myl4 Myosin, light polypeptide 4 Calcium ion binding; motor activity
Dkk3 Dickkopf homolog 3 Cellular remodelling; growth signaling
Fkbp5 FK506 binding protein 5 Oxidative stress response
Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 Inflammatory response
Acot1 Acyl-CoA thioesterase 1 Lipidmetabolism
Upk3b Uroplakin 3B Unknown
Zbtb16 Zinc finger and BTB domain containing 16 Oxidative stress response
2310009B15Rik RIKEN cDNA 2310009B15 gene Unknown
Klf10 Kruppel-like factor 10 Cell remodelling: growth signaling
Stard10 START domain containing 10 Unknown
Tagln Transgelin Cell remodelling: growth
Fgf12 Fibroblast growth factor 12 Cell remodelling; growth
1110036O03Rik RIKEN cDNA 1110036O03 gene Unknown
Isyna1 Myo-inositol 1-phosphate synthase A1 Phospholipid synthesis; Cell membrane remodelling
Control C18:1
0.01 0.04 0.4 1.0 1.5 3.1 >12
Figure 5.2: Cardiac Angptl4 expression is highly sensitive to dietary fatty acids. Top 20 of genes upregulated after
oral gavage of synthetic triglyceride composed of either linolenic acid (C18:3), linoleic acid (C18:2), or oleic acid
(C18:1). The heatmaps were generated directly from the GCRMA normalized microarray data. Genes are ranked ac-
cording to mean fold-change with wildtype mice receiving CMC serving as control. Only probesets showing significant
upregulation by the different fatty acids were included in the analysis (P<0.05).
22-23, data not shown).
Long-chain fatty acids are bona fida ligands for the peroxisome proliferator activated receptors
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Figure 5.3: Similarity in cardiac gene regulation between linolenic acid and linoleic acid. Graphs show fold-change in
gene expression after treatment with C18:3TG (y-axis) plotted against fold-change in gene expression after treatment
with C18:2TG (A) or C18:1TG (B) (x-axis). Analysis shows more significant similarity in gene regulation between
C18:3 and C18:2, compared to between C18:3 and C18:1.
EC
CM
VSM
Figure 5.4: Angptl4 protein localizes specifically to the cardiomyocytes and not to endothelial cells. High magnification
image of the human heart tissue stained with an antibody against Angptl4 (bottom) or negative control (top). Arrows
point to endothelial cells (EC), vascular smooth muscle cells (VSM) and cardiomyocytes (CM).
(PPARs). The previous demonstration that Angptl4 is a direct PPAR target gene prompted us to
investigate the role of PPARs in Angptl4 gene regulation by dietary fatty acids. Since cardiomy-
ocytes predominantly express PPARα and PPARβ/δ and only low amounts of peroxisome prolif-
erator activated receptor γ (PPARγ) (Gilde et al. 2003), the focus was on PPARα and PPARβ/δ.
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Figure 5.5: PPARβ/δ but not PPARα mediates the induction of Angptl4 expression by dietary linolenic acid. Wildtype,
PPARα-/-, and PPARβ/δ-/- were given a single oral gavage of 0.5% CMC (open bars) or synthetic TG composed entirely
of C18:3 (closed bars). mRNA expression levels of Angptl4 (A) and Ucp3 (B) were determined in mouse heart using
real-time PCR. Results are expressed as fold-change compared to the WT control mice. (C-F) ChIP was performed on
hearts of wildtype mice given an oral gavage of either CMC or C18:3. Chromatin was precipitated using antibodies
against PPARα or PPARβ/δ. Rabbit IgG was used as a specificity control. Real-time qPCR was performed on reverse-
crosslinked chromatin templates using primers specific to the known PPRE in intron 3 of the Angptl4 gene (C), the
TSS of Angptl4 (D), the TSS of Ucp3 (E), and the negative control gene RpLp0 (F). (G) Rat neonatal cardiomyocytes
were incubated with increasing concentrations of linolenic acid (0, 62.5, 125 and 250 µM) or GW501516 (1µM) for
6h. Angptl4 expression was determined by qPCR. (H) Rat neonatal cardiomyocytes were incubated with linolenic acid
(250µM), GW501516 (1µM), or Wy14643 (10µM), for 24h. Expression of Angptl4 and known PPAR targets Acsl1 and
Acox1 was determined by qPCR. Error bars represent SEM. Statistical significance was determined with a Student’s
T-test (P<0.05).
PPARα -/- mice , PPARβ/δ -/- mice, and the corresponding wildtype mice were given an oral gav-
age of C18:3 as synthetic TG. Hearts were collected 6 hours thereafter for analysis of gene expres-
sion by quantitave PCR. Remarkable, upregulation of Angptl4 by C18:3 was entirely abolished
in the PPARβ/δ -/- mice, while it was retained in the PPARα-/- mice (Figure 5.5a). In contrast,
upregulation of Ucp3, another well-characterized PPAR target gene, was retained in PPARβ/δ -/-
mice and completely abolished in PPARα-/- mice (Figure 5.5b). No compensatory increase in
PPARβ/δ and PPARα expression was observed in PPARα-/- and PPARβ/δ -/- mice, respectively
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(Figure 5.6). To examine whether regulation of Angptl4 by PPARβ/δ and not PPARα was sup-
ported by binding of PPARβ/δ to the Angptl4 gene, we performed chromatin imunoprecipitation
(ChIP). Previously, we located the response element responsible for PPAR-mediated upregulation
to intron 3 of the Angptl4 gene (Mandard et al. 2004). Consistent with data on Angptl4 gene
regulation, ChIP on hearts of wildtype mice six hours after oral gavage of C18:3 showed enhanced
binding of PPARβ/δ but not PPARα to the intronic PPRE (Figure 5.5c). Nuclear receptors and
other transcription factors bound to such distal sites likely contact the basal transcription machin-
ery via DNA looping, and accordingly binding of PPAR to distant PPREs can be demonstrated by
showing cross-linking of PPAR to the transcriptional start site (TSS) (Palstra et al. 2008, Saramki
et al. 2009). Indeed, oral gavage of C18:3 enhanced binding of PPARβ/δ but not PPARα to TSS
of the Angptl4 gene (Figure 5.5d), while C18:3 enhanced binding of PPARα but not PPARβ/δ to
the TSS of the Ucp3 gene (Figure 5.5e). No binding of either PPARα or PPARβ/δ to the negative
control gene Rplp0 was observed (Figure 5.5f). These results demonstrate that the induction of
Angptl4 gene expression by dietary C18:3 is mediated by PPARβ/δ.
To further investigate whether the fatty acid- and PPARβ/δ-mediated induction of cardiac
Angptl4 expression was occurring in cardiomyocytes, rat neonatal cardiomyocytes were incubated
for 6h with increasing concentrations of C18:3 or with the synthetic PPARβ/δ agonist GW501516.
The results show that C18:3 caused a dose-dependent increase in Angptl4 mRNA, which at the
highest concentration was equivalent to that obtained using GW501516 (Figure 5.5g). Our results
do not imply that Angptl4 is an exclusive target gene of PPARβ/δ under any type of circum-
stances. Indeed, we find that in cardiomyocytes Angptl4 is induced to a similar extent by synthetic
PPARα and PPARβ/δ agonists, similar to other cardiac PPAR targets such as Acsl1 and Acox1
(Figure 5.5h). Instead, our data suggest that the stimulatory effect of dietary fatty acids on cardiac
Angptl4 expression is mediated specifically by PPARβ/δ.
To study the effect of Angptl4 on the metabolic response to dietary fat, we performed the
oral fat load with C18:3 TG in wildtype, Angptl4-/- and Angptl4-Tg mice. In agreement with
inhibition of LPL by Angptl4, the post-prandial increase in plasma TG was dramatically increased
in Angptl4-Tg mice, whereas it was entirely blunted in Angptl4-/- mice (Figure 5.7a). Consistent
with LPL inhibition, Angptl4 overexpression markedly reduced cardiac fatty acid uptake from
[3H]triolein-labeled VLDL-like particles (Figure 5.7b). These results suggest that upregulation of
Angptl4 by dietary fatty acids will lead to reduced cardiac uptake of fatty acids via inhibition of
LPL, thereby suppressing the stimulus that led to induction of Angptl4 expression.
To examine whether the inhibitory effect of Angptl4 on cardiac fatty acid uptake is associ-
ated with reduced fatty acid-induced oxidative stress, expression of Fkbp5, Lcn2, and Gsta3 was
determined 6h after oral gavage with either control treatment (CMC) or C18:3TG in wildtype,
Angptl4-/- and Angptl4-Tg mice. All three genes represent markers of oxidative stress (Roudkenar
et al. 2007, Edwards et al. 2003, Black et al. 2008). Consistent with a protective role of Angptl4
against fatty acid-induced oxidative stress, the magnitude of induction of Fkbp5, Lcn2, and Gsta3
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Figure 5.6: No compensatory increase in PPARβ/δ and PPARα expression in PPARα-/- and PPARβ/δ -/- mice, respec-
tively. Wildtype, PPARα-/-, and PPARβ/δ-/- were given a single oral gavage of 0.5% CMC (open bars) or synthetic TG
composed entirely of C18:3 (closed bars). mRNA expression levels of PPARβ/δ (left panel) and PPARα (right panel)
were determined in mouse heart using real-time PCR. Results are expressed as fold-change compared to the WT control
mice.
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Figure 5.7: Angptl4 overexpression raises post-prandial plasma TG levels and decreases cardiac fatty acid uptake.
(A) Wildtype (grey squares), Angptl4-/- (open squares) and Angptl4-Tg (black squares) mice were given a single oral
gavage of synthetic TG composed entirely of C18:3. Plasma TG were determined in blood collected via the tail vein.
(B) [3H]-labeled triolein was incorporated into VLDL-like emulsion particles and directly injected into the tail vein of
wildtype and Angptl4-Tg mice. The heart was collected 30 min after the injection for determination of radioactivity. ∗
= significantly different between WT and Angptl4-Tg mice according to Student’s T-test (P<0.05).
by C18:3 was inversely correlated with Angptl4 expression (Figure 5.8a & b). Expression of
Fkbp5, Lcn2, and Gsta3 after the oral fat load was not related to plasma free fatty acid (FFA) lev-
els, which followed an opposite pattern (Figure 5.8c). Expression of the ER stress marker Herpud1
mimicked the pattern of the oxidative stress markers (Figure 5.8a).
Finally, we examined whether Angptl4 may exert a similar effect in the context of a chronic fat
overload. To that end, we measured expression of the oxidative stress markers and performed im-
munohistochemical and quantitative analysis of 4-HNE protein adducts in wildtype and Angptl4-/-
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Figure 5.8: Markers of oxidative stress are inversely correlated with Angptl4 expression after oral fat load. Wildtype,
Angptl4-/- and Angptl4-Tg mice were given a single oral gavage of 0.5% CMC (open bars) or synthetic TG composed
entirely of C18:3 (closed bars). Mice were sacrificed 6 hours later. (A) mRNA expression levels of oxidative stress genes
Fkbp5, Lcn2,and Gsta3, and ER stress marker gene Herpud1 as determined by real-time PCR. Bars with different letters
are significantly different (Student’s T-test, P<0.05). (B) mRNA expression levels of Angptl4. (C) Plasma levels of FFA
and TG.
mice fed a high fat diet (HFD) for 8 weeks. 4-HNE is one of the major biologically active alde-
hydes formed during inflammation and oxidative stress. Formation of 4-HNE- protein adducts
is a marker for lipid peroxidation. Although high fat feeding did not influence expression lev-
els of Fkbp5, Lcn2 and Gsta3, expression was significantly higher in Angptl4-/- mice fed HFD
compared to wildtype mice fed HFD (Figure 5.9a). A similar trend was observed for Herpud1.
Furthermore, lipid peroxidation was increased in Angptl4-/- mice fed HFD, as shown by enhanced
4-HNE staining (Figure 5.9b). These results were supported by quantitative analysis of 4HNE pro-
tein adducts (Figure 5.9c) and MDA adducts (Figure 5.9d), which were significantly increased in
Angptl4-/- mice fed HFD compared to wildtype mice fed HFD. These data indicate that Angptl4
protects against oxidative stress in the context of a chronic fat overload. No differences in cardiac
triglyceride levels were observed between wildtype and Angptl4-/- mice (Figure 5.9e).
5.4 Discussion
In the present paper we show that the gene most significantly and consistently upregulated by short
term treatment with dietary fatty acids is Angptl4. Induction of Angptl4 by dietary fatty acids is
mediated by PPARβ/δ and confers a protective effect against fatty acid-induced oxidative stress by
restricting cardiac fatty acid uptake via inhibition of LPL. Overall, our data suggest that upregu-
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Figure 5.9: (A) Wildtype and Angptl4-/- mice were fed a LFD or HFD for 8 weeks. Expression levels of Fkbp5, Lcn2,
Gsta3 and Herpud1 in the heart were measured by real-time PCR. Results are expressed as fold-change compared
to wildtype mice on LFD. (B) Immunohistochemistry of 4-HNE protein adducts in mouse cardiac tissue from mice
fed HFD for 8 weeks. Representative sections are shown. Right panel shows negative control obtained using rabbit
serum. Quantitative measurement of 4HNE protein adducts (C) and MDA adducts (D). (E) Cardiac triglyceride content.
Grey bars = wildtype mice, black bars = Angptl4-/- mice. ∗ = significantly different between WT and Angptl4-/- mice
according to Student’s T-test (P<0.05).
lation of Angptl4 by fatty acids is part of a feedback mechanism aimed at preventing myocardial
fatty acid accumulation, thereby minimizing lipid-induced oxidative stress and lipotoxicity (Fig-
ure 5.10). Lipotoxicity describes the untoward consequences of fat overload in a particular tissue
and may be related to fatty acid-induced oxidative stress, accumulation of lipotoxic intermedi-
ates such as ceramides and fatty acyl-CoA, and excess storage of triglycerides (Schaffer 2003).
Chronic lipotoxicity in the heart has been shown to promote cardiomyopathy in several animal
models (Chiu et al. 2001, Chiu et al. 2005, Finck et al. 2002, Yagyu et al. 2003). Most of these
models are characterized by a mismatch between myocardial fatty acid uptake and utilization, as in
mice with heart-specific overexpression of acyl-CoA synthetase (ACS), fatty acid transport protein
1, or lipoprotein lipase (Chiu et al. 2001, Chiu et al. 2005, Yagyu et al. 2003). Although triglyc-
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erides are unlikely to be the actual culprit in cardiac lipoxicity, they may be guilty by association
as its levels may be positively correlated with lipotoxic intermediates. However, we did not see
increased cardiac triglyceride levels in Angptl4-/- mice compared to wildtype mice after 8 weeks
of high fat feeding, suggesting that the increase in fatty acid uptake is limited or that the incom-
ing fatty acids are efficiently oxidized. In the present study, it was not possible to investigate the
effect of Angptl4 deletion on cardiac lipid storage, oxidative stress, and parameters of cardiac dys-
function after a more prolonged period of HFD, as a cachectic phenotype progressively emerges
after 12 weeks of HFD (Lichtenstein et al., in preparation). In a previous study, heart-specific
Angptl4 overexpression reduced cardiac LPL activity and reversed the excessive lipid storage in
hearts of lipotoxic ACS-transgenic mice 20. In agreement with these data, we find that Angptl4
overexpression reduced cardiac fatty acid uptake and protects against fatty acid-induced oxidative
stress. Angptl4 was discovered by screening for target genes of PPARα and PPARγ in liver and
adipose tissue, respectively (Yoon et al. 2000, Kersten et al. 2000). It is produced by a variety
of organs and may exert both paracrine/autocrine and endocrine effects. Intravenous injections
of recombinant Angptl4 protein as well as numerous studies using Angptl4 transgenic or knock-
out mice have invariably shown a stimulatory effect of Angptl4 on plasma TG levels, which is
achieved by inhibiting LPL activity (Yoshida et al. 2002, Yu et al. 2005, Backhed et al. 2004, Ge,
Yang, Yu, Pourbahrami and Li 2004, Xu et al. 2005, Koster et al. 2005, Mandard et al. 2006, Desai
et al. 2007). These data have established Angptl4 as an important circulating regulator of plasma
TG levels. The present data suggest that Angptl4 not only acts as an endocrine factor, but also
acts locally in an autocrine/paracrine manner in response to dietary fatty acids to inhibit local
LPL activity and consequently fatty acid uptake. The PPAR-dependent upregulation of Angptl4
and Ucp3 by dietary linolenic acid underscores the importance of TG-rich lipoproteins as a po-
tent source of PPAR ligands in the heart, which are liberated via the action of LPL (Ziouzenkova
et al. 2003, Augustus et al. 2004). Remarkably, upregulation of Angptl4 by C18:3 was mediated
by PPARβ/δ and not PPARα, while the induction of Ucp3 was regulated exclusively via PPARα.
These data were supported by ChIP data showing C18:3-induced binding of PPARβ/δ and not
PPARα to the Angptl4 gene. This is somewhat surprising as Angptl4 was originally identified as
PPARα target gene in liver and has been shown to be potently activated by PPARα agonists in
numerous organs and cell lines, including liver, small intestine, kidney, and C2C12 myotubes (Yu
et al. 2005, Mandard et al. 2004a, Kersten et al. 2000, Ge et al. 2005, Bunger et al. 2007).
At the same time, Angptl4 has been shown to be highly inducible by PPARβ/δ agonists, as
observed in liver, skeletal muscle, adipose tissue, keratinocytes, fibroblasts, and C2C12 myotubes
(Akiyama et al. 2004, Schmuth et al. 2004, Schug et al. 2007, Rieck et al. 2008); our unpub-
lished observations). It is unclear what mechanism may underlie the differential regulation of
Angptl4 and Ucp3 by PPARβ/δ vs. PPARα, respectively. Gel shift and transactivation studies
have failed to provide convincing evidence for the existence of response elements or promoters
that are specifically or selectively bound or regulated by a particular PPAR isotype (Juge-Aubry
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Figure 5.10: Model of the role of Angptl4 in the heart. Triglycerides arrive at the heart as TG packaged into chy-
lomicrons or VLDL particles. Plasma TG are hydrolyzed by lipoprotein lipase to release fatty acids, which are taken
up by the cardiomyocyte. Excess uptake of fatty acids gives rise to oxidative stress and leads to induction of Angptl4
expression via PPARβ/δ. Angptl4 will feed back on fatty acid uptake by inhibiting lipoprotein lipase.
et al. 1997, Heinaniemi et al. 2007). Indeed, in vitro transactivation experiments revealed that
all three PPARs are inherently able to transactivate the human and mouse Angptl4 gene ( Man-
dard et al. 2004). Clearly, our knowledge of the molecular determinants of PPAR binding and
promoter regulation in vivo is insufficient. In the present study, induction of cardiac Angptl4 by
dietary fatty acids in vivo was exclusively mediated by PPARβ/δ. In cultured cardiomyocytes we
found that Angptl4 expression was equally induced by C18:3 and the synthetic PPARβ/δ agonist
GW501516. In these cells, Angptl4 is also upregulated by synthetic agonists for PPARα (our
unpublished data), which may account for the inhibitory effect of PPARα activation on LPL ac-
tivity in these cells (Carroll and Severson 2001). Currently, the effect of PPARβ/δ activation on
LPL activity in cardiomyocytes remains unclear. Recently, targeted PPARβ/δ overexpression was
shown to have a clear differential effect on cardiac metabolism compared to PPARα overexpres-
sion (Burkart et al. 2007). In contrast to PPARα, PPARβ/δ overexpression did not impact fatty acid
transport and failed to induce myocardial lipid accumulation. Based on the data presented here
it can be hypothesized that PPARβ/δ is neutral towards cardiac lipid storage by inducing Angptl4
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expression, which in turn feeds back on fatty acid uptake. Multiple studies support an effect of
Angptl4 on angiogenesis and endothelial function, although presently it is unclear whether its role
is primarily pro- or anti-angiogenic (Le Jan et al. 2003, Ito et al. 2003, Cazes et al. 2006, Galaup
et al. 2006, Hermann et al. 2005, Padua et al. 2008). Our immunohistochemical results indicate
that Angptl4 is absent from vascular endothelial cells in the heart, whereas it is abundantly present
in cardiomyocytes. These data are in line with previous studies showing that Angptl4 is absent
from a number of different endothelial cells, yet is dramatically induced under hypoxic conditions
53, 55. Hypoxia also upregulates Angptl4 in cardiomyocytes (Belanger et al. 2002). Induction of
Angptl4 by hypoxia and the associated inhibition of fatty acid uptake may be an adaptive mech-
anism to shift fuel use towards glucose, which requires less oxygen for oxidation. In conclusion,
our data show that an acute oral load of triglycerides stimulates an oxidative stress response in the
heart. The concomitant upregulation of Angptl4 by dietary fatty acids is mediated by PPARβ/δ
and is part of a feedback mechanism aimed at protecting the heart against lipid overload and con-
sequently fatty-acid induced oxidative stress, one of the hallmarks of lipotoxic cardiomyopathy.
Submitted for publication as: L. Lichtenstein, N.J. de Wit, G.J. Hooiveld, E. Oosterink, R. van de Meer, A. Ko¨ster, J.
T. Tamsma, N. Soon Tan, M. Mu¨ller and S. Kersten – “Angptl4 protects against severe pro-inflammatory effects of
dietary saturated fat,” 2009
Chapter 6
Angptl4 protects against severe pro-inflammatory effects
of dietary saturated fat
Abstract
Consumption of saturated fat is linked to numerous chronic diseases, including cardiovascular disease and
inflammatory bowel disease. Here we identify Angiopoietin-like protein 4 as a fat-sensitive intestinal hor-
mone produced by specific enteroendocrine cells whose expression is critical for the proper response to
dietary saturated fats. Strikingly, in mice lacking Angptl4 dietary saturated fat induces a severe and ulti-
mately lethal phenotype consisting of fribrinopurulent peritonitis, intestinal inflammation and fibrosis, and
cachexia. These clinical abnormalities are preceded by a massive acute phase response, which is specif-
ically induced by a high saturated but not unsaturated fat diet. Further analysis revealed that Angptl4-/-
mice exhibit decreased mucosal immune function. Angptl4 was shown to bind integrin αVβ5 which was lo-
calized to intestinal neutrophils, suggesting Angptl4 modulates mucosal immunity via integrin αVβ5. Taken
together, we demonstrate that Angptl4 governs mucosal immunity and protects against the pro-inflammatory
and ultimately lethal effects of dietary saturated fat.
6.1 Introduction
Elevated saturated fat consumption is associated with increased risk for numerous chronic dis-
eases, including cardiovascular disease, inflammatory bowel disease, and type 2 diabetes (Mann
2002). However, the underlying mechanism and why specifically saturated fat is harmful largely
remains unknown. Consequently, there is a need to better understand the physiological and molec-
ular mechanisms that underlie the response to high fat consumption. While much is known about
the acute effects of dietary fats, including effects on satiety and satiation, there is poor understand-
ing of the regulatory mechanisms invoked upon chronic fat overconsumption. The gastro-intestinal
(GI) tract serves as the entry point for nutrients and energy in the body and hence represents a
key organ for therapeutic targeting of diseases related to nutrient overconsumption. Besides car-
rying out nutrient digestion and absorption via the production of numerous digestive enzymes,
the GI-tract also produces a variety of hormones that play pivotal roles in nutrient handling and
energy homeostasis. These gut hormones are synthesized by specialized enteroendocrine cells
located in the epithelial layer along the GI-tract. Functions of gut hormones include priming
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the body for subsequent absorption of dietary nutrients, controlling the delivery of bile and pan-
creatic juice into the gut lumen, orchestrating the renewal of the gut epithelium, and regulating
food intake (Drucker 2007, Sanger and Lee 2008). Release of several gut hormones is known
to be influenced by fat entering GI tract, including GLP-1 and cholecystokinin (Beglinger and
Degen 2004, Herrmann et al. 1995). In addition, dietary fat may induce gut hormones at the
level of gene expression, representing a more chronic type of regulation. We hypothesized that
by studying the changes in expression of secreted proteins in response to chronically elevated sat-
urated fat consumption, we would be able to identify key hormones involved in the handling of
dietary saturated fats.
6.2 Materials and Methods
Animals: All animal studies were done using pure-bred WT and Angptl4 -/- mice on a C57Bl/6
background (Koster et al. 2005). In study 1 male 11-week old mice were fed a LFD or HFD for 8
or 19 weeks, providing 10 or 45% energy percent as triglycerides (D12450B or D12451, Research
Diets Services, Wijk bij Duurstede, The Netherlands). Mice were anaesthetized with a mixture
of isoflurane (1.5%), nitrous oxide (70%) and oxygen (30%). Blood was collected by orbital
puncture into EDTA tubes. The mice were killed by cervical dislocation, after which tissues were
excised and directly frozen in liquid nitrogen or prepared for histology. In study 2 male 10-18
week old mice were fed HFD for 3 weeks. The fat source of the HFD was either palm oil (HFD
used in the first study), lard, MCT oil, or saﬄower oil. Blood was collected from the tail vein at
weekly intervals. The animal studies were approved by the Local Committee for Care and Use of
Laboratory Animals at Wageningen University. Two terminally ill animals were transferred to the
Small Animal Pathology laboratory of the Faculty of Veterinary Medicine at Utrecht University
for a formal autopsy by a licensed animal pathologist. A detailed macroscopic, microscopic and
cytologic report was prepared.
Lipid excretion and absorption: During week 3-5 of high fat feeding, the amount of lipid
excreted was measured in the faecal samples using established methods. Measurement of intestinal
lipid absorption using 3H-labeled triolein and 14C-labeled palmitic acid was carried out exactly as
previously described (Goudriaan et al. 2002).
Ascites: Diagnostic assays on the ascites fluid (WBC, RBC, albumin, protein, triglycerides)
was carried out at the clinical chemistry laboratory of the Gelderse Vallei Hospital (Ede, the
Netherlands) using standard methodology. Lipoprotein profiling of the ascites fluid was carried
out by FPLC as previously described (Lichtenstein et al. 2007).
Plasma analyses: Plasma levels of serum amyloid A (SAA) and endotoxins (Limulus Amoe-
bocyte Lysate) were determined by ELISA (Biosource International, Breda, The Netherlands and
SanBio, Uden, The Netherlands) following instructions from the manufacturer. Plasma con-
centrations of multiple inflammation markers were measured by multiplex immunoassay (Ro-
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dentMAP) (Rules BasedMedicine, Austin, TX). Liver triglycerides were determined as previously
described (Mandard et al. 2006).
Gene expression analysis: Isolation of RNA and subsequent analysis of gene expression by
qPCR were carried out as previously described (Sanderson et al. 2008). Cyclophilin, 18S, or 36B4
were used as housekeeping genes. PCR primer sequences were taken from the PrimerBank and
ordered from Eurogentec (Seraing, Belgium). Sequences of the primers used are available upon
request. The small intestine was divided into three equal parts along the longitudinal axis (referred
to as part 1, 2 and 3). Affymetrix Genechip analysis was carried out on part 1 and 2 combined
and on part 3 as previously described (de Wit et al. 2008). Data were analyzed using MAS5.0
software. Analysis of Gene ontology classes over-represented in the Angptl4-/- mice was carried
out using ErmineJ.
Histology/Immunohistochemistry: For IgG immunostaining in small intestine, five-micrometer
sections of paraffin-embedded distal part of the small intestine were mounted on Superfrost mi-
croscope slides. These sections were dewaxed in xylene and rehydrated in a series of graded
alcohols. To block endogenous peroxidase activity, slides were incubated with 3% H2O2 for 20
minutes. Antigen retrieval was performed by placing the slides in citrate buffer (pH 6.0) and
heat them in a microwave oven 5 min 700 W (without lid) and 4 times 5 min 500 W (with lid).
After cooling down to room temperature, the sections were briefly washed with PBS. Prior to
staining, a 20 minutes preincubation was performed using 20% normal rabbit serum (Vector Lab-
oratories, Burlingame, CA, USA). The sections were incubated for 30 minutes at room temper-
ature using HRP-conjugated rabbit anti-mouse IgG antibodies (Serotec), diluted 1:250 in PBS.
Diaminobenzidine tetrahydrochloride (DAB, Vector Laboratories) was used as substrate to vi-
sualize the bound antibodies. After counterstaining with Meyer’s hematoxylin, sections were
mounted with DePex mounting medium (Gurr, BDH, Poole, Dorset, UK). For detection of liver
macrophages, immunohistochemistry was performed using an antibody against Cd68 respectively
(Serotec, Oxford, UK). Sections were pre-incubation with 20% normal goat serum followed by
overnight incubation at 4◦C with the primary antibody diluted 1:50 in PBS/ 1% Bovine Serum
Albumin (BSA). After incubation with the primary antibody, a goat anti rat IgG conjugated to
horseradish peroxidase (Serotec) was used as secondary antibody. Visualization of the complex
was done using AEC Substrate Chromogen for 6 minutes. Negative controls were used by omit-
ting the primary antibody. Haematoxylin and Eosin staining of sections was done using standard
protocols. For Angptl4 and β5-integrin immunostaining, paraffin embedded samples of the ter-
minal human ileum were obtained from Dr. Andries Mulder at the Rijnstaete Hospital (Arnhem,
the Netherlands). Immunohistochemistry was performed using an antibody directed against the
C-terminus of Angptl4 (AA186-406) or against β5 integrin (Abcam, Cambridge, UK). Sections
were incubated one hour with the primary antibody diluted 1:50 in PBS 1X. A goat anti-rabbit IgG
conjugated to horseradish peroxidase (Serotec) was used as secondary antibody. Visualization of
the complex was done using AEC Substrate Chromogen for 10 minutes. For Sirius Red staining
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paraffin-embedded samples of the small intestine were mounted on Superfrost microscope slides.
These sections were dewaxed in xylene and rehydrated in a series of graded alcohols. Slides were
stained in picrosirius red 0.1% picric acid for 90 minutes and rinced in acidified H2O 0.5% acetic
acid.
Binding assay Angptl4 and integrin αVβ5: In the first assay, 96-well microtiter plates were
coated with 100 µl/well of integrin αVβ5 (USBiological, 37K, Swampscott, MA, USA; 5 µg/ml
in PBS 1X, pH 7.35) and incubated overnight at 4◦C. The plate was washed four times with wash
buffer (PBS, pH 7.4, 0.1% Tween-20), and 300 µl/well of blocking buffer (PBS, pH 7.35, 1%
BSA) was added for 1 hour at room temperature, 100 rpm. Various amounts (0, 0.31 µg, 0.62
µg, 1.25 µg, 2.5 µg, or 5 µg) of hAngptl4 (3485-AN, R&D Systems) were prepared in diluent
buffer (0.1% BSA, PBS 1X, pH 7.4, 0.5% Tween 20) and 100 µl/well was added to the plate for
2 hours at room temperature, 100 rpm. Plates were washed with buffer and 100 µl of diluted
biotinylated anti-hAngptl4 polyclonal goat IgG antibody (BAF3485, R&D Systems) was added at
0.02 mg per well, followed by 2 hours incubation. After four washes, 100 µl/ well streptavidine-
conjugated horseradish peroxidase (1X PBS, 1%BSA, 1:200 HRP R&D DY998) was added for
20 min at room temperature, 100 rpm. After washing, 100 µl/well of tetramethylbenzidine (TMB)
(Sigma T4444) was added and incubated in the plates for 6 min at room temperature. 50 µl/well
Stop solution (10% H2SO4) was added to stop the reaction. Absorbance was read at 450 nm.
In the second assay, 96-well microtiter plates were coated with 100 µl/well of integrin αVβ5 (5
µg/ml in PBS 1X, pH 7.35) and incubated overnight at 4◦C. The plate was washed four times with
wash buffer (PBS, pH 7.4, 0.1% Tween-20), and 300 µl/well of blocking buffer (PBS, pH 7.35, 1%
BSA) was added for 1 hour at room temperature, 100 rpm. hANGPTL4 (5 µg/ml) alone, or with
anti-β5 antibody (5 µg/ml; Ab15459 Abcam) or with IgG-hAngptl4-Cterminal (5 µg/ml; AA186-
406), or with anti-albumin antibody (Sigma A0433), were prepared in diluent buffer (0.1% BSA,
PBS 1X, pH 7.4, 0.5% Tween 20), and incubated for 30 minutes. Samples were added to plates
(100 µl/well in the amounts incubated above) and incubated for 2 hours at room temperature, 100
rpm. Plates were washed with buffer and 100 µL of diluted biotinylated anti-hAngptl4 polyclonal
goat IgG antibody (BAF3485, R&D Systems) was added at 0.02 mg per well, followed by 2 hours
incubation. After four washes, 100 µl/ well streptavidine-conjugated horseradish peroxidase (1X
PBS, 1%BSA, 1:200 HRP R&D DY998) was added for 20 min at room temperature, 100 rpm.
After washing, 100 µl/well of TMB was added and incubated in the plates for 6 min at room
temperature. 50 µl/well Stop solution (10% H2SO4) was added to stop the reaction. Absorbance
was read at 450 nm. In the third assay, human recombinant Vitronectin (2349-VN, R&D Systems),
human recombinant Angptl4, or BSA (5 µg/ml in PBS1X, pH 7.35) were coated on a 96-well
microtiter plates and incubated overnight at 4◦C. The plate was washed four times with wash
buffer (PBS, pH 7.4, 0.1% Tween-20), and 300 µl/well of blocking buffer (PBS, pH 7.35, 1%
BSA) containing either IgG-hAngptl4-Cterminal (5 µg/ml; AA186-406) or anti-albumin antibody
was added for 1 hour at room temperature, 100 rpm. Plate was washed with buffer and 100 µL
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of αVβ5 (5µg/ml in diluent buffer; 0.1% BSA, PBS 1X, pH 7.4, 0.5% Tween 20) was added and
incubated for 2 hours at room temperature, 100 rpm. Plate was washed and anti-β5 antibody (5
µg/ml) was prepared in diluent buffer, and incubated for 2 hours at room temperature with gentle
agitation. After washing anti-rabbit IgG-HRP conjugated (1:3000, Sigma A0545) was added for
1 hour with gentle agitation. After washing, 100 µl/well of TMB was added and incubated in the
plates for 6 min at room temperature. 50 µl/well Stop solution (10% H2SO4) was added to stop
the reaction. Absorbance was read at 450 nm.
6.3 Results
To screen for novel gut hormones that are under control of dietary saturated fat, we gave mice
a chronic fat overload and analyzed changes in expression of genes encoding secreted proteins
using transcriptomics (de Wit et al. 2008). One of the genes that was consistently upregulated
by dietary saturated fat in small intestine encoded Angptl4 (Figure 6.1a), a secreted protein be-
longing to the family of angiopoietins also known as fasting-induced adipose factor and PPARγ
angiopoietin-related (Kersten et al. 2000, Yoon et al. 2000). Angptl4 has been shown to govern
lipid metabolism by inhibiting plasma triglyceride clearance and stimulating adipose tissue lipol-
ysis (Kersten 2005). In addition, several studies support an effect of Angptl4 on endothelial func-
tion (Cazes et al. 2006, Ito et al. 2003, Padua et al. 2008). Expression of Angptl4 was highest in
the distal part of the small intestine (Figure 6.1b). Immunohistological staining of Angptl4 protein
on sections of human ileum showed that Angptl4 is present in isolated cells within the mucosa,
which were identified as enteroendocrine cells by counter staining using the specific enteroen-
docrine marker chromogranin A (Figure 6.1c). These data establish Angptl4 as a gut hormone that
is induced by dietary saturated fat. To examine the role of Angptl4 in the response to saturated
fat, WT and Angptl4-/- mice were fed a high fat diet (HFD) rich in palm oil. As expected, weight
gain was increased in mice receiving HFD. Remarkably, bodyweights of Angptl4-/- mice fed HFD
reached a plateau around 12 weeks and declined thereafter (Figure 6.2a). The decrease in body-
weight was related to anorexia, which was noticeable after about 10 weeks of HFD (Figure 6.2b).
If left undisturbed all Angptl4-/- mice fed HFD would ultimately die anywhere between 15 and
25 weeks. The cause of death was identified by an animal pathologist as severe fibrinopurulent
peritonitis connected with ascites In the Angptl4-/- mice fed HFD, large amounts of fibrin exudate
covered the abdominal organs (Figure 6.2c). Other macroscopic abnormalities included intestinal
fibrosis (Figure 6.2d), a compressed liver, hyperplasic spleen, and subcutaneous hyperemia (data
not shown). No such abnormalities were observed in Angptl4-/- mice fed a LFD, even at advanced
age (>1.5 years). We performed routine clinical tests on the ascites fluid, which varied in color
from purulent white to purulent red. Ascites white blood cell count was extremely high in all
animals (25.5-34.1*109/L), as was the endotoxin concentration (50-120 EU/mL). Ascites fluid of
some animals tested positive for E. Coli. The combination of high protein concentration (3.43-
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Figure 6.1: Angptl4 is produced by enteroendocrine cells and is stimulated by HFD. (A) Angptl4 mRNA expression in
total small intestine of C57Bl/6 mice after 2, 4 or 8 weeks of LFD or HFD. Grey bars = WT, Black bars = Angptl4-/-.
Error bars represent SEM. ∗ = significantly different between WT and Angptl4-/- mice according to Student’s T-test
(p<0.05). (B) Angptl4 mRNA expression was determined in different parts of the mouse small intestine by qPCR. (C)
High magnification image of serial sections of human intestinal ileum stained with an antibody against ANGPTL4
(right panel), or chromogranin A (left panel), which is a specific marker for neuroendocrine cells. ANGPTL4 positive
cells are present in the mucosa adjacent to goblet cells and enterocytes.
4.28 g/dL) and low serum-ascites albumin gradient (SAAG, 0.11-0.34 g/dL) indicated exudative
ascites. The ascites triglyceride concentration was highly variable but clearly elevated (4.8-75.5
mM). Analysis of ascites fluid by lipoprotein profiling indicated an abundance of chylomicrons
(Figure 6.3a). Plasma endotoxin levels were significantly elevated in Angptl4-/- mice fed HFD
(Figure 6.3b). Microscopic examination indicated that the fibrin exudate contained an abundance
of foam cells, polynuclear giant cells, and various other leukocytes (data not shown). The same
cells as well as focal lymphocyte infiltrates were observed in the mesentery and small intestine
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Figure 6.2: : Angptl4-/- mice chronically fed HFD develop fibrinopurulent peritonitis and ascites. (A) Bodyweight
changes in WT and Angptl4-/- mice fed LFD or HFD for 19 weeks. (B) Mean daily food intake in WT and Angptl4-/- mice
fed LFD or HFD for 19 weeks. (C) Whole animal photographs taken immediately following sacrifice of representative
WT and Angptl4-/- mice fed either LFD or HFD for 19 weeks. Pictures on the far right were taken after removal of the
peritoneum. Ascites fluid collected from two Angptl4-/- mice fed HFD is shown at the bottom. (D) Photograph of small
intestine of WT and Angptl4-/- mouse fed LFD or HFD for 19 week.
(Figure 6.4a & b), in the latter encapsulated by collagen as shown by Sirius Red staining (Figure
6.4c) Adipose tissue was very reddish and exhibited coagulation necrosis and steatitis as shown
by presence of granulocytes and other infiltrates, mainly at the periphery (Figure 6.5a & b). In the
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Figure 6.3: : Chylous ascites and endotoxemia in Angptl4-/- mice fed HFD. (A) Lipoprotein profiling of ascites fluid by
FPLC reveals markedly elevated levels of chylomicrons. Results from two mice varying in ascites fluid TG concentration
are shown. (B) Plasma endotoxin levels in WT and Angptl4-/- mice fed LFD or HFD for 19 weeks, as determined by LAL
Chromogenic endotoxin assay. Grey bars = WT, Black bars = Angptl4-/-. Error bars represent SEM. ∗ = significantly
different between WT and Angptl4-/- according to Student’s T-test (p<0.05).
liver, which generally looked ischemic, portal triads were poorly visible and cords and sinusoids
were missing, indicating collapse of liver (Figure 6.5c & d). Additionally, clumping of nuclei and
aggregates of eosinophils were observed,and liver fat was almost absent (Figure 6.5e). Weights
of liver and adipose tissue were significantly lower in Angptl4-/- mice after 19 weeks of HFD
(Figure 6.5f & g). From these data it is evident that Angptl4-/- mice fed a HFD develop a severe
phenotype characterized by anorexia,cachexia, intestinal inflammation and fibrosis, ascites, and
fibrinopurulent peritonitis, ultimately leading to the death of the animal Previously it was shown
that Angptl4-/- mice on a mixed Sv129-C57Bl/6 background die shortly after birth due to defective
separation of the intestinal lymphatic and blood microvasculature (Ba¨ckhed, Crawford, O’Donnell
and Gordon 2007). Although we did not observe these abnormalities in Angptl4-/- mice on a pure
C57Bl/6 background and adult mice in the proper Mendelian ratios were obtained, it is conceiv-
able that there is an underlying weakness in intestinal lymph vessels that only becomes manifest
under condition of increased chyle flow associated with HFD. Subsequent leakage of chyle into
intestinal lumen and peritoneal cavity may lead to impaired fat absorption and chylous ascites,
respectively. However, according to that scenario ascites should develop shortly after starting the
HFD, which was not the case. Additionally, one would expect loss of protein, fat and water from
lymph into the GI lumen, leading to osmotic diarrhea and steatorrhea. No diarrhea was observed
and surprisingly, fecal fat excretion was markedly decreased in Angptl4-/- mice, indicating more
efficient fat absorption (Figure 6.6a). An acute intestinal lipid absorption test using 3H-triolein
and 14C-palmitic acid failed to show any differences in rate of appearance of either label in blood
between WT and Angptl4-/- mice (Figure 6.6b & c), suggesting that chylomicron formation and
release into the bloodstream is similar betweenWT and Angptl4-/- mice. In contrast, in all parts of
the intestine accumulation of both labels five hours after the lipid load was markedly higher in the
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Figure 6.4: Severe intestinal inflammation in Angptl4 -/- mice chronically fed HFD. H&E staining of small intestine
(A) or mesentery (B) of WT and Angptl4-/- mice fed HFD for 19 weeks. (C) Sirius red staining of small intestine of WT
and Angptl4-/- mice fed HFD for 19 weeks. Arrow indicates inflammatory infiltrate.
Angptl4-/- mice (Figure 6.6d&e). Similar data for 3H-triolein and 14C-palmitic acid argue against
an effect of Angptl4 inactivation on triglyceride digestion but instead suggest enhanced fatty acid
uptake into enterocytes. This is supported by elevated expression of target genes of the fatty acid-
activated transcription factor PPAR α in small intestine of Angptl4-/- mice, indicating enhanced
gene regulation by fatty acids (Figure 6.6f & g). Overall, these data do not support the notion
that ascites and intestinal inflammation are caused by a primary lymph vessel defect, suggesting a
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week. Angptl4-/- mice reveal steatitis as shown by massive infiltration of granulocytes and other leukocytes around the
periphery. (C) Photograph of livers of WT and Angptl4-/- mouse fed LFD or HFD for 19 week. Livers of WT mice fed
HFD were enlarged and pale, indicating steatosis. Livers of Angptl4-/- mice fed HFD were rigid and compressed. (D)H
&E staining of livers of WT and Angptl4-/- mouse fed HFD for 19 weeks. Staining reveals missing cords and sinusoids,
poorly visible portal triads and lack of hepatic fat in Angptl4-/- mice fed HFD. (E) Liver triglycerides after 19 weeks of
LFD or HFD. Weights of epididymal fat (F) and liver (F) after 19 weeks of LFD or HFD. Grey bars = WT, Black bars
= Angptl4 -/-. Error bars represent SEM ∗ = significantly different according to Student’s T-test p < 0.05
different etiology. To investigate the cause of the diverse clinical abnormalities in the Angptl4-/-
mice, we studied WT and Angptl4-/- mice after 8 weeks of HFD before the onset of any clinical
signs. Importantly, at that point no ascites, intestinal fibrosis, fibrin exudate, or other macroscopic
abnormalities were observed. Also, anorexia and cachexia were absent (Figure 6.2a & b). As men-
tioned above, the ascites in the Angptl4-/- mice was characterized as exudative ascites. Exudative
ascites excludes portal hypertension as the primary origin and indicates increased capillary and/or
lymphatic permeability, which is often related to inflammation and/or infection. To investigate
whether the ascites is preceded by excessive inflammation and/or infection, inflammatory mark-
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Figure 6.6: Absence of fat malabsorption in Angptl4-/- mice. (A) Fat excretion expressed as a percentage of dietary fat
intake during week 2-5 of LFD or HFD. (B)(C) Mice fasted for 5h were given 400 L of olive oil containing 7 Ci glycerol-
tri[3H] oleate and 2 Ci [14C]palmitate. Blood was collected every hour. 3H- and 14C-radioactivity are expressed as a
percentage of total oral dose. (D)(E) Five hours thereafter, small intestine was collected and cut into 3 parts. 3H- and
14C-radioactivity are expressed as a percentage of total oral dose. (F) Heat map showing fold changes in expression
of PPAR -target genes in small intestine of Angptl4-/- vs. WT mice. (G) mRNA expression of selected PPAR targets in
small intestine of WT and Angptl4-/- mice. Grey bars = WT, Black bars = Angptl4-/-. Error bars represent SEM. ∗ =
significantly different between WT and Angptl4-/- mice according to Student T-test (p<0.05).
ers were measured in WT and Angptl4-/- mice after 8 weeks of HFD. Strikingly, plasma levels
of the acute phase protein Serum Amyloid A were dramatically increased in Angptl4-/- mice fed
HFD (Figure 6.8a), which was also true for numerous cytokines, chemokines, and other inflamma-
tory markers (Figure 6.7). These changes were paralleled by similar massive induction of hepatic
mRNA for serum amyloid 2 (Figure 6.8b), haptoglobin, and lipocalin 2 (Figure 6.8c)
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Antigen units WT Angptl4-/-
CD40 Ligand pg/mL 470±93 1553±182
MCP-1 pg/mL 32±7 55±5
MCP-3 pg/mL 73±9 136±10
MCP-5 pg/mL 5.0±1.4 18.5±4.6
MDC pg/mL 249±5 347±27
IL-1beta ng/mL 6.5±0.1 7.3±0.3
IL-5 ng/mL 0.9±0.1 1.4±0.0
IL-6 pg/mL nd 63±26
MIP-1gamma ng/mL 13±1 24±3
MIP-3beta ng/mL 0.8±0.0 1.1±0.1
MMP-9 ng/mL 78±5 180±28
MPO ng/mL 47±2 188±23
TIMP-1 ng/mL 0.6±0.0 2.5±0.6
vWF ng/mL 97±5 225±83
Factor VII ng/mL 5.7±0.3 7.1±0.4
CRP µg/mL 6.7±0.1 10.5±0.7
Haptoglobin µg/mL 34±12 201±32
IgA µg/mL 18±1 34±3
Fibrinogen mg/mL 10±1 36±7
Apo A1 µg/mL 35±1.2 28±0.5
Figure 6.7: Plasma cytokine profiling in WT and Angptl4-/- mice fed HFD for 8 weeks
Hepatic expression of the inflammatory mediator Stat3 and macrophage (Kupffer cell) marker
Cd68 was also markedly induced (Figure 6.8c), and Cd68 immunostaining was increased (Fig-
ure 6.8d). Furthermore, Angptl4-/- mice fed HFD had dramatically enlarged mesenteric lymph
nodes (see below), and the mesentery showed an abundance of leukocytes, indicating intestinal
infection (Figure 6.9). These data indicate that Angptl4-/- mice fed HFD exhibit chronic inflam-
mation and a massive acute phase response several weeks prior to development of ascites and
other external clinical symptoms, which is likely related to intestinal infection. The HFD used
contains predominantly palm oil, which is rich in saturated fat. To assess the time course of in-
duction of the inflammation and to study whether induction was exclusive to saturated fat, WT
and Angptl4-/- mice were fed diets of different fat composition and plasma SAA levels monitored.
Remarkably, HFDs based on palm oil or lard caused a dramatic increase in plasma SAA levels
in the Angptl4-/- mice, which was already noticeable after one week of feeding (Figure 6.8e). In
contrast, HFDs based on saﬄower oil, which contains almost exclusively unsaturated fatty acids,
or based on medium chain triglycerides (MCT) did not raise plasma SAA levels. Consistent with
these data, size of mesenteric lymph nodes was dramatically enlarged in Angptl4-/- mice fed palm
oil or lard compared to saﬄower or MCT oil (Figure 6.8f). Since saﬄower oil promotes chyle
flow compared to medium chain triglycerides, these data argue against increased chyle flow and
consequent leakage as a critical early event in the development of the acute phase response and
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Figure 6.8: High fat feeding provokes a massive acute phase response in Angptl4-/- mice. (A) Plasma serum amyloid
(SAA) levels in WT and Angptl4-/- mice fed LFD or HFD. (B) Hepatic SAA2 mRNA levels, as determined by qPCR.
(C) Hepatic mRNA levels of acute phase proteins haptoglobin and lipocalin 2, the transcription factor Stat3 and the
macrophage marker Cd68, as determined by qPCR. Expression data were normalized against 36B4. Grey bars = WT,
Black bars = Angptl4-/-. Error bars represent SEM. ∗ = significantly different according to Student T-test (p<0.05). (D)
Cd68 immunostaining of liver sections of WT and Angptl4-/- mice fed HFD for 8 weeks. (E) Plasma SAA levels in WT
mice (black symbols) and Angptl4-/- mice (red symbols) fed LFD or HFD for 3 weeks. The fat source of the HFD was
either lard (squares), palm oil (circles), MCT oil (triangle), or saﬄower oil (reverse triangle). (F) Size of mesenteric
lymph nodes in WT and Angptl4-/- mice fed the various diets for 8 weeks. ∗ = significantly different from LFD according
to Student T-test (p<0.05).
clinical abnormalities. Taken together, these data indicate that saturated but not unsaturated fat ex-
erts a marked pro-inflammatory effect, which is suppressed by Angptl4 expression. Recent studies
have indicated that high saturated fat feeding causes changes in the intestinal microflora, which in
turn may lead to inflammatory stress, e.g. metabolic endotoxemia (Cani et al. 2008, Turnbaugh
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Figure 6.9: Inflamed mesentery in Angptl4-/- mice fed HFD. H&E staining of mesentery of WT and Angptl4-/- fed HFD
for 6 week. Angptl4-/- mice fed HFD exhibit massive infiltration of granulocytes and other leukocytes.
et al. 2008). To study if the impaired tolerance to saturated fats in Angptl4-/- mice may be re-
lated to a poor defense to the changing microflora, we assessed indicators of intestinal immune
function. Remarkably, already under LFD the number of IgG-positive cells was significantly de-
creased in Angptl4-/-mice (Figure 6.10a). In support of these data, expression of genes involved in
immune function was suppressed in Angptl4-/- mice, including the B-cell marker CD79 and Igj, a
marker for differentiation of B-cells to plasma cells (Figure 6.10b). In addition, expression of the
bactericidal lectin Reg3 was severely reduced. Further analysis by gene expression profiling con-
firmed a dramatic and comprehensive down-regulation of numerous genes involved in the immune
response in the intestine (Figure 6.10c), Consistent with these data, analysis of gene ontology
revealed highly significant alterations in humoral immune response, antigen presentation, acute
phase response, immune cell activation and defense response to bacteria (Figure 6.11). These data
strongly suggests that deletion of Angptl4 is associated with decreased mucosal immunity, which
is already evident on LFD Impaired immune function in the intestine of Angptl4-/- mice is hard to
reconcile with the function of Angptl4 as LPL inhibitor. Analogous to Angptl3 and consistent with
the presence of an RGD sequence representing a cell attachment signal that mediates interactions
with certain integrins, Angptl4 may bind to integrins as well (Camenisch et al. 2002). Indeed,
we found that Angptl4 directly interacts with integrin β5 and regulates migration, proliferation
and differentiation of keratinocytes (Goh et al, submitted). Using Elisa, dose-dependent binding
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Figure 6.10: Decreased innate immunity in small intestine of Angptl4-/- mice. (A) IgG immunostaining of sections
of small intestine from WT and Angptl4-/- mice fed LFD. (B) mRNA expression of B cell markers Cd79 and Igj and
the anti-bacterial lectin Reg3 in small intestine of WT and Angptl4-/- mice fed LFD. Grey bars = WT, Black bars =
Angptl4-/-. Error bars represent SEM. ∗ = significantly different according to Student T-test (p<0.05). (C) Heat map
showing fold changes in expression of genes involved in immune response of Angptl4-/- vs. WT mice fed LFD.
of coated integrin αVβ5 to Angptl4 was observed (Figure 6.12a). Importantly, this interaction
was reduced by co-incubation with an antibody against Angptl4 and integrin β5, but not albumin
(Figure 6.12b). Conversely, coated Angptl4 bound to integrin αVβ5, which was abolished by the
anti-Angptl4 antibody but not control antibody (Figure 6.12c). Vitronectin, which binds integrin
αVβ5, and BSA were used as positive and negative controls, respectively. To study whether the
effects of Angptl4 on intestinal immune function may be exerted via integrin αVβ5, we assessed
the location of integrin β5 in the small intestine by immunohistochemistry. In agreement with a
role of integrin β5 in intestinal immune function, specific staining of isolated immune cells in the
lamina propria was observed (Figure 6.12d & e). Based on the distribution of integrin β5-positive
cells, which differed from CD3 (T-cells), CD20 (B-cells) and CD35 (dendritic cell) positive cells,
their absence from Peyers patches (data not shown), and their lobulated nucleus (Figure 6.12e),
these cells very likely represent neutrophil granulocytes. Together with the data by Goh et al.,
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ID P value Name
GO:0006959 6.62E-09 humoral immune response
GO:0042591 1.67E-06 antigen presentation, exogenous antigen via MHC class II
GO:0006953 1.91E-06 acute-phase response
GO:0019882 2.13E-06 antigen presentation
GO:0045321 2.59E-05 immune cell activation
GO:0019884 3.10E-05 antigen presentation, exogenous antigen
GO:0016064 3.16E-05 humoral defense mechanism (sensu Vertebrata)
GO:0042742 3.27E-05 defense response to bacteria
GO:0019886 9.26E-05 antigen processing, exogenous antigen via MHC class II
GO:0009617 1.47E-04 response to bacteria
GO:0006954 1.90E-04 inflammatory response
GO:0048002 2.01E-04 antigen presentation, peptide antigen
GO:0045576 2.01E-04 mast cell activation
GO:0050728 2.31E-04 negative regulation of inflammatory response
GO:0050777 2.31E-04 negative regulation of immune response
GO:0045582 2.58E-04 positive regulation of T-cell differentiation
GO:0030333 2.68E-04 antigen processing
GO:0042116 5.73E-04 macrophage activation
Figure 6.11: Overrepresented gene ontology classes in distal small intestine of Angptl4-/- mice fed LFD
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Figure 6.12: Effect of Angptl4 on immunity may be mediated via binding to integrin β5 on intestinal neutrophils. (A)
Binding assay showing dose-responsive binding of recombinant Angptl4 to coated integrin αvβ5. (B) Coated integrin
αVβ5 interacts with Angptl4, which is reduced by antibodies directed against integrin β5 and Angptl4 but not albumin.
(C) Coated vitronectin and Angptl4 but not BSA interact with integrin αVβ5. Binding between Angptl4 and integrin
αVβ5 is abolished by antibody against Angptl4 but not control antibody. Immunostaining of the human ileum using an
antibody against integrin β5 at low (D) or high (E) magnification.
these results suggest that Angptl4 may influence mucosal immune function via integrin-mediated
signaling in specific immune cells in the small intestine .
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Our studies support a major pro-inflammatory effect of dietary saturated fat, which is suppressed
by Angptl4. Recent studies have indicated that ultra high fat feeding in mice (72en% fat) induces
a state of metabolic endotoxemia, characterized by mildly but chronically elevated plasma LPS
levels (Cani et al. 2007, Cani et al. 2008). These effects are likely related to changes in intestinal
microflora and may be associated with increased gut permeability. Our observations are consis-
tent with a scenario in which Angptl4 deletion reduces protection against the intestinal microflora,
which becomes highly pro-inflammatory upon high saturated fat feeding but not high unsaturated
fat or MCT feeding. Subsequent translocation of bacteria elicit mesenteric lymphadenitis and
a full blown acute phase response, followed by cachexia, intestinal inflammation, and capillary
and lymphatic leakage, which in turn causes chylous ascites and accumulation of fibrin exudate.
Alternatively, it is conceivable that saturated fat has a direct pro-inflammatory effect in the in-
testine, which is suppressed by Angptl4. Recent studies indicate that saturated fatty acids can
activate Toll-like receptor 4, which plays a critical role in the innate immune system by activat-
ing pro-inflammatory signaling pathways in response to microbial pathogens (Hwang 2001, Lee
et al. 2001, Lee et al. 2003, Shi et al. 2006, Suganami et al. 2007). Whether Angptl4 impacts
Toll-like receptor signaling is unknown and requires further investigation. Our data indicate that
in addition to its role in lipid metabolism and angiogenesis, Angptl4 plays a major role in in-
testinal immunity. Gene expression analysis of small intestine specifically points to a role for
Angptl4 in the humoral immune response, including antigen presentation and the defense response
to bacteria. Indeed, already under baseline conditions, numerous immunoglobulins and class II
histocompatibility proteins, as well as specific lymphocyte markers such as Cd44 and Cd79 and
the anti-bacterial Reg3 were markedly downregulated in small intestine of Angptl4-/- mice. By
serving as a ligand for integrin αVβ5, it was shown that Angptl4 activates integrin-mediated in-
tracellular signaling (Goh et al. submitted). Interestingly, αV integrins have been shown to be
involved in mucosal immunity (Lacy-Hulbert et al. 2007). The dominant production of Angptl4
by specific enteroendocrine cells raises the possibility of paracrine activity by Angptl4 on adjacent
integrin a αVβ5-positive neutrophils to modulate mucosal immunity. Clearly, additional research
is required to elucidate the effect of Angptl4 on intestinal immune cell signaling and its specific
role in regulation of mucosal immune function. Expression of Angptl4 in the intestine was pre-
viously shown to diminish after introducing a normal intestinal microbiota into the intestine of
germ free mice, which was proposed to account for the stimulatory effect of the intestinal mi-
croflora on bodyfat (Backhed et al. 2004, Backhed, Manchester, Semenkovich and Gordon 2007).
Whether the induction of Angptl4 by HFD is related to changes in intestinal microbial population
elicited by HFD or reflects a direct effect of fatty acids on Angptl4 mRNA levels remains unclear
(Cani et al. 2007). It can be speculated that induction of Angptl4 by dietary saturated fat may be
an adaptive response to the pro-inflammatory and metabolic consequences of saturated fat con-
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sumption. (Chylous) ascites represents a rare phenotype among transgenic mouse models. It has
been observed in mice heterozygous for the transcription factor Prox1 as well as in mice lacking
angiopoietin-2. Both proteins are essential for development of the lymphatic vasculature (Gale
et al. 2002, Harvey et al. 2005). Accordingly, it is tempting to hypothesize a similar role for
Angptl4. However, it should be emphasized that the Prox1+/- and Ang2-/- mice already develop
chylous ascites shortly after birth, reflecting a severe developmental defect. In contrast, Angptl4-/-
mice do not show any changes in lymphatic endothelial integrity and do not exhibit ascites unless
challenged with HFD for at least 12 weeks. Furthermore, clinical abnormalities are exclusive to
mice fed a diet rich in saturated fat but not unsaturated fat, suggesting a mechanism independent
of chyle flow. Taken together, we demonstrate that Angptl4 protects against the pro-inflammatory
and ultimately lethal effects of chronic overconsumption of saturated fat. Our data characterize
Angptl4 as a novel modulator of intestinal immune function and suggest that dysfunctional reg-
ulation of Angptl4 may contribute to the pathology of chronic inflammatory intestinal diseases.
Angptl4 can be added to a growing list of secreted factors involved in regulation of fat metabolism
that also impact inflammation and immunity (Tilg and Moschen 2006).
Chapter 7
General discussion
The objective of this thesis was to functionally characterize the ANGPTL4 protein in mouseand human. Since its discovery in 2000, research on ANGPTL4 has evolved from in vitro
studies to in vivo mouse studies, and most recently to human genetic studies. It is now very
evident that ANGPTL4 is a key regulator of lipoprotein metabolism by interacting with the key
enzyme lipoprotein lipase (LPL). LPL is a rate-limiting enzyme in the clearance of the triglyceride
rich lipoproteins chylomicrons (CM) and very-low density lipoprotein (VLDL). Many genetically
modified mouse models have been developed in the last 2 decades that illustrate the importance
of this enzyme in plasma lipid metabolism. Lipid metabolism differs substantially post-prandially
and after a period of fasting. During fasting a fall in plasma glucose is followed by a decrease in
insulin secretion, and an increase in secretion of glucagon. In adipose tissue those changes inhibit
lipogenesis, lead to inactivation of LPL and activate hormone sensitive lipase. As a consequence,
plasma free fatty acids (FFA) rise. On the contrary, insulin levels increase post-prandially, which
leads to activation of LPL in adipose tissue, thereby allowing the ingested fat to be stored. When
there is a chronic dietary fat overload, for examples during chronic high fat feeding, elevated fatty
acid uptake into the adipose tissue may lead to obesity. Although obesity and fasting appear to
represent metabolic opposites, a number of parallels can be drawn. For example, both conditions
are associated with elevated plasma free fatty acid levels. Depending on the particular tissue,
both fasting and high fat induced obesity increase ANGPTL4 mRNA and protein expression. We
have taken advantage of those two nutritional extremes to study the role of ANGPTL4 in lipid
metabolism.
LPL exerts it action at the surface of endothelial cells bound to heparin sulphate proteoglycans
(HSPG). Once secreted LPL adopts a head to tail subunit orientation to form the active homod-
imer (Wong et al. 1997). Dissociation of LPL monomers leads to loss of activity, and consequently
to aggregation of the inactive monomers (Hata et al. 1992, Osborne et al. 1985). Within the blood
circulation, LPL binds to lipoproteins via apolipoproteins. Markku et al showed that native LDL
binds to monomeric LPL. However. Vilella et al. showed that both LPL mass and activity of
postheparin (PHP) plasma eluted with LDL. Molecular research described that this binding is al-
lowed by LPL recognition and binding to ApoB (Choi et al. 1997). In vitro studies have shown
that ANGPTL4 promotes the conversion of LPL dimers into monomers (Sukonina et al. 2006),
which we are able to confirm in vivo using our ANGPTL4-Tg mice (chapter 3). We showed
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that in blood plasma ANGPTL4 is physically associated with LDL-bound LPL monomers. One
could hypothesize that ANGPTL4 binds to LPL monomers, thereby pulling the equilibrium to-
wards LPL monomers and away from LPL dimers. The complex between LPL monomers and
ANGPTL4 may then bind to LDL and is subsequently taken away for further processing. In
contrast to Angptl3, ANGPTL4 seems to cause permanent inactivation of LPL activity which
is in agreement with the scenario explained above. A surprising observation that we made was
that PHP LPL activity was reduced to almost zero in ANGPTL4-Tg mice, while the reduction
in LPL-dimers in post-heparin plasma was much less. Recently, it was suggested that much of
the LPL released upon heparin injection may represent extravascular LPL, which may be bound
to HSPGs in subendothelial compartments or on the surface of adipocytes or myocytes and is
not involved in lipolysis of TG-rich lipoproteins (Weinstein et al. 2008). Accordingly, it is pos-
sible that ANGPTL4 only inactivated the functional LPL present on the endothelium yet had no
effect on ”subendothelial LPL”. In this context it is interesting to mention that the dramatic de-
crease in PHP LPL activity in ANGPTL4-Tg mice was observed using a modified LPL activity
assay, yet no decrease in PHP LPL activity was found when using a traditional LPL assay (data
not shown). One could speculate that the modified LPL assay only measures functional LPL on
the endothelial surface while the traditional LPL assay measures all LPL (total extracellular LPL
mass), the major portion of which is not targeted by ANGPTL4. Beside LPL inhibition, we ob-
served inhibition of hepatic lipase HL in ANGPTL4-Tg mice. HL is a triglyceride lipase as well
as phospholipid (PL) lipase for IDL and HDL, and thus completes the work of LPL. Genetic mu-
tations of HL has been shown to lead to an increase in both HDL cholesterol and PL (Connelly
et al. 1990, Breckenridge et al. 1982), explaining the rise in IDL and HDL cholesterol/triglyceride
we observed in Angptl4-Tg mice. Interestingly, we are the only group to report HL inhibition by
ANGPTL4. Since our ANGPTL4-Tg mice overexpress ANGPTL4 in numerous tissue including
liver, it is possible that HL inhibition is mediated exclusively by liver-derived ANGPTL4. In turn,
ANGPTL4 produced extra-hepatically may specifically serve to target LPL. However, adenovi-
ral or transgene-induced liver-specific ANGPTL4 overexpression was associated with decreased
PHP LPL activity. Whether this reflects spillover of ANGPTL4 into the blood plasma as a result
of massive ANGPTL4 overexpression is unclear. Whereas Angptl3 has been described to inhibit
endothelial lipase (EL), no comparable investigations have been done supporting the same role for
ANGPTL4. EL is a recently discovered enzyme that hydrolyzes TG and especially PL hydrolysis
within HDL (Jaye et al. 1999). Both genetic ablation and loss of function mutations for EL lead to
elevated HDL cholesterol levels (Brown et al. 2009). We observed that ANGPTL4 overexpression
was associated with elevated HDL-phospholipid and -cholesterol levels, whereas the opposite ef-
fects were observed in ANGPTL4-/- mice. These results suggest that ANGPTL4 may inhibit EL.
However, further evidence including from in vitro studies is necessary.
In human, different tissues are capable of synthesizing ANGPTL4 protein, with the high-
est expression levels found in liver, followed by adipose tissue, thyroid, brain and small intes-
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tine (chapter 4). Once synthesized, ANGPTL4 protein is partially cleaved into N-terminal and
C-terminal fragments, which can be detected in human plasma (Mandard et al. 2004). A lim-
ited number of studies has measured ANGPTL4 protein levels in human plasma. Steyskal et
al developed an ELISA assay using a polyclonal antibody directed against AA26-229 of human
ANGPTL4. The median plasma ANGPTL4 concentration was determined at ± 8 ng/ml. No dif-
ference in plasma ANGPTL4 levels was observed between patients with metabolic syndrome and
healthy patients. There was no association of plasma ANGPTL4 with BMI, waist circumference
or QUICKI (quantitative insulin sensitivity check index). However, ANGPTL4 correlated signif-
icantly with plasma HDL-cholesterol, FGF21, glucose and TG levels. Staiger et al. measured
a mean plasma ANGPTL4 concentration of 1.73 ± 0.11 ng/ml (means ± SE; range 0.37-8.00
ng/ml). ANGPTL4 muscle mRNA correlated significantly with plasma ANGPTL4 levels. Im-
portantly, plasma ANGPTL4 levels were positively associated with plasma FFAs. In contrast, no
significant correlation were found between plasma ANGPTL4 levels and plasma glucose, insulin,
or triglyceride concentrations. Although Staiger and Stejskal used the same supplier for the an-
tibody, it is unclear whether they used the exact same antibody. Importantly, it is also not clear
whether their ELISA assays measure total plasma ANGPTL4 or only a particular subfraction (e.g.
N-terminal ANGPTL4 or full length ANGPTL4). Xu et al used monoclonal antibody ED12B9
to measure plasma ANGPTL4 protein in patients with type diabetes mellitus. This antibody rec-
ognizes both full length and the N-terminal fragment of ANGPTL4. Mean plasma ANGPTL4
concentration was determined at 345.04 ng/ml. Serum levels of ANGPTL4 were significantly
lower in obese diabetic patients compared to obese non-diabetic patients. We measured plasma
ANGPTL4 using an ELISA protocol that was later adopted and commercialized by R&D systems.
Plasma levels of ANGPTL4 in our analysis were in the same order as Stejskal et al. Importantly,
in Northern blot the antibody used in our ELISA analysis only detected full length ANGPTL4,
which led us to conclude that we are only measuring full length ANGPTL4. Previous work has
shown that the N-terminal fragment of ANGPTL4 is sufficient to inhibit LPL activity. However,
it is not clear whether nANGPTL4 truly represents the metabolically active form. While it would
be interesting to know the plasma concentration of the N-terminal fragment of ANGPTL4, it is
equally important to assess the plasma concentration of the full-length protein. The most striking
finding was that plasma ANGPTL4 levels varied dramatically between subjects yet were relatively
stable within subjects. So far we have not been able to get a handle on the origin of the large inter-
individual variation. A specific link with polymorphisms within the ANGPTL4 gene can likely
be excluded. One interesting possibility is that individuals differ in the formation of ANGPTL4
oligomers, which may be differentially recognized by the ELISA assay. Despite the large inter-
individual variation, we found that conditions associated with elevated plasma FFA such as fasting,
caloric restriction and exercise increased plasma ANGPTL4 level. In several cell lines, fatty acid
markedly induced ANGPTL4 expression, suggesting a direct stimulatory effect of plasma FFA on
ANGPTL4 production. Besides dyslipidemia ANGPTL4 has also been connected with several
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other clinical conditions including cancer. Accordingly, it may be of interest to explore plasma
ANGPTL4 as a cancer biomarker.
Overload of lipid into the heart can dramatically impair heart function, thereby predispos-
ing to heart failure. Accordingly, strict regulation of cardiac lipid uptake is vital. Under normal
conditions, the heart utilizes fatty acids as its principal energy substrate. However, lipid accu-
mulation within cardiomyocyte can lead to lipotoxicity and contractile dysfunction. We observed
that cardiac Angptl4 gene expression is highly induced by dietary fatty acids, which feeds back to
lower cardiac fatty acid uptake. It has been previously shown that heart specific overexpression
of ANGPTL4 leads to impaired heart function due to LPL inhibition and subsequent inhibition
of fatty acid uptake (Yu et al. 2005). ANGPTL4-Tg mice showed a strong overexpression of
ANGPTL4 in the heart, especially after 24 hours fasting. We showed that fasting-mediated up-
regulation of ANGPTL4 impaired cardiac uptake of TG-derived FA. Augustus et al. showed that
by specifically knocking out cardiac-LPL, the expression of FA metabolism key genes were down
regulated. Poly-unsaturated fatty acids (PUFA) have been described to have deleterious effects de-
pending on the position of the double bond. While n-3 are considered to be beneficial, n-6 PUFA
has been described to be pro inflammatory and may increase cardiovascular risk. This is explained
by the fact that n-6 PUFA may lead to the formation of arachidonic acid, which serves a precursor
for numerous inflammatory mediators. Limiting the excess uptake of FA in the heart would be ex-
pected to be relevant to limit the deleterious effects on cardiomyocyte function. This principle has
been illustrated in chapter 5. Lipotoxicity has a major effect on the mitochondrial electron trans-
port chain, leading to formation of reactive oxygen formation (ROS) as a consequence of incom-
plete reduction of oxygen. The formation of superoxide radical has been shown to be at the origin
of lipid peroxidation. As this process occur in parallel to ATP synthesis, one of the ways to lower
ROS formation is to uncouple ATP synthesis. Uncoupling proteins family (UCPs) are composed
of several members which display tissue specific expression. UCP1 is expressed in brown adipose
tissue, UCP2 is expressed ubiquitously, and UCP3 is expressed preferentially in fast glycolytic
fibers of skeletal muscle and in mouse heart. Expression of UCP3 has been shown to be increased
after prolonged increases in plasma free fatty acid concentration as a consequence of acute exer-
cice (Schrauwen et al. 2002). In the same study we observed that levels of ANGPTL4 protein
in plasma increased in parallel with expression of UCP3. UCP3 has been proposed to protect
against ROS production in muscle (Vidal-Puig et al. 2000). The induction of cardiac ANGPTL4
by free fatty acid and by an acute oral fat load may represent a protective mechanism against fatty
acid-induced lipotoxicity, which is correlated with induction of UCP3. Recently, a link was made
between the small intestine and obesity via the microbiota. It was shown that introduction of mi-
crobiota into conventionalized mice promoted weight gain. Additionally, evidence was provided
that dietary induced obesity is associated with changes in the intestinal microbiota, which may
contribute to chronic inflammation. Recent work on diet induced obesity showed that ANGPTL4
is induced along the longitudinal axis of small intestine already after two weeks of high fat diet
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(HFD) (de Wit et al. 2008). Based on our data we propose that either full length ANGPTL4 or
its C-terminal fragment constitutes a new gut hormone that is secreted by enteroendocrine cells,
especially after a fat-rich meal (chapter 6). Ba¨ckhed et al reported the importance of the protec-
tive effect of ANGPTL4 to obesity development using germ free mice. It was suggested that the
effect of microbiota on bodyweight may be mediated by ANGPTL4, expression of which is sup-
pressed by introduction of microbiota into germ free mice. Reduced ANGPTL4 expression was
suggested to contribute to the enhanced fat storage of conventionalized mice via increased activity
LPL activity (Backhed et al. 2004). ANGPTL4 has also been proposed to be involved in regulating
lymphangiogenesis-via Prox1 (Backhed, Manchester, Semenkovich and Gordon 2007), a determi-
nant factor for normal lymph vessel development. It can be speculated that ANGPTL4 deficiency
impacts weight gain control via regulation of lymphangiogenesis, similar to what has been pro-
posed for Prox1 (Harvey et al). It is important to emphasize that using ANGPTL4 deficient mice on
C57Bl/6 background we fail to see any of the lymph abnormalities reported by Backhed et al. The
reason for the discrepancy is not clear but may be related to differences in the genetic background
of the mice. Instead, we find that ANGPTL4 deletion only leads to a severe phenotype when mice
are fed a high fat diet. Serum Amyloid-A (SAA) is an acute phase response protein that is synthe-
sized by the liver upon inflammatory stimuli (Benditt et al. 1971, Levin et al. 1972), including high
fat feeding (Scheja et al. 2008). The acute phase response is the immediate response of an organ-
ism to an inflammation and is aimed at restoring normal physiological functions. Inflammatory
cascades are initiated by the activation and recruitment of plasma monocytes and macrophages
to the site of injury. Upon activation, macrophages synthesize and release pro-inflammatory cy-
tokines such as IL-1b, IL-5, IL-6, and monocyte chemoattractant protein. Induction of SAA by
lipopolysaccharide was abolished in IL-6 deficient mice, suggesting its involvement in SAA gene
regulation (Bopst et al. 1998, Betts et al. 1993). Hepatic SAA2 mRNA expression as well as
plasma SAA concentration were strongly increased in ANGPTL4-/- mice already shortly after
starting saturated fat feeding. After short term high saturated fat feeding in ANGPTL4 -/- mice,
the mesenteric lymph nodes were massively increased, suggesting their involvement in the acute
phase cascade in ANGPTL4-/- mice. Also, expression of IL-6 and TNFalpha was increased in
mesenteric lymph nodes of ANGPTL4 -/- mice, which was not observed in small and large intes-
tine. These results suggests that the initial inflammatory event in ANGPTL4-/- mice occurs in the
lymph nodes. Currently, we are exploring two different scenarios. These scenarios need to take
account the specific effect of high saturated fat as opposed to high unsaturated fat on inflammation.
Second, they need to incorporate an important modulating role for ANGPTL4 since the inflam-
mation only occurs in ANGPTL4-/- mice. The first scenario is based on the role of ANGPTL4 as
LPL inhibitor. LPL is expressed in a number of cell types including muscle and adipose tissue.
However, LPL is also well expressed in macrophages which are abundant in mesenteric lymph
nodes. Mesenteric lymph nodes are exposed to large amounts of chylomicron-rich chyle which
passes through the lymph nodes before being taken up into the circulation. Since ANGPTL4 in-
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hibits LPL, in the absence of ANGPTL4, LPL activity and thus uptake of fatty acids from lymph
chylomicrons into macrophages may be elevated, which is further enhanced by high fat feeding.
According to this scenario, medium chain fats do not elicit an inflammatory response since they
are not processed through the lymph. Similarly, unsaturated fats do not have any effect because
macrophages are only activated by saturated fatty acids. One potential mediator for the effect
of saturated fatty acids on macrophage inflammation is the Toll-like receptor 4, which has been
shown to be activated by saturated fatty acids. Activation of TLR4 would initiate an inflamma-
tory cascade leading to synthesis of IL-6 and numerous other cytokines. This model is based on
the well established ability of ANGPTL4 to inhibit LPL. Alternatively, we consider a scenario in
which the pro-inflammatory effect of high fat diet is not exerted by the high fat content perse but
is related to the changes in intestinal microbiota elicited by high saturated fat feeding. Recently, it
was shown that high fat feeding alters the intestinal microbiota and leads to elevated production of
endotoxins. Accordingly, the ability of high saturated fat but not medium chain fat or unsaturated
fat to induce inflammation may be due to specific changes in intestinal microflora uniquely elicited
by saturated fat. The reason why inflammation specifically develops in ANGPTL4-/- mice may
be related to the effect of ANGPTL4 on immune function. As explained in chapter 6, ANGPTL4
promotes intestinal immune function. We hypothesize that the effect of ANGPTL4 on immune
function is related to its C-terminal domain, and is independent of its ability to inhibit LPL. Our
immunohistochemical staining results in human intestine suggest that C-ter ANGPTL4 is secreted
by enteroendocrine cells within the gut lumen, thus playing an endocrine function. While most of
the research so far has focused on the N-terminal fragment of ANGPTL4, studies suggest that the
C-terminal fragment is important for governing angiogenic function (Yang et al. 2008). Indeed,
the other family members such as Angiopoietin 1 and 2 have been described to have angiogenic
properties mediated by binding to the Tie2 receptor. However, ANGPTL4 does not bind to Tie1
or Tie2 receptors. In analogy with Angptl3, which bind to αVβ3 integrin, ANGPTL4 may be hy-
pothesized to bind to integrin homologues. Recently, Goh et al. demonstrated that the C-terminal
domain of ANGPTL4 binds to integrin αVβ5 on keratinocytes promoting extra-cellular matrix
remodeling in a wound-healing context. We were able to confirm ANGPTL4 binding to αVβ5
integrins using an ELISA assay. Since integrins contribute to the regulation of immune function
within the intestine, one could expect that the effect of ANGPTL4 on immune function to be
mediated by αVβ5 integrin, leading to efficient protection against deleterious effects of saturated
fat consumption. To further substantiate this second scenario, the role of ANGPTL4 in intestinal
immune function needs to be better characterized. Furthermore, specific effect of saturated fat
vs unsaturated fat on the intestinal microbiota need to be demonstrated, for instance by using the
MITChip. To differentiate against these two scenarios we have put ANGPTL4-/- mice on a high
saturated fat diet with or without oral antibiotics. We will then follow the acute phase protein
concentration in plasma. If induction of plasma SAA is maintained in the presence of antibiotics,
we will conclude that the effect of saturated fat on inflammation is independent of the intestinal
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microbiota. In that case, we will focus specifically on the effect of saturated fatty acids on lymph
node macrophages. Beside angiopoietins, another protein that shows homology with ANGPTL4
is ficolin-A. Ficolin-A binds to surface bacterial sugar residues and plays a role in innate immunity
by activating the lectin complement pathway (Endo et al. 2006). Ficolin A is characterized by a
fibrinogen-like domain (FBG) responsible of recognition of microorganisms, and plays an impor-
tant role in internal defense (Endo et al. 2007, Honor et al. 2007). In invertebrate, several FBG-like
domain containing proteins have been described to be involved in nonself recognition, also known
as fibrinogen-related proteins (FREP). Invertebrates only rely on innate immune response, while
vertebrates have both innate and adaptive immune response. These data lend credence to the no-
tion that ANGPTL4 may carry multiple functions, part of which are exerted via its C-terminal
FBG domain which lacks the ability to inhibit LPL.
This thesis has contributed important new information to our understanding of ANGPTL4
function. We showed that ANGPTL4 is a strong regulator of lipid metabolism via a number of
approaches. We first confirmed in vivo that ANGPTL4 inhibits LPL by converting active dimers
into inactive monomers. Our work showed that ANGPTL4 is also able to critically inhibit HL.
As a consequence, uptake of cholesterol in the liver is decreased in ANGPTL4-Tg mice, leading
to upregulation of hepatic cholesterol synthesis. Furthermore, we showed that ANGPTL4 plays
a protective role against lipotoxicity in both the heart and small intestine. We have developed an
accurate and reproducible ELISA assay to quantitatively measure ANGPTL4 protein in plasma
and showed that plasma ANGPTL4 are regulated by plasma FFA levels. Although a number of
important aspects related to ANGPTL4 function have been resolved, the research described here
has also raised a number of important new questions. Importantly, future research must be directed
towards the C-terminal fragment of ANGPTL4 and study how it influences cellular signaling. In
addition, future research should be aimed at understanding the role of ANGPTL4 in human and to
further explore the applicability of plasma ANGPTL4 as a possible biomarker.
Chapter 8
Summary
Obesity is caused by an imbalance between energy intake and energy expenditure. Exces-sive fat accumulation in the adipose tissue gives birth to a succession of metabolic distur-
bances, such as insulin resistance, hypertension and a pro-thrombotic state, collectively termed
metabolic syndrome. Often metabolic syndrome is also associated with dysregulation of lipopro-
tein metabolism, leading to changes in the plasma level LDL-cholesterol, HDL-cholesterol and/or
triglycerides (TG). TG circulate in the bloodstream in the form of chylomicrons (CM) origi-
nating from the small intestine, and very low density lipoproteins produced by the liver. The
enzyme lipoprotein lipase (LPL) hydrolyses the TG within CM and VLDL, making it a key
regulator of plasma TG clearance. Numerous studies have attempted to find a link between
changes in the adipose tissue consequent to obesity and the development of metabolic syndrome.
Part of the research focuses on factors secreted from adipose tissue and that have profound ef-
fects elsewhere in the body: the so-called adipocytokines. A new adipocytokine was discovered
in 2000 by several groups which is referred to as FIAF/ANGPTL4 (Fasting Induced Adipose
Factor/angiopoietin-like protein 4). Angptl4 is a 50 KDa secreted protein that belongs to the fam-
ily of fibrinogen/angiopoietin-like proteins. In this thesis we further characterized the function of
Angptl4 in lipid metabolism, focusing on its impact on plasma lipoproteins, on fatty acid-induced
inflammation and lipotoxicity, and on the regulation of the level of Angptl4 in human plasma.
In chapter 3 we explored the metabolic function of Angptl4 using transgenic (Tg) mice overex-
pressing Angptl4. Taking advantage of the induction of the Angptl4 transgene by fasting, we inves-
tigated plasma lipoprotein and hepatic cholesterol metabolism in wildtype and Angptl4 transgenic
mice after 24 hr of fasting. Angptl4 overexpression increased plasma levels of free fatty acids,
glycerol, total cholesterol, and triglycerides. Increased plasma triglycerides could be attributed
to inhibition of LPL. It was found that Angptl4 overexpression decreased post-heparin LPL ac-
tivity by stimulating conversion of endothelial-bound LPL dimers to circulating LPL monomers.
Fasting augmented the inhibitory effect of Angptl4 on plasma TG clearance: while no effect of
Angptl4 over-expression on VLDL clearance could be detected in the fed state, a dramatic de-
crease in VLDL clearance and associated tissue cholesterol and fatty acid uptake was found in the
24 hr fasted state. Consequently, hepatic cholesterol content was significantly decreased, leading
to universal up-regulation of cholesterol and fatty acid synthesis pathways.
In chapter 4 we report the development, validation and utilization of an ELISA assay to quan-
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titatively assess Angptl4 levels in human plasma. While the impact of Angptl4 on plasma lipids
is relatively clear, little is known about the physiological determinants of plasma Angptl4 in hu-
mans. We found that plasma Angptl4 levels are relatively stable within an individual but they
are highly variable between individuals. Treatment of patients with the drug fenofibrate signif-
icantly increased plasma hAngptl4 levels. Fasting also significantly increased plasma Angptl4
level, which was further augmented by subsequent endurance exercise. The exercise-induced in-
crease in plasma Angptl4 was completely abolished when subjects were given glucose. Intralipid
injection as well as treatment with a β-adrenergic agonist, both of which lead to elevated plasma
FFA levels, increased plasma ANGPTL4 levels compared to control treatment. Finally, no re-
lationship was observed between plasma hAngptl4 levels and adipose tissue mRNA expression.
Overall, these data reveal a large inter-individual variation in plasma Angptl4 levels, the origin of
which is unclear. Within an individual, Angptl4 levels rise in response to elevation of plasma free
fatty acids.
In chapter 5 we investigated the role of Angptl4 in the heart. Intramyocardial lipid overload
can have dramatic consequences for heart function, possibly leading to non-ischemic heart fail-
ure. Accordingly, strict regulation of cardiac lipid uptake is vital. In healthy conditions, the heart
mainly utilizes fatty acids as its principal energy substrate. However, when lipids are taken up in
excess subsequent lipid accumulation within cardiomyocyte may lead to lipotoxicity and contrac-
tile dysfunction. Dietary unsaturated fatty acids have a major impact on human health, which is
likely achieved via changes in gene expression. Fatty acids are believed to regulate gene expression
mainly via specific nuclear receptors, including the PPARs. Angptl4 was shown to be significantly
upregulated in hearts of mice fed with synthetic triglycerides composed of either linoleic acid or
linolenic acids. Angptl4 regulation by dietary fat was entirely dependent on PPARβ/δ, and inde-
pendent of PPARα, in direct contrast to UCP3. Upregulation of Angptl4 resulted in decreased
cardiac uptake of plasma triglyceride (TG)-derived fatty acids and decreased fatty acid-induced
oxidative stress and lipid peroxidation. In contrast, Angptl4 deletion led to enhanced oxidative
stress in the heart, both after an acute oral fat load and after prolonged high fat feeding. The data
suggest that stimulation of cardiac Angptl4 gene expression by dietary fatty acids and PPARβ/δ
is part of a feedback mechanism aimed at protecting the heart against lipid overload and conse-
quently fatty-acid induced oxidative stress.
In chapter 6 we investigated the possible role of Angptl4 in the small intestine. It is well
established that elevated saturated fat consumption is associated with increased risk for numer-
ous chronic diseases, including cardiovascular disease, inflammatory bowel disease, and obesity.
However, the underlying mechanisms and why specifically saturated fat is harmful largely remain
unknown. Besides carrying out nutrient digestion and absorption via the production of numer-
ous digestive enzymes, the GI-tract also produces a variety of hormones that play pivotal roles
in nutrient handling and energy homeostasis. These gut hormones are synthesized by special-
ized enteroendocrine cells located in the epithelial layer along the GI-tract. Several gut hormones
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are known to be influenced by dietary fat, including GLP-1 and cholecystokinin. In chapter 6
we report that Angptl4 is fat sensitive hormone produced by enteroendocrines cells. Noticeably,
chronic saturated fat feeding led to complex and dramatic phenotype in Angptl4-/- mice. Angptl4-
/- fed saturated fat developed a severe pathology consisting of fibrinopurulent perotinitis, intestinal
fibrosis connected with ascites and cachexia. This lethal phenotype is preceded by excessive in-
flammation as shown by a dramatic hepatic acute phase response. The data show that Angptl4
protects against the pro-inflammatory and ultimately lethal effects of chronic overconsumption of
saturated fat.
Taken together, the studies described in this thesis have increased our understanding of Angptl4
function. In addition, they have yielded some exciting new insights that will provide the basis
for future investigations. It is expected that the important role of Angptl4 in regulation of lipid
metabolism will be increasingly acknowledged.
Chapter 9
Samenvatting
Obesitas wordt veroorzaakt door een dysbalans tussen energie inname en energiegebruik. Deabnormale vetophoping in het vetweefsel zorgt voor verstoringen in de stofwisseling zoals
insuline resistentie, hypertensie, en een verhoogde stollingsneiging, wat gezamenlijk metabool
syndroom wordt genoemd. Vaak gaat metabool syndroom tevens gepaard met verstoringen in het
lipoproteine metabolisme, wat leidt tot veranderingen in het plasma gehalte aan LDL-cholesterol,
HDL-cholesterol en/of triglyceriden (TG). TG circuleren in het bloed in de vorm van chylomicro-
nen afkomstig uit de dunne darm, en very-low density lipoproteinen geproduceerd door de lever.
Het enzym lipoproteine lipase (LPL) hydrolyseert de TG in CM en VLDL en fungeert aldus als
een belangrijke regulator van de klaring van plasma TG. Talloze studies hebben gezocht naar een
link tussen de veranderingen in vetweefsel die ontstaan als gevolg van obesitas en de ontwikkel-
ing van metabool syndroom. Een deel van het onderzoek concentreert zich op factoren die door
vetweefsel worden uitgescheiden en elders in het lichaam hun effect uitoefenen: de zogenaamde
adipocytokinen. Een nieuw adipocytokine dat in 2000 door een aantal groepen werd ontdekt heet
FIAF/ANGPTL4 (Fasting Induced Adipose Factor/angiopoietin-like protein 4). Angptl4 is een
eiwit van 50 kDa behorende tot de familie van fibrinogen/angiopoietin-like proteins. In dit proef-
schrift hebben we de functie van Angptl4 in het vetmetabolisme verder gekarakteriseerd waarbij
de nadruk lag op de effecten op plasma lipoproteinen, op vetzuur-geinduceerde ontsteking , en op
de regulatie van het plasma Angptl4 gehalte bij de mens.
In hoofdstuk 3 hebben we de metabole functie van Angptl4 onderzocht met behulp van trans-
gene muizen die Angptl4 tot overexpressie brengen. Gebruik makend van de inductie van het
Angptl4 transgen door vasten hebben we plasma lipoproteinen en het cholesterol metabolisme in
lever onderzocht in wildtype en Angptl4 transgene muizen na 24 uur vasten. Angptl4 overex-
pressie leidde tot een verhoging in plasma gehalte aan vrije vetzuren, glycerol, totaal cholesterol
en TG. De verhoging in plasma TG kon worden toegeschreven aan remming van LPL. Angptl4
overexpressie leidde tot een verlaging van de postheparine LPL activiteit door de omzetting van
endotheel-gebonden LPL dimeren tot circulerende LPL monomeren te stimuleren. Het remmende
effecten van Angptl4 op klaring van plasma TG werd verstrekt door vasten: er werd geen effect
gevonden van Angptl4 over-expressie op VLDL klaring in de gevoede toestand. Daarentegen
werd na 24 uur vasten een sterke verlaging waargenomen in VLDL klaring en de daarmee gepaard
gaande opname van cholesterol en vetzuren in de weefsels. Als gevolg daarvan was de opname
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van cholesterol in de lever significant verlaagd, wat aanleiding gaf tot een algemene inductie van
cholesterol en vetzuursynthese.
In hoofdstuk 4 beschrijven we de ontwikkeling, validatie en toepassing van een ELISA assay
om de Angptl4 concentratie in humaan plasma kwantitatief te kunnen bepalen. Ondanks het sterke
effect van Angptl4 op plasma lipiden is er nog maar weinig bekend over de fysiologische deter-
minanten van het plasma Angptl4 gehalte in mensen. Het plasma Angptl4 gehalte bleek relatief
stabiel te zijn binnen een persoon maar grote variatie te vertonen tussen personen. Behandeling van
patinten met het medicijn fenofibraat zorgde voor een significante verhoging in plasma Angptl4
gehalte. Plasma Angptl4 ging ook omhoog na landurig vasten, wat verder versterkt werd door
duurinspanning. De verhoging in plasma Angptl4 door inspanning werd volledig teniet gedaan
door tevens glucose toe te dienen. Plasma Angptl4 werd verder verhoogd door intralipid injec-
tie alsmede behandeling met een β-adrenerge agonist. Tenslotte werd er geen relatie gevonden
tussen plasma Angptl4 gehalte en Angptl4 mRNA expressie in vetweefsel. Deze data laten zien
dat Angptl4 in plasma erg variabel is tussen personen. Binnen een persoon gaat plasma Angptl4
omhoog als de plasma vrije vetzuur spiegels stijgen.
In hoofdstuk 5 hebben we de rol van Angptl4 in het hart onderzocht. Een ophoping van
vet in het myocardium kan ernstige consequenties hebben voor het functioneren van het hart en
mogelijk leiden tot hartfalen. Om die reden is het belangrijk de vetopname in het hart strict te
reguleren. In gezonde toestand gebruikt het hart voornamelijk vetzuren als energiebron. Wan-
neer de vetzuuropname verhoogd is kan echter vet gaan stapelen in de hartcel wat aanleiding kan
geven tot lipotoxiciteit en verstoorde contracties. Onverzadigde vetzuren in de voeding benvloe-
den onze gezondheid op diverse manieren, onder andere door de expressie van genen te benvloe-
den. Vetzuren reguleren genexpressie voornamelijk via de zogenaamde nucleaire hormoon recep-
toren, waaronder de PPARs. Wij vonden dat de expressie van Angptl4 significant omhoog ging in
muizen die gevoed werden met synthetische triglyceriden bestaande uit linolzuur of linoleenzuur.
De regulatie van Angptl4 door vet was volledig afhankelijk van PPARβ/δ en onafhankelijk van
PPARα, in tegenstelling tot UCP3. De inductie van Angptl4 leidde tot een verminderde opname
van vetzuren door het hart en tot verminderde oxidatieve stress en vetzuurperoxidatie in het hart.
Daarentegen ging de afwezigheid van Angptl4 gepaard met verhoogde oxidatieve stress, zowel na
een acute vet bolus als na langdurig gebruik van een vetrijk dieet. De data suggereren dat de in-
ductie van Angptl4 door vetzuren in de voeding en door PPARβ/δ deel uitmaakt van een feedback
mechanisme dat erop gericht is het hart te beschermen tegen een overdaad aan vet en de daarmee
gepaard gaande vetzuur genduceerde oxidatieve stress.
Hoofdstuk 6 richt zich op de mogelijke rol van Angptl4 in de dunne darm. Het is bekend dat
een hoge consumptie van verzadigde vetten het risico op diverse ziekten verhoogt, waaronder hart
en vaatziekten, IBD (inflammatory bowel disease) en obesitas. Het echter is grotendeels onbekend
waarom nu precies verzadigd vet schadelijk is. Naast haar betrokkenheid bij de vertering en op-
name van voedsel door middel van productie van talloze enzymen produceert de darm ook diverse
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hormonen die betrokken zijn bij de verwerking van voedingsstoffen en energie homestase. Deze
darmhormonen worden geproduceerd door gespecialiseerde enteroendocriene cellen die aanwezig
zijn in het darmepitheel. De productie van een aantal hormonen zoals CCK (cholecystokinin) en
GLP-1 (glucagon-like peptide 1) wordt beinvloed door vetconsumptie. In hoofdstuk 6 laten we
zien dat Angptl4 een darmhormoon is wiens productie wordt gereguleerd door de hoeveelheid vet
in de voeding. De afwezigheid van Angptl4 in muizen in combinatie met het consumeren van
een vetrijk voer leid tot een ernstig ziektebeeld waaronder fibrinopurulente peritonitis, intestinale
fibrose gecombineerd met ascites en cachexie. Dit lethale ziektebeeld wordt voorafgegaan door
ernstige ontsteking wat blijkt uit een extreme acute fase respons in de lever. De resulaten laten zien
dat Angptl4 beschermt tegen de pro-inflammatoire en uiteindelijk dodelijke effecten van chronis-
che overconsumptie van verzadigd vet.
De in dit proefschrift beschreven studies hebben belangrijke nieuwe informatie opgeleverd
over de functie van Angptl4. Bovendien zijn er een aantal interessante ontdekkingen gedaan die
de basis zullen vormen voor toekomstig onderzoek. Het ligt in de lijn der verwachting dat het
belang van Angptl4 in de regulatie van het vetmetabolisme steeds meer erkend zal worden.
Chapter 10
Sommaire
L’obe´site´ est la cause d’une mauvaise balance entre la prise et la de´pense d’e´nergie. L’accumula-tion excessive de lipides dans le tissus adipeux donne naissance a` une succession de per-
turbation me´taboliques, comme la re´sistance a` l’insuline, l’hypertension ainsi qu’un e´tat pro-
thrombotique, collectivement appele´ syndroˆme me´tabolique. Le syndroˆme me´tabolique est le plus
souvent associe´ a` une de´re´gulation du me´tabolisme lipoprote´ique, menant a` des changements des
taux plasmatiques de choleste´rol LDL, HDL et/ou de triglyce´rides (TG). Les TG circulent dans le
compartiment sanguin sous la forme de chylomicrons (CM) originaires de l’intestin greˆle, et de
VLDL, d’origine essentiellement he´patique (very low density lipoprotein). Dans ce contexte la
LPL (lipase lipoprote´ique), capable d’hydrolyser les TG des CM et des VLDL, joue un roˆle clef
de la clairance plasmatique des TG. De nombreuses e´tudes ont tente´ d’identifier le lien entre les
changements ayant lieu dans le tissus adipeux lors de l’obe´site´ et le de´veloppement du syndroˆme
me´tabolique. Une partie de ces recherches s’est concentre´e sur les facteurs se´cre´te´s par le tissus
adipeux ayant un effet important dans le corps: les adipokynes. De´couverte en 2000 par diffe´rentes
e´quipes, Angptl4 (FIAF/ANGPTL4 : Fasting Induced Adipose Factor/angiopoietin-like protein 4)
est une prote´ine se´cre´te´e de poids molculaire e´gal a` 50KDa, appartenant a` la famille des fib-
rinoge`ne/angiopoietin-like proteins. Dans cette the`se nous avons caracte´rise´ en de´tail la fonction
d’Angptl4 dans le me´tabolisme lipidique, son impact au sein des lipoprote´ines, son implication
dans l’inflammation et la lipotoxicite´ induite par les acides gras, ainsi que sa re´gulation au niveau
plasmatique.
Dans le chapitre 3 nous avons explore´ la fonction me´tabolique d’Angptl4 en utilisant des
souris transge´niques (Tg) qui surexpriment Angptl4. Prenant avantage de l’induction du transge`ne
d’Angptl4 par le jeuˆne, nous avons e´tudie´ le me´tabolisme des lipoprote´ines plasmatiques et du
choleste´rol he´patique dans les souris normale et transge´niques, apre`s 24 heures de jeuˆne. La sur-
expression d’Angptl4 augmente les concentrations plasmatiques d’acide gras libres, de glyce´rol,
de choleste´rol total et de triglyce´rides. L’augmentation de la concentration plasmatique de triglyce´-
rides a e´te´ attribue´e a` l’inhibition de l’activite´ de la LPL. Nous avons de´montre´ que la surexpres-
sion d’Angptl4 diminue l’activite´ post-he´parine de l’enzyme LPL, stimulant la conversion des
dime`res attache´s a` l’endothe´lium en monome`res circulants. Nous avons observe´ par le jeuˆne une
augmentation de l’effet inhibiteur d’Angptl4 sur la clairance des TG plasmatiques alors qu’aucun
effet n’a e´te´ observe´ sur la production de VLDL a` l’e´tat nourris dans les souris transge´niques,
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une diminution dramatique de la clairance des VLDL, de meˆme que le stockage de choleste´rol et
d’acide gras ont e´te´ drastiquement perturbe´ dans les souris transge´niques apre`s 24h de jeuˆne. Par
conse´quent, le contenue en choleste´rol he´patique s’est trouve´ significativement diminue´, menant
a` une re´gulation a` la hausse des voix de synthe`se de choleste´rol et d’acide gras.
Dans le chapitre 4, nous rapportons la mise au point d’un essais ELISA e´valuant les quan-
tite´s d’Angptl4 dans le plasma humain. Alors que l’impact d’Angptl4 sur les lipides plasmatiques
est relativement clair, les de´terminants physiologiques d’Angptl4 plasmatique chez les humains
restent peu connus. Nous avons constate´ que les niveaux plasmatiques d’Angptl4 sont relative-
ment stables au sein d’un individu mais hautement variables entre les individus. Le traitement
de patients avec fe´nofibrate augmente sensiblement les niveaux plasmatiques d’hAngptl4. Chez
des sujets ayant subit un exercice d’endurance, le jeuˆne augmente e´galement les niveaux plasma-
tiques d’Angptl4. Cette augmentation induite par l’exercice a e´te´ comple`tement aboli lorsque les
sujets ont pris du glucose. Une injection d’intralipides, ainsi que le traitement avec un agoniste
β-Adre´nergiques, ont conduit a` des niveaux plasmatiques e´leve´s d’acide gras libres, augmentant la
concentration plasmatique d’Angptl4, par comparaison avec le groupe control. Enfin, aucune rela-
tion n’a e´te´ observe´e entre les concentrations plasmatiques d’hAngptl4 et l’expression d’Angptl4
dans le tissus adipeux. Dans l’ensemble, ces donne´es re´ve`lent une grande variation interindividu-
elle des niveaux plasmatiques d’Angptl4, dont l’origine est incertaine. Au sein d’un individu, les
niveaux d’Angptl4 augmentent en re´ponse a` une e´le´vation des acides gras libres plasmatiques.
Dans le Chapitre 5, nous avons examine´ le roˆle d’Angptl4 dans le cœur. Une surcharge de lipi-
des dans le myocarde peut avoir des conse´quences dramatiques pour la fonction cardiaque, menant
e´ventuellement a` un arreˆt cardiaque non-ische´mique. En conse´quence, une re´glementation stricte
de l’assimilation cardiaque de lipides est vitale. Dans des conditions normales, le cœur utilise
les acides gras comme source principale de substrat e´nerge´tique. Toutefois, lorsque les lipides
sont repris en exce`s, une accumulation de lipides au sein de cardiomyocyte a lieu pouvant con-
duire a` une lipotoxicite´ accompagne´e de dysfonctionnement contractile. Les acides gras insature´s
alimentaires ont un impact majeur sur la sante´ humaine, pouvant eˆtre la conse´quence de modifi-
cations dans l’expression ge´ne´tique. Les acides gras re´gulent l’expression ge´ne´tique principale-
ment via l’interme´diaire de re´cepteurs nucle´aires spe´cifiques, y compris les PPARs. Angptl4 a
e´te´ montre´ eˆtre conside´rablement upre´gule´ dans le cœur des souris nourris avec des triglyce´rides
synthe´tiques compose´s d’acide linole´ique ou d’acide linole´nique. La re´gulation d’Angptl4 par les
acides gras alimentaires est entie`rement de´pendante de PPARβ/δ mais inde´pendante de PPARα,
en directe opposition avec UCP3. L’upre´gulation d’Angptl4 a entraıˆne´ une absorption cardiaque
diminue´e des acides gras de´rive´s des TG plasmatiques diminuant ainsi le stress oxydant ainsi que
la pe´roxydation des lipides. En revanche, la suppression d’Angptl4 a augmente´ le stress oxydatifs
dans le cœur, aussi bien apre`s une consommation aigue¨ d’acide gras tant apre`s une consommation
chronique comme durant une intervention high fat diet (HFD). Les donne´es sugge`rent que stimu-
lation de l’expression d’Angptl4 au niveau du cœur par les acides gras alimentaires et de PPARβ/δ
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fait partie d’une me´canisme re´troactif visant a` prote´ger le cœur contre la surcharge lipidique et par
conse´quent le stress oxydant induit par les acides gras.
Dans le chapitre 6 nous avons examine´ le roˆle possible de Angptl4 dans l’intestin greˆle. Il est
bien e´tabli qu’une consommation e´leve´e d’acides gras sature´s est associe´e a` un risque accru pour
de nombreuses maladies chroniques, y compris les maladies cardiovasculaires, maladies inflam-
matoires de l’intestin, et l’obe´site´. Toutefois, les me´canismes sous-jacents permettant d’expliquer
pourquoi les matie`res grasses sature´e sont spe´cifiquement nocives restent en grande partie in-
connu. En plus d’eˆtre responsable de la digestion et de l’absorption des e´le´ments nutritifs, aide´ par
la production de nombreuses enzymes digestives, les voies digestives produisent e´galement une
varie´te´ d’hormones jouant un roˆle pivot dans la supple´mentation d’e´le´ments nutritifs ainsi que dans
l’home´ostasie e´nerge´tique. Ces hormones intestinales sont synthe´tise´s par cellules spe´cialise´es,
les cellules enteroendocrines, situe´es dans la couche e´pithe´liale tout au long des voies digestives.
Plusieurs hormones intestinales sont connus pour eˆtre influence´s par les acides gras alimentaires,
y compris GLP-1 et chole´cystokinine. Dans le chapitre 6 nous avons de´montre´ qu’Angptl4 est une
hormone sensible aux acides gras, produite par les cellules enteroendocrines. Visiblement, une al-
imentation chronique riche en acides gras sature´s conduit a` un phe´notype complexe et dramatique
chez les souris de´ficientes pour Angptl4. Angptl4-/- nourries avec des lipides sature´s de´veloppent
une pathologie grave consistant en une pe´ritonite fibrinopurulente, fibrose intestinale lie´e une as-
cite et cachexie. Ce phe´notype le´tal est pre´ce´de´ d’une inflammation excessive illustre´e par une
phase aigue¨ he´patique spectaculaire. Les donne´es montrent qu’Angptl4 prote`ge contre les effets
pro-inflammatoires et finalement le´tales de surconsommation chronique de lipides sature´s.
En conclusion, les e´tudes de´crites dans cette the`se ont permit d’augmenter notre compre´hension
de la fonction d’Angptl4. Ces e´tudes ouvrent de nouvelles perspectives qui serviront de base pour
les recherches futures qui devraient mettrent en e´vidence un roˆle essentiel de Angptl4 dans la
re´glementation du me´tabolisme lipidique.
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